MAHARASHTRA MEDICAL GOODS PROCUREMENT AUTHORITY

Tender for Supply of Essential Medicines

(Year 2025-26)

Tender reference No: E-215/MMGPA/ Essential Medicines (2025-26)

1st Floor, Aarogya Bhawan
St. George's Hospital Compound,
Near C.S.M.T. Railway Station, Mumbai - 400 001.
Maharashtra

Website :http://mahatenders.gov.in

Email : maha.mmgpa2023@gmail.com
Phone : 022-22717527

Table of Contents

Table of Contents **2**

Disclaimer **5**

Abbreviations and Glossary **7**

Bid Schedule **10**

Fact Sheet **12**

1. Section 1: Introduction **13**

2. Section 2: General Definitions **15**

3. Section 3: General Terms and Conditions **18**

3.1. Responsibility of verification of contents of Tender Document 18

3.2. Authorized Signatory for the Tender Document 18

3.3. Period of Validity of Bid 18

3.4. Earnest Money Deposit (EMD) 18

3.5. Submission of Bids 19

3.6. Language 23

3.7. Format of Bid 23

3.8. Number of Bids and Cost of bidding: **23**

3.9. Amendment of Tender document: **23**

3.10. Acknowledgement by Bidder 24

3.11. Right to accept or reject any or all Bids. 24

3.12. Pre-Bid Meeting 25

3.13. Clarifications post Pre bid Meeting 26

3.14. Modification/substitution/withdrawal of Bids 26

3.15. Proprietary data 26

3.16. Correspondence with the Bidder 26

3.17. Opening and Evaluation of Bids 27

3.18. Confidentiality 28

3.19. Clarifications regarding Evaluation 28

3.20. Selection of Bidder 29

3.21. Unethical Practices 30

3.22. Code of Integrity 31

3.23. Payment Provisions 32

3.24. Termination of Contract 32

3.25. Dispute Resolution 34

3.26. Governing law and jurisdiction 34

3.27. Indemnification 34

3.28. Saving clause: 34

3.29. Force Majeure 35
4. Section 4: Specific Terms and Conditions **35**
4.1. Eligibility Criteria and Supporting Documents to be Submitted 35
4.2. Manufacturing/Importing and Product Permissions 43
4.3. Minimum Tender Quantity 43
4.4. Market Standing 44
4.5. Inspection of Manufacturing Facilities 45
4.6. Shelf Life of the Drugs 46
4.7. Method of Placing Purchase Orders 46
4.8. Execution of Contract 46
4.9. Performance Security 46
4.10. Supply Conditions 47
4.11. Packing and Labeling 48
4.12. Schedule for packaging of essential drugs 49
4.13. Aggregation and "parent-child" relationship serialisation 52
4.14. Deduction & Damages on Quality Failure 53
4.15. Blacklisting of Product/Tenderer on withdrawal of Tender: 55
4.16. Blacklisting for Non-Supply of purchase Order(s): 55
4.17. Blacklisting of Product(s) based on Quality Test by the Empanelled Laboratories 55
4.18. Blacklisting of Product(s) based on Quality Test by Statutory Authorities 56
4.19. Blacklisting of the Supplier on Quality Failure: 57
4.20. Procedure for Blacklisting/Debarment: 57
Appendix-A: Schedule of Requirements: **58**
Appendix-B: Checklist 118
Annexure 1: Technical Specifications and Compliance 120
Annexure-2: Letter Comprising Technical Bid 122
Annexure-3: Proforma for Production and Sale Statement 125
Annexure-4: Details of Manufacturing Unit 126
Annexure-5: Details of Items Quoted with Drug Code 130
Annexure 6: Annual Turnover Statement for Three Years 131
Annexure-7: Format for Power of Attorney for signing of Bid 132
Annexure-8: Affidavit for blacklisting 134
Annexure- 9: Litigation Affidavit 135
Annexure-10: Mandate Form 136
Annexure-11: Indicative format for PRICE BID (BOQ) to be submitted online only 138
Annexure-12: Statement showing comparative prices offered by the tenderer in other tenders of the same product 139

Schedule 1: Contract Form 140
Schedule-2 Performance Security Form 143
Schedule-3: Supply Schedule 145
Schedule 4: Schedule for Packing of Drugs and Medicines 146
Schedule-5: Bar Code & Advance Shipment Notification details....**Error! Bookmark not defined.**

Disclaimer

The information contained in this Tender Document or subsequently provided to Bidder(s), whether verbally or in documentary or any other form, by or on behalf of the Maharashtra Medical Goods Procurement Authority or any of its employees or advisors, is provided to Bidder(s) on the terms and conditions set out in this Tender Document subject to which such information is provided.

This Tender Document is not an agreement and is neither an offer nor invitation by the MMGPA to the prospective Bidders or any other person. The purpose of this Tender Document is to provide interested parties with information that may be useful to them in making their financial offers (Bids) pursuant to this Tender Document. This Tender Document includes statements, which reflect various assumptions and assessments arrived at by the MMGPA in relation to the project. Such assumptions, assessments and statements do not purport to contain all the information that each Bidder may require. This Tender Document may not be appropriate for all persons, and it is not possible for the MMGPA, its employees or advisors to consider the investment objectives, financial situation and particular needs of each party who reads or uses this Tender Document. The assumptions, assessments, statements and information contained in this Tender Document may not be complete, accurate, adequate or correct. Each Bidder should, therefore, conduct its own investigations and analysis and should check the accuracy, adequacy, correctness, reliability and completeness of the assumptions, assessments, statements and information contained in this Tender Document and obtain independent advice from appropriate sources.

Information provided in this Tender Document to the Bidder(s) is on a wide range of matters, some of which may depend upon interpretation of law. The information given is not intended to be an exhaustive account of statutory requirements and should not be regarded as a complete or authoritative statement of law. The MMGPA accepts no responsibility for the accuracy or otherwise for any interpretation or opinion on law expressed herein.

The MMGPA, its employees and advisors make no representation or warranty and shall have no liability to any person, including any Bidder under any law, statute, rules or regulations or tort, principles of restitution or unjust enrichment or otherwise for any loss, damages, cost or expense which may arise from or be incurred or suffered on account of anything contained in this Tender Document or otherwise, including the accuracy, adequacy, correctness, completeness or reliability of the Tender Document and any assessment, assumption, statement or information contained therein or deemed to form part of this Tender Document or arising in any way for participation in this Tender Document.

The MMGPA also accepts no liability of any nature whether resulting from negligence or otherwise howsoever caused arising from reliance of any Bidder upon the statements contained in this Tender Document.

The MMGPA may, in its absolute discretion but without being under any obligation to do so, update, amend or supplement the information, assessment or assumptions contained in this Tender Document.

The Bidder shall bear all its costs associated with or relating to the preparation and submission of its Bid including but not limited to preparation, copying, postage, delivery fees, expenses

associated with any demonstrations or presentations which may be required by the MMGPA or any other costs incurred in connection with or relating to its Bid. All such costs and expenses will remain with the Bidder and the MMGPA shall not be liable in any manner whatsoever for the same or for any other costs or other expenses incurred by a Bidder in preparation or submission of the Bid, regardless of the conduct or outcome of the bidding process.

Abbreviations and Glossary

Abbreviations and Acronyms	Description
BET	Bacterial Endotoxin Test
BG	Bank Guarantee
BIS	Bureau of Indian Standards
BOQ	Bill of Quantity/(ies)
BP	British Pharmacopeia
CA	Chartered Accountant
CLA	Central Level Authority
COPP	Certificate of Pharmaceutical Products
CT	Clinical Trials
DCGI	Drug Controller General of India
DMER	Directorate of Medical Education & Research
DPCO	Drug Price Control Order
DPIIT	Department for Promotion of Industry and Internal Trade
EMD	Earnest Money Deposit
ESIC	Employees State Insurance Corporation
FDA	Food and Drug Administration
FEMA	Foreign Exchange Management Act 1999
GMP	Good Manufacturing Practices
G.R.	Government Resolution
GST	Goods and Services Tax
GS1	Global Standards1
HBPCL	Haffkine Bio-Pharmaceutical Corporation Limited
IEC	Import Export Code
IP	Indian Pharmacopeia
ISI	Indian Standards Institute
I.V.	Intra Venous
LLP	Limited Liability Partnership
LCBS	Least Cost Based Selection
MCGM	Municipal Corporation of Greater Mumbai
MDR	Medical Device Rules
MMGPA	Maharashtra Medical Goods Procurement Authority
MRP	Maximum Retail Price
MSC	Market Standing Certificate
MSEs	Micro and Small Enterprises
NABL	National Accreditation Board for Laboratories
NEFT	National Electronic Funds Transfer
NSQ	Not of Standard Quality
NPPA	National Pharmaceutical Pricing Authority
OEM	Original Equipment Manufacturer
PAN	Permanent Account Number
PoA	Power of Attorney

Abbreviations and Acronyms	Description
PVC	Poly Vinyl Chloride
PVdC	Poly Vinylidene Chloride
RFP	Request For Proposal
RTGS	Real Time Gross Settlement
SLA	State Level Authority
SSI	Small Scale Industries
TAA	Tender Accepting Authority
TIA	Tender Inviting Authority
UDIN	Unique Document Identification Number
USP	United States Pharmacopeia
WHO	World Health Organization

MAHARASHTRA MEDICAL GOODS PROCUREMENT AUTHORITY

Bid Notice

Tender reference No: E-215/MMGPA/Essential Medicines

(2025-26)

Chief Executive Officer, Maharashtra Medical Goods Procurement Authority, Mumbai invites **ONLINE BID** for the year **2025-26** in **two envelope system** from the manufacturers/importers for the purchase of following items.

S. No.	Description	Tender Fee (Rs.)	EMD (Rs.)
1.	**As per Appendix– A**	**50,000/-**	Subject to Clause 3.4, a Bidder is required to furnish/pay a minimum EMD amount of Rs.2.00 lacs. However, if the Bidder is submitting its quote for more than 8 drugs, then for each additional drug beyond 8 number of drugs, the EMD amount shall correspondingly increase by a value of Rs. 25,000/- per additional drug, subject to a maximum EMD amount of Rs. 5.00 lacs.

Bid Schedule

All bid related activities (process) like downloading of bid document, submission of bid and submission of EMD and other documents will be governed as per the time schedule given below:

Sr. No.	Activity	Period
1	Period of sale of Tender Document/ download	From – 04-09-2025, 03:00 PM
2	Date for submission of queries	Before pre-bid meeting
3	Date of pre-bid meeting	11-09-2025 at 2:00 PM To 03:00 PM (Bidder should have to submit queries in the prescribed format, through email or hard copy before scheduled time of meeting to be held at Ground Floor, Aarogya Bhawan, Commissionerate of Health Services, Mumbai 400001)
4	E- tender submission duration	From- 04-09-2025 03:00 PM to 29-09-2025 up to 3:00 PM
5	Last date and time for submission of Bid: (Bid Due Date)	29-09-2025 up to 3:00 PM
6	Date and time of opening of Technical Bid (envelope No.1)	30-09-2025 at 3:00 PM
7	Date and time of opening of Price Bid (envelope No. 2)	To be notified to the technically qualified Bidders.
8	Validity of Tender	180 days from the Bid Due Date

Address for communication : 1st Floor, Aarogya Bhawan,
St. Georges Hospital Compound,
Near CSMT Railway Station, Mumbai- 400 001.

Tender Document is available to be downloaded from the Official Website (https://mahatenders.gov.in), however at the time of submission of Bid, any interested eligible bidder would be required to pay by online payment of a non-refundable tender fee of INR 50,000 and enclose a copy of the receipt of payment with the technical bid. The payment of the Tender fee shall be made only online through payment gateway in **A/c of** "**Maharashtra Medical Goods Procurement Authority, Mumbai**".

As per Revised Manual of Office Procedures for Procurement by the Government Department issued through Government Resolution no. Bha.kha.sa-2014/ Pra. Kra. 82/Section-III/Industry–4 by Department of Industry , Energy & Labour, Government of Maharashtra, dated 01.12.2016 – Bidder including Government Boards/Corporation/Undertakings and manufactures/ suppliers who are MSEs

registered under "Micro, Small and Medium Enterprises Development Act 2006" are exempted from paying Tender Fee and Earnest Money Deposit.

Non-payment of Earnest Money Deposit, unless exempted herein, will result in the rejection of the bid summarily without any notice. The conditional bid shall be rejected.

Chief Executive Officer, Maharashtra Medical Goods Procurement Authority, Mumbai reserves all the rights regarding this Tender Document and the procedure outlined therein

Sd/-
CHIEF EXECUTIVE OFFICER,
MAHARASHTRA MEDICAL
GOODS PROCUREMENT
AUTHORITY MUMBAI

Fact Sheet

Clause Reference	Topic
Price Bid Evaluation	***The method of selection is LCBS (Least Cost Based Selection-L1).***
Downloading Tender Document	Tender Document can be downloaded from https://mahatenders.gov.in and from website of MMGPA for reference ("**Official Websites**").
Earnest Money Deposit (EMD)	Bidders are required to pay the EMD/Bid Security **as per the Clause 3.4.** through online mode on https://mahatenders.gov.in.
Scope of Work	Supply of essential medicines **(2025-26)** in accordance with terms of this Tender Document.
Pre-bid meeting and clarifications	A pre-bid meeting will be held on dt. **11-09-2025 02:00 PM,** Meeting will be held in two sessions: **A) Issues Regarding specifications, B) Issues Regarding overall tender documents The participants should have an authority letter of the company which they are representing. Maximum two representative will be allowed per firm / company. Only authorised participants inside the meeting hall.** Bidder may submit queries through email or hard copy before scheduled time of pre-bid meeting.
Taxes	For all goods/services supplied, the Bidder shall be entirely responsible for bearing of all taxes, stamp duties, license fees, and other such levies imposed/incurred until delivery of the contracted products or services.
Bid Validity	Bids must remain valid till 180 days from the Bid Due Date.
Submission of Responses	Bidders must upload and submit all the documents on the e-tendering portal https://mahatenders.gov.in ("**E-Tender Portal**"). *Each of the documents must be uploaded in the format specified in this Tender Document.*
Submission of Bids	This is online process; interested Bidders are required to submit the Bids online by the date and time specified in the Tender Document.
Last Date of Submission	Bids submitted after Dt. 29.09-2025 **03:00PM** will not be accepted by the e-Tender portal.
Tender Fee	All Bidders shall pay Tender Fee of Rs.50,000

Section 1: Introduction

Maharashtra Medical Goods Procurement Authority (MMGPA), Mumbai has been formed as per the Maharashtra Medical Goods Procurement Authority Act 2023 (Mah. Act No. XIII of 2023) ("**Act**'). MMGPA works as a single point procurement of certain medical goods and execution of turnkey projects with highest standards of transparency, fairness, equity and for timely supply at optimum and uniform rates and of desired quality and quantity for the Public Health Department, Medical Education & Drug Department of Government of Maharashtra and other departments as mentioned in the said Act. To meet the objective of the Act, MMGPA in exercise of its powers under section 36 of the Act issued the regulations named, Maharashtra Medical Goods Procurement Authority Regulations, 2025 ("**Regulations**") as amended from time to time.

1.1 **Chief Executive Officer, Maharashtra Medical Goods Procurement Authority, Mumbai**, hereinafter referred to as the **("Purchaser") invites** online Bid in two envelope systems for supply of item specified in '**Appendix-A** Schedule of Requirements', for use in public health facilities in the State of Maharashtra. Any applicable orders/ circulars issued by Govt. of Maharashtra from time to time will be applicable to this bidding process.

1.2 All bid related activities (process) like Tender Document downloading, bid submission and submission of EMD and other documents will be governed by the bid schedule given in bid notice.

1.3 All activities of this bid are carried out **online** on website **https://mahatenders.gov.in.** The Tender Document is uploaded on Government of Maharashtra, (GoM) e-tendering website **https://mahatenders.gov.in** and has to be downloaded as well as filled up and submitted **online only**. The Bidders are required to submit online Tender Fees (non-refundable) as mentioned, through **online payment gateway in A/c of** "**Maharashtra Medical Goods Procurement Authority, Mumbai"**. In no case, the Tender Fee should be mixed with EMD amount. The Bid shall be liable to be rejected summarily upon failure to follow procedure prescribed in the Tender Document.

1.4 **The quantities mentioned in the Bid are only approximate estimated quantities ("Tendered Quantity"). The Chief Executive Officer, Maharashtra Medical Goods Procurement Authority, Mumbai reserves the right to increase or decrease the quantities', maximum up to 50% of the quantities to be purchased without assigning any reason thereof.**

1.5 If any Bidder wishes to lodge any complaint regarding the evaluation of his Bid, the Bidder shall submit the complaint within 48 (forty-eight) hours from the declaration of Bidders whose Bids are technically qualified along with deposit of **Rs. 50,000 (Rupees Fifty Thousand only)** online in favour of **Chief Executive Officer, Maharashtra Medical Goods Procurement Authority, Mumbai** in the form of deposit. This complaint will be submitted to appropriate forum along with facts. The amount so deposited shall be refunded, if after scrutiny the complaint is found to be true by the appropriate forum. However, if the complaint is found to be false and malafide the deposit will be forfeited. No interest shall be paid against this deposit.

1.6 E-bidding process related Queries can be sent on email – eproc.support@maharashtra.gov.in /Help: The 24 x 7 Toll Free Telephonic Help Desk Number1800-3070-2232. / Mobile: +91-7878107985 , +91-7878107986 ,+ 91-7878007972 and +9-7878007973

Sd/-
Chief Executive Officer,
Maharashtra Medical Goods
Procurement Authority Mumbai

Section 2: General Definitions

2.1. Applicable Laws: shall mean all laws and regulations brought into force and effect by GOI or the State Government of Maharashtra or Food and Drug Administration including the CDSCO norms, Drugs and Cosmetics Act, 1940, Medical Device Rules, 2017 (MDR), NPPA, CVC Guidelines, New Drugs and Clinical Trials Rules, 2019, Drug Price Control Orders, rules, regulations, notifications, directives, policies and office memorandums, made thereunder and as amended from time to time and judgements, decrees, injunctions, writs and orders of Hon'ble Supreme Court or High Court, applicable to this Tender Document and the exercise, performance and discharge of the respective rights and obligations of the parties hereunder, as may be in force and effect during the tenure of the Tender Document or Contract.

2.2. Bid / Tender: shall mean the two-envelope submitted i.e., envelope no. 1 (Technical Bid) and envelope No. 2 (Price Bid), collectively.

2.3. Blacklisting/Debarring: The occurrence of any event, as mentioned hereinbelow, shall make the Bidder ineligible from participating in the future bids of Purchaser for a period of 2 to 5 years, as specified in the blacklisting order. The period of Blacklisting/Debarring shall be decided on the basis of number/nature of violations of the tender conditions and the loss/hardship caused/likely to be caused to the Purchaser on account of each such violations, generally relating to:

a) supply of substandard, misbranded, adulterated or spurious or any drugs/products manufactured/imported in contravention of any of the laws of the land and/ or,
b) indulging in unethical practices as detailed in Clause 3.21 and/ or,
c) indulging in fraudulent practices at the time of making the bid or at any time during the validity of the tender or the contract thereof. The event will include, among all other things, making false/misleading declarations statements, presenting false/ misleading/ fabricated/ forged document(s), trying to influence/ affect/ stall the tender/ procurement/ payment processes in anyway, making false/ baseless complaints about other bidders or bids or drugs or any person/organization/related to the tender activities etc., and such activities as specified in the Tender Document.
d) Any supplied drug/medicines if declared as Not of Standard Quality (NSQ) by the competent authority during the statutory sampling of the relevant drug/medicines shall also be ground for blacklisting by the Purchaser.

2.4. BOQ: Bill of Quantity or the Schedule of Quantity in which the rates are to be filled in by the Bidder or commonly called the price bid.

2.5. Contract: A Contract for the supply of an approximate quantity of item(s) at a specified price and period as mentioned in Purchase Order(s) issued by the Purchaser from time to time during the Period of Contract.

2.6. Drug Inspector: As defined under the Drugs and Consmetics Act, 1940, including any amendments thereof.

2.7. Empaneled Laboratory: Drug Testing Laboratory approved under the Drugs and Cosmetics Act 1940 and accredited by NABL, selected by the Purchaser either

through open tender process or by expression of interest or otherwise for the purpose of conducting analytical testing/evaluation of drugs procured through the tender.

2.8. Government: means the Central Government or the Government of Maharashtra, as the case may be, and includes agencies and public sector enterprises under it, in specific contexts**.**

2.9. MDR, 2017 – Medical Device Rules published under sub-section (1) of Section 12 and Sub-section (1) of Section 33 of the Drugs and Cosmetics Act, 1940 (23 of 1940), in the Gazette of India to regulate the import, manufacture, distribution and sale of Medical Devices and any subsequent amendments thereto.

2.10. Market Standing Certificate: A Market Standing Certificate (MSC) is a document that verifies a company's good standing and track record in the pharmaceutical or medical device industry issued by State Drug Control Authority or Central Drugs Standard Control Organization (CDSCO).

2.11. New Drugs and Clinical Trials Rules, 2019- Rules published under sub-section (1) of Section 12 and Sub-section (1) of Section 33 of the Drugs and Cosmetics Act, 1940 (23 of 1940) and any subsequent amendments thereto, in the Gazette of India which shall apply to all new drugs, investigational new drugs for human use, clinical trial, bioequivalence study, bioavailability study and ethics committee.

2.12. Notification of Award (NoA): is an intimation informing the successful Bidder, the approximate quantity for which the Tender Document is awarded and requiring the Bidder to execute an agreement in the prescribed format and to submit the Performance Security within a specified time so as to become a Supplier.

2.13. NPPA: The National Pharmaceutical Pricing Authority, the Government regulatory agency that controls the price of pharmaceutical formulations in India.

2.14. Period of Contract: the rate price mentioned for the drugs by the Bidder shall be valid for a period of one year from the date execution of Contract.

2.15. Price Bid shall have the meaning as ascribed to it in Clause 3.5 of this Tender Document.

2.16. Purchase Order means an order issued by the Purchaser to the Supplier informing to supply the required quantity of the drugs at the contract price and to supply to various consignees as mentioned in the purchase order.

2.17. Revised Manual of Office Procedures for Procurement by Government Departments: Government Resolution no. Bha.kha.sa-2014/ Pra. Kra. 82/Section-III/Industry–4, dated 1.12.2016 issued by Department of Industries and Labour, Government of Maharashtra and any subsequent amendments/revisions thereto.

2.18. Risk Purchase is the additional cost incurred by the Purchaser in making alternate purchases of the quantity defaulted by the Supplier from other sources at a higher cost as compared to Price Bid quote.

2.19. Supplier: is the selected Bidder(s) to whom Purchase Order(s) is placed on fulfilling the qualification criteria and terms and conditions laid down in this Tender Document.

2.20. **Supply Schedule** means the schedule for supply of drug which shall be adhered to for supply as per Clause 4.10 unless altered with mutual consent on the basis of the movement /consumption of drugs, exigencies and other reasons suiting the requirements of Purchaser.

2.21. **Tender Document:** The document published by the Purchaser containing the details of the drugs/medicines/consumables to be purchased, the quantity and delivery, and which includes designs, specifications, quality requirements and other Specific/General conditions which will govern the contract on acceptance of the Bid.

2.22. **Unit:** means the smallest unit of the drug(s) for which rates are to be quoted and to be made available on demand. The rate to be given on the price bid shall be quoted for this basic unit as mentioned in the BOQ.

Note: The words and expressions used in this Tender Document, but not defined, shall have the same meaning as respectively assigned to them under the prevailing Applicable Laws.

Section 3: General Terms and Conditions

This section deals with the general conditions of contract and contains the following terms & conditions governing the tender.

3.1. Responsibility of verification of contents of Tender Document

3.1.1. It shall be the responsibility of the Bidders to read/examine all instructions, forms, terms and specifications in the Tender Document and confirm that the required documents as specified in Clause 3.5 are duly uploaded. Failure to furnish any information required by the Purchaser in any respect shall result in the rejection of bids, without any notice.

3.2. Authorized Signatory for the Tender Document

3.2.1. Only authorized signatory identified and nominated in power of attorney submitted in the format prescribed in Annexure 7, shall be eligible to sign all documents and annexure related to the Tender Document. It is advisable for the Bidder to authorize only that person for this Tender Document, who is salaried employee of the Bidder. Further, the Bid shall be typed or written in indelible ink and the authorized signatory of the Bidder shall alone digitally sign and upload all required documents and annexures. All the alterations, omissions, additions or any other amendments made to the Bid shall be initialed by the person(s) signing the Bid. The Bid shall contain page numbers.

3.3. Period of Validity of Bid

3.3.1. The bid shall remain valid for a period of 180 days from the Bid Due Date (envelope no.1). Prior to the expiration of the bid validity the Purchaser may request the Bidders to extend the bid validity for the period as required by the Purchaser.

3.4. Earnest Money Deposit (EMD)

3.4.1. A Bidder needs to furnish/pay a minimum EMD amount of Rs.2.00 lacs, however if the Bidder is submitting its quote for more than 8 drugs, then for each additional drug beyond 8 number of drugs, the EMD amount shall correspondingly increase by a value of Rs. 25,000/- per additional drug, subject to a maximum of Rs. 5.00 lacs, unless exempted under Clause 3.4.7. In case, the value of EMD submitted by the Bidder does not correspond in value as per terms above, to the number of drugs for which the Price Bid is submitted, then the number of drugs starting at the top which corresponds to the actual EMD amount will only be considered for evaluation. For avoidance of doubt, the quoted items by the Bidder will be counted in sequence up to the value of EMD deposited. However, without minimum EMD the Bid will not be considered at all.

3.4.2. The payment of Earnest Money Deposit shall be made only online through payment gateway as provided in the tender portal and any other form such as Cheque/Cash/Postal order will not be accepted. The bids submitted without EMD will be summarily rejected.

3.4.3. Unsuccessful Bidder's EMD will be discharged/ returned within 2 months through e-Tender Portal after acceptance of NOA by the successful Bidder.

3.4.4. The Bidder shall not be entitled for any interest on EMD.

3.4.5. The successful Bidder's EMD will be discharged after signing the Contract and submitting the Performance Security & processing fee as stipulated.

3.4.6. Without prejudice to any other right or remedy that may be available to the Purchaser under the Tender Documents and/ or under the Contract, or otherwise, the Purchaser may forfeit the EMD and/or blacklist the Bidder upon occurrence any of the below-mentioned circumstances:

i. A Bidder quotes prices higher than allowed as per DPCO, NPPA or higher than MRP; or

ii. a Bidder engages in an Unethical Practice as defined in Clause 3.21 of this Tender Document; or

iii. a Bidder withdraws its Bid during the period of Bid validity as specified in this Tender Document and as extended by mutual consent of the respective Bidder(s) and the Purchaser; or

iv. the Selected Bidder fails within the specified time limit -:

a. to sign and return the duplicate copy of NOA; or

b. To sign the Contract in accordance with terms and conditions or.

c. To furnish Performance Security and processing fee within the period prescribed therefor in this Tender Document.

v. The entire EMD paid shall be forfeited from the Bidder(s) whose manufacturing facilities were rejected on the grounds of non-compliance to statutory requirements as per the Applicable Laws.

3.4.7. Exemption for payment of EMD as per the Revised Manual of Office Procedures for Procurement by Government Departments (including Appendix-8 - Tender Form Fee and Earnest Money Deposits).

Micro and small-scale manufacturing industries registered under Micro, Small and Medium Enterprises development act 2006 are exempted from paying Tender Form Fees and EMD.

The above exemption is subject to submission of copy of Udyam Registration Certificate' or any other valid registration Certificate/Proof notified by the Government of India in respect of the drugs manufactured and quoted by them for participation in this tender floated by Purchaser. Further, the Purchaser reserves the right to inspect the manufacturing unit, whenever it is deemed necessary by it, in order to satisfy themselves with regard to verifying the credentials of the Bidder with respect to quality and production capacity and other relevant factors.

3.5. Submission of Bids

3.5.1. The Bidder shall submit the Bid no later than the date and time specified as the Bid Due Date, on the E-Tender Portal specified by the Purchaser, duly signed in digital form by the authorised signatory of the Bidder, by uploading the complete and legible scanned/digital copies of the Technical and Price Bids in BOQ/digital format (i.e. scanned copy of original signed documents and the supporting documents). The documents submitted in the Bid should be scanned in at least 100 dpi. It is further clarified, that if any document submitted with the Bid is not legible, the same may

not be considered by the Purchaser for further evaluation and the Bidder shall be solely responsible for any consequences thereof. The documents should be uploaded in the respective fields/space as per the provisions made on the portal. Each file of the document should be separate, and it should be uploaded in the given space/field only.

3.5.2. The Bid is to be submitted in accordance with the document downloaded including corrigendum issued thereto from the E-Tender Portal or the Official Website. The Bidder shall be responsible for its accuracy and correctness as per the version uploaded by the Purchaser and shall ensure that there are no changes caused in the content of the downloaded document.

To prepare and submit the bid/offer online all Bidders are required to have e-token based DIGITAL SIGNATURE CERTIFICATE. The Digital signature certificate should be obtained from competent authority;

3.5.3. **Technical Bid (Envelope No. 1):** The documents comprising the Technical Bid shall include:

1. Proof of Tender fees and EMD paid (if exempted as per Clause 3.4.7, attested copy of valid registration made by manufacturer for offered product under Micro & Small, Medium Industries Development Act, 2006).
2. Attested photocopy of valid manufacturing drug license with product list duly approved by the central licensing authority/ state licencing authority for each and every product quoted as per technical specification in the bid. The license must have been duly renewed up to date and the items quoted shall be clearly highlighted in the license. If quoted item is manufactured at different places, Manufacturing License & Performance certificate from all such places from respective Licensing Authority/ State Drug Authority should be enclosed. **However, Loan Licensee/ third party licensee are not allowed.**
3. World Health Organization - Good Manufacturing Practice certificate (with product list or COPP) highlighting the quoted products.
4. Copy of permission from DCGI for "New drug & Fixed Dose Combination"
5. Market Standing Certificate valid for a period of 3 years (i.e., for financial year 2022-23 and 2023-24 and 2024-25) as a manufacturer/importer for each drug(s) quoted in the tender within the Bid Due date. The period of Market Standing will be reckoned from the date of issue of Product permission. In case of an importer, their principal manufacturer located overseas should have 3 years market standing in India and the importer shall have 3 years market standing in the pharmaceutical field. In cases involving new drugs/ drugs out of patent period it is sufficient to possess relevant market standing certificate, as applicable.
6. Appendix-A (Schedule of Requirements)
7. Appendix-B (Checklist)
8. Annexure-1 (Technical Specifications and Compliance)
9. Annexure-2 (Letter Comprising Technical Bid)
10. Annexure-3 (Proforma for Production and Sale Statement)

11. Annexure-4 (Details of Manufacturing Unit)
12. Annexure-5 (Details of Items Quoted with Drug Code)
13. Annexure-6 (Annual Turnover Statement for Three Years) along with Copies of Balance Sheet and Profit and Loss Accounts for last three years i.e., (2022-23, 2023-24, 2024-25) certified by the Statutory Auditor or Chartered Accountant.
14. GST Registration certificate along with copy of the GST return of last quarter.
15. Annexure-7 (Format of Power of Attorney for signing of Bid) except for proprietorship.
16. Annexure-8 (Affidavit for Blacklisting)
17. Annexure-9 (Litigation Affidavit)
18. Annexure-10 (Mandate Form)
19. Incorporation / Registration Certificate of Bidder

Other Documents:

20. Schedule-1 (Contract Form)
21. Schedule-2 (Performance Security form)
22. Schedule-3 (Supply Schedule)
23. Schedule-4 (Schedule for Packing of Drugs and Medicines)
24. Schedule-5 (Bar Code & Advance Shipment Notification details)
25. Authorization letter nominating a responsible person of the Bidder to attend the meetings like pre-bid & negotiation meeting.

Note: In case the annual accounts for the latest financial year are not audited and therefore the Bidder cannot make it available, the Bidder shall give an undertaking to this effect and the statutory auditor/chartered accountant shall certify the same. In such a case, the Bidder shall provide the audited annual reports for 3 (three) years preceding the year for which the audited annual report is not being provided.

3.5.4. Bids submitted by special messenger, fax, telex, telegram, e-mail, or in any way other than on the specified e-tender platform for bidding, shall not be entertained and shall be rejected.

3.5.5. **Price Bid (envelope no. 2):**

i. The composition and strength of each drug should be as per specifications given in Appendix A. Any variation, if found, will result in rejection of the tender/drug. However, the imported/combination drugs are allowed to be quoted in trade / brand name subject to clarification from the Bidder about composition of the drug.

ii. The Price Bids of only those firms who qualify in the technical evaluation as per the terms herein, alone will be eligible for opening and evaluation of their Price Bid. Every Bidder shall submit their rates in the prescribed Proforma 'Price Bid Form' (BOQ) (refer Annexure 11) attached to the online bid document in Indian Rupees only for each of the required medicines separately on door delivery basis according to the unit in which prices has been sought. The Price Bid shall be submitted only online in the format given. The price bid (BOQ) file shall be

available to be downloaded from the E-Tender Portal and the Bidder shall quote the prices for respective drug as per Annexure 11 and upload the same on the E-Tender Portal. The Bidders shall not rename the BOQ files downloaded. Bidders are allowed to enter the Bidder's name & values only. Price bid in Annexure-11 should not be submitted in Technical Bid. If the Price Bid is submitted as part of the Technical Bid, the Bid will be rejected.

iii. Bid for the supply of drugs, medicines, etc. with conditions like 'At Current Market Rates' shall not be accepted. The Purchaser shall not be responsible for damages, handling, clearing, transport charges and the same will not be paid. The deliveries should be made as stipulated in the Purchase Order placed with successful Bidder. Conditional bids are not accepted and liable for rejection.

iv. The price shall be quoted on unit mentioned in BOQ format and not in respect of any other supply units. Any corrections in future in any respect shall not be entertained.

v. The price quoted by the Bidder shall not in any case, exceed the controlled price, if any, fixed by the Central Government under DPCO OR NPPA and the Maximum Retail Price (MRP). The Purchaser will exercise the right to revise the price at any stage so as to conform with the controlled price or MRP as the case may be. The right under this clause will be exercised without prejudice to any other action that may be taken against the Bidder. Only landed cost (including all charges and taxes) mentioned in the Price Bid (quoted by the Bidder) is considered for rate comparison. Payment of all applicable taxes to concerned authority is the responsibility of the Bidder.

vi. If at any time during the Period of Contract, the price of quoted items is reduced or brought down by any Applicable Law or by the Bidder itself, the Bidder shall be morally and statutorily bound to inform the Purchaser immediately about such reduction in the contracted prices. The Purchaser shall be empowered to reduce the rates accordingly.

vii. In case of any enhancement in GST/other taxes due to statutory Act of the Govt. or any other taxes newly levied by Govt. after the date of submission of Bid and during the Period of Contract, the quantum of additional GST/other taxes so levied will be allowed to be charged extra as separate item without any change in price structure of the drugs approved under the bid. For claiming the additional cost on account of the increase in GST/other taxes, the Bidder should produce a letter from the concerned competent authorities for having paid additional GST/other taxes on the goods supplied to the Purchaser and can also claim the same in the invoice. Similarly, in case of reduction in GST / other taxes, the Purchaser will pay the reduced the GST / other taxes amount from the effective date of reduction in the aforesaid GST / other taxes.

viii. **Fall Clause**: During the Period of Contract, the price at which Supplier will supply drugs shall not exceed the lowest price charged by Supplier to any other customer during the Period of Contract and in the event of Supplier supplies drugs to any other customer at a price below the price bid of Supplier, it shall

promptly furnish such information to Purchaser in order to correspondingly revise the rate of subsequent supplies.

ix. The rates accepted by the Purchaser shall be binding on the Bidder during validity of the Bid and after execution of Contract for at least one year from the date execution of Contract. Any increase in the price will not be entertained till the completion of the Period of Contract.

x. Purchases may be made on staggered basis as per the requirement of the Purchaser.

xi. The total amount including taxes in column 8 of Annexure 11 (total amount in words) will only be considered for bid ranking.

xii. In case it is noticed that a drug name has appeared in Annexure A for more than one time, then in such cases the Bidder having quoted the least price among such item will be considered as L1

3.6. Language

3.6.1. The Bid and all related correspondence and documents in relation to the bidding process shall be in English language. Supporting documents and printed literature furnished by the Bidder with the Bid may be in any other language provided that they are accompanied by translations of all the pertinent passages in the English language, duly authenticated and certified by the Bidder. Supporting materials, which are not translated into English, may not be considered. For the purpose of interpretation and evaluation of the Bid, the English language translation shall prevail.

3.7. Format of Bid

3.7.1. The Bidder shall provide all the information sought under this RFP. The Purchaser will evaluate only those Bids that are received in the required formats, in specified sequence, duly paginated and complete in all respects. Incomplete and /or conditional Bids shall be liable to rejection.

3.8. Number of Bids and Cost of bidding:

3.8.1. No Bidder shall submit more than one Bid under the Tender Document. A Bidder applying shall not be entitled to submit another Bid.

3.8.2. The Bidder shall bear all costs associated with the preparation and submission of their online bids and the Purchaser will in no case be responsible or liable for those costs, regardless of the conduct or outcome of the bidding process.

3.9. Amendment of Tender document:

3.9.1. At any time prior to the Bid Due Date, the Purchaser may amend the Tender Document by issuing addendum/corrigendum.

3.9.2. Any addendum/corrigendum as well as clarification thus issued shall be a part of the Tender Document. And it will be assumed that the information contained in the amendment will have been taken into account by the Bidder. Any addendum / corrigendum thus issued hereunder shall be hosted on the E-Tender portal.

3.9.3. To give prospective Bidders reasonable time in which to take the amendment into account in preparing their bids, the Purchaser shall extend, at its discretion, the deadline for submission of Bids, in which case, the Purchaser will notify all Bidders by placing it on Official Websites.

3.10. Acknowledgement by Bidder

3.10.1. It shall be deemed that by submitting the Bid, the Bidder has:

i. made a complete and careful examination of the Tender Documents.
ii. received all relevant information requested from the Purchaser.
iii. satisfied itself about all matters, things, and information necessary and required for submitting an informed Bid, . of the Contract/ Purchase Order in accordance with the Tender Document and performance of all of its obligations thereunder.
iv. acknowledged and agreed that inadequacy, lack of completeness or incorrectness of information provided in the Tender Documents shall not be a basis for any claim for compensation, damages, extension of time for performance of its obligations, loss of profits etc. from the Purchaser, or a ground for termination of the Contract by the Supplier;
v. acknowledged that it does not have a Conflict of Interest; and
vi. agreed to be bound by the undertakings provided by it under and in terms hereof.

3.10.2. The Purchaser shall not be liable for any omission, mistake or error in respect of any of the above or on account of any matter or thing arising out of or concerning or relating to the tender process or the bidding process, including any error or mistake therein or in any information or data given by the Purchaser.

3.11. Right to accept or reject any or all Bids.

3.11.1. Notwithstanding anything contained in this Tender Documents, the Purchaser reserves the right to accept or reject any Bid and to annul the bidding process and reject all Bids, at any time without any liability or any obligation for such acceptance, rejection, or annulment, and without assigning any reasons therefor. In the event that the Purchaser rejects or annuls all the Bids, it may, in its discretion, invite all eligible Bidders to submit fresh Bids hereunder.

3.11.2. The Purchaser reserves the right to reject any Bid if:

i. at any time, a material misrepresentation is made or uncovered, or
ii. the Bidder does not provide, within the time specified by the Purchaser, the supplemental information sought by the Purchaser for evaluation of the Bid.

Such misrepresentation/ improper response shall lead to the disqualification of the Bidder.

3.11.3. If disqualification/ rejection of a Bidder occurs after the Bids have been opened and the lowest Bidder gets disqualified/ rejected, then the Purchaser reserves the right to:

i. invite the remaining Bidders to match the Lowest Bidder rate in accordance with the Tender Documents; or
ii. take any such measure as may be deemed fit in the sole discretion of the Purchaser, including annulment of the bidding process.

3.11.4. In case it is found during the evaluation or at any time before signing of the Contract or after its execution and during the period of subsistence of Purchase Order that one

or more of the qualification conditions have not been met by the Bidder, or the Bidder has made material misrepresentation or has given any materially incorrect or false information, the Bidder shall be disqualified forthwith if not yet appointed as the Supplier either by issue of the NOA or entering into the Contract, and if the Bidder has already been issued the NOA or has entered into the Contract, as the case may be, the same shall, notwithstanding anything to the contrary contained therein or in this Tender Document, be liable to be terminated, by a communication in writing by the Purchaser to the Bidder, without the Purchaser being liable in any manner whatsoever to the Bidder. The Purchaser shall be entitled to forfeit and appropriate the EMD or Performance Security, as the case may be, as damages, and without prejudice to any other right or remedy which the Purchaser may have under this Tender Document, the Contract, Purchase Order or otherwise.

3.11.5. The Purchaser reserves the right to verify all statements, information and documents submitted by the Bidder in response to the Tender Documents and the Bidder shall, when so required by the Purchaser, make available all such information, evidence and documents as may be necessary for such verification. Any such verification or lack of such verification by the Purchaser shall not relieve the Bidder of its obligations or liabilities hereunder nor will it affect any rights of the Purchaser thereunder.

3.11.6. The Purchaser may, in its sole discretion and on grounds of reciprocity, disqualify a Bidder, if any or all of its constituents are entities incorporated in a country where an entity incorporated in India does not have similar rights of bidding for contracts contemplated hereunder.

3.12. Pre-Bid Meeting

3.12.1. The pre-bid meeting will be held at the date, time and venue mentioned in the bid notice and Bid Schedule. The Bidder shall note that, any corrigendum issued regarding this bid notice will be published on the https://mahatenders.gov.in.

3.12.2. A prospective Bidder requiring any clarification of the Tender document shall contact the Purchaser by letter or email to submit their suggestions/ observations/ Queries if any**,** preferably prior to the date of pre bid meeting on GEM portal or through Maha Tender Portal.

3.12.3. Only suggestions / observations related to Tender Documents, received in writing within stipulated time will be discussed and clarified in pre-bid meeting and any modification of the Tender documents, which may become necessary as a result of pre-bid meeting, shall be made by Purchaser exclusively through the issue of an addendum/ corrigendum. The bid uploaded shall be read along with any modification. Authorized representatives of prospective Bidder(s) can attend the said meeting and obtain clarification regarding specifications, scope of works & tender conditions. Authorized representatives should have authorization letter to attend the pre-bid meeting, subject to the condition that queries are submitted in time.

3.12.4. Any amendment to the Tender Document shall be placed on the E-Tender Portal (https://mahatenders.gov.in)/ GEM portal or on official website-mmgpa.maharashtra.gov.in

3.12.5. The Bidder will not be communicated separately regarding the amendment.

3.12.6. Non-attendance at pre-bid meeting shall not be a cause for disqualification of the Bidder. The suggestions/ objections/ queries received in pre-bid meeting may not be considered, if the same are not in consonance with the requirement of the bid. Purchaser reserves the right to reject the same.

3.13. Clarifications post Pre bid Meeting

3.13.1. Bidders requiring any clarification on the Tender Document may notify the Purchaser in accordance with Clause 3.12. They should send in their queries on or before the date specified in the Bid schedule of bidding process. The Purchaser shall endeavour to respond to the queries within reasonable time. The Purchaser will post all the queries and its responses on the E-Tender Portal (https://mahatenders.gov.in)/ GEM portal or on official website- mmgpa.maharashtra.gov.in

3.13.2. The Purchaser may respond to the questions raised or clarifications sought by the Bidders in writing. However, the Purchaser reserves the right not to respond to any question or provide any clarification, in its sole discretion, and nothing in this Clause shall be taken or read as compelling or requiring the Purchaser to respond to any question or to provide any clarification.

3.14. Modification/substitution/withdrawal of Bids

3.14.1. No Bid shall be modified, substituted or withdrawn by the Bidder on or after the closing time on the Bid Due Date.

3.14.2. Any alteration/ modification in the Bid or additional information or material supplied subsequent to the closing time on the Bid Due Date, unless the same has been expressly sought for by the Purchaser, shall be disregarded.

3.15. Proprietary data

3.15.1. All documents and other information supplied by the Purchaser or submitted by a Bidder to the Purchaser shall remain or become the property of the Purchaser. Bidders are to treat all information as strictly confidential and shall not use it for any purpose other than for preparation and submission of their Bid. The Purchaser will not return any Bid, or any information provided along therewith.

3.16. Correspondence with the Bidder

3.16.1. No tenderer shall contact MMGPA, on any matter relating to its Bid, from the time of bid opening to the time of contract is awarded.

3.16.2. Any effort by the tenderer to influence MMGPA, in the purchasers bid evaluation, bid comparison or contract award decisions may result in rejection of the tenderers bid.

3.16.3. The tenderer shall not make any attempt to establish unsolicited and unauthorized contact with MMGPA or tender scrutiny committee after opening of the bids and prior to the notification of award and any attempt by any tenderer to bring to bear extraneous pressure on the tender accepting authority, tender inviting authority or tender scrutiny committee, shall be sufficient reason to disqualify the tenderer.

3.16.4. Notwithstanding anything contained in clause (3.16.3.) above MMGPA, may seek bonafide clarifications from the Bidders relating to the bid submitted by them during the evaluation of bids.

3.17. Opening and Evaluation of Bids

3.17.1. The Purchaser shall open the Technical Bids on the Bid Due Date as specified in Bid Schedule, online portal www.mahatenders.gov.in/ GEM Portal and in the presence of the Bidders who choose to attend.

3.17.2. The Purchaser will subsequently examine and evaluate Bids in accordance with the provisions set out in this Tender Document.

3.17.3. Bids of firms who have furnished all the required documents for each of the drug quoted alone will be considered. A firm quoting for more than one drug and if the required/proper document is not furnished for any of the drug(s), then offer of that drug(s) will be rejected. Utmost care should be taken to see that all the required/proper documents are uploaded.

3.17.4. **Test of Responsiveness:**

Prior to evaluation of Bids, the Purchaser shall determine whether each Technical Bid is responsive to the requirements of the Tender Document. A Technical Bid shall be considered responsive if:

i. it is received as per the specified format and sequence mentioned in Clause 3.5;

ii. the following mandatory documents are submitted with the Bid online, as on Bid Due Date:

a. in case of exemption claimed for Tender Fee and EMD, attested copy of valid registration made by manufacturer for offered product under Micro & Small, Medium Industries Development Act, 2006.

b. Copy of valid manufacturing drug license with product list duly approved by the Licensing Authority/ State drug authority for each and every product quoted as per specification in the bid. The license must have been duly renewed up to date and the items quoted shall be clearly highlighted in the product permission with their respective drug code as mentioned in the Appendix-A;

c. World Health Organization-Good Manufacturing Practice (with product list or COPP);

d. it is accompanied by the Technical Specifications and Compliance as per the Annexure-1;

e. it is accompanied by the Letter comprising Technical Bid as per theAnnexure-2;

f. it is accompanied by the Proforma for Production and Sale Statement as per theAnnexure-3;

g. it is accompanied by the Details of Manufacturing Unit as per theAnnexure-4;

h. it is accompanied by the Annual Turnover Statement for Three Years) along with Copies of Balance Sheet and Profit and Loss Accounts for last three years i.e., (2022-23, 2023-24, 2024-25) certified by the Statutory Auditor or Chartered Accountant., as per theAnnexure-5;

i. it is accompanied by the Copy of certificate of incorporation/registration along with charter documents and GST Registration certificate;

j. it is accompanied by the Affidavit for Blacklisting as per theAnnexure-8;

k. it is accompanied by the Affidavit for Litigation as per theAnnexure-9; and

iii. it is not non-responsive in terms hereof.

The Purchaser reserves the right to reject any Bid which is non-responsive and no request for alteration, modification, substitution or withdrawal shall be entertained by the Purchaser in respect of such Bid. Provided, however, that the Purchaser may, in its discretion, allow the Bidder to rectify any infirmities or omissions if the same do not constitute a material modification of the Bid.

3.17.5. The technical evaluation shall be on the basis of documents submitted and relevant standards of pharmacopoeia and provisions of Drugs and Cosmetics Act 1940 and Drugs and Cosmetics Rules 1945. Each item/medicine will be evaluated separately. Purchaser may at its discretion call for any documents for verification and the Bidder shall be duty bound to produce the same documents before the tender evaluation committee within stipulated time period. The status of bidders/items after technical bid evaluation will be published on the portal www.mahatenders.gov.in/GEM Portal and shall be final.

3.17.6. After the evaluation of Technical Bids, the Purchaser would announce a list of qualified Bidders who will be eligible for opening of their Price Bids. All communications relating to qualification shall be uploaded on Official Website. The Purchaser will not entertain any query or clarification from Bidders who fail to qualify.

3.17.7. Any information contained in the Bid shall not in any way be construed as binding on the Purchaser, its agents, successors or assigns, but shall be binding against the Bidder if the Contract is subsequently awarded to it on the basis of such information.

3.17.8. The Purchaser reserves the right not to proceed with the bidding process at any time without notice or liability and to reject any or all Bid(s) without assigning any reasons.

3.18. Confidentiality

3.18.1. Information relating to the examination, clarification, evaluation, and recommendation of the Bidders shall not be disclosed to any person who is not officially concerned with the process or is not a retained professional advisor advising the Purchaser in relation to, or matters arising out of, or concerning the bidding process. The Purchaser will treat all information, submitted as part of Bid, in confidence and will require all those who have access to such material to treat the same in confidence. The Purchaser may not divulge any such information unless it is directed to do so by any statutory entity that has the power under law to require its disclosure or is to enforce or assert any right or privilege of the statutory entity and/ or the Purchaser or as may be required by law or in connection with any legal process.

3.19. Clarifications regarding Evaluation

3.19.1. To facilitate evaluation of Bids, the Purchaser may, at its sole discretion, seek clarifications from any Bidder regarding its Bid. Such clarification(s) shall be provided within the time specified by the Purchaser for this purpose. Any request for clarification(s) and all clarification(s) in response thereto shall be in writing.

3.19.2. If a Bidder does not provide clarifications sought under Clause 3.19.1 above within the prescribed time, its Bid may be rejected. In case the Bid is not rejected, the Purchaser may proceed to evaluate the Bid by construing the particulars requiring clarification to the best of its understanding, and the Bidder shall be barred from subsequently questioning such interpretation of the Purchaser.

3.19.3. Bidder shall ensure that, all correspondence with the Purchaser shall be through the official email id mentioned in Annexure 4 submitted by the Bidder.

3.20. Selection of Bidder

3.20.1. The Bidders are required to register on the e-Tender Portal for submission of their Bids in accordance with the procedure set out therein. Bidders are requested to visit the e-Tender Portal for the details related to online registration and submission of Bids. A Bidder may familiarize itself with the e-Tender Portal and in accordance with the instructions given on the e-Tender Portal (Bidders Manual Kit) and the terms of the Tender Document, submit its Bid. To participate in the bidding process, the Bidder should complete all stages of purchase, download of Tender Document from e-Tender Portal and undertake the final Bid submission through the e-Tender Portal. Bids which are submitted on the e-Tender Portal alone will be accepted by the Purchaser .

3.20.2. A Bidder may submit its Price Bid for one or more drugs in accordance with terms of this Ternder Document. A Bidder is required to furnish all the specified documents in respect of each drug for which the Bidder submits its Price Bid.

3.20.3. Bids of Bidder who have furnished all the required documents in respect of each of the drug quoted alone will be considered. If a Bidder does not submit the required document complete in all respects as per the terms herein, then offer related to such drug(s) will be rejected. Utmost care should be taken to see that all the required documents are uploaded.

3.20.4. The Bidder's whose Bids are determined to be responsive to the requirements outlined in clause 3.17.4 shall be eligible for technical evaluation in accordance with clause 4.1 of the Tender Document.

3.20.5. The Bidder who meets the technical eligibility criteria and requirements of Supporting documentation (as per clause 4.1) shall be eligible for opening of the Price Bid.

3.20.6. After the conclusion of Price Bid opening (Envelope 2), the lowest offer of the Bidder(s) for the respective drug(s) will be considered for negotiation and respective L1 rates shall be arrived after negotiation for the drug(s). The Bidder(s) offering the L1 rate for the specified drug(s) will be declared as the selected Bidder for those drug(s) ("**Supplier**").

3.20.7. In the event that 2 (two) or more Bidders are qualified in terms hereof as L1 (referred to as "tie bidders"), then such Bidder having the higher production capacity as per

the eligibility criterion would be given first preference. Further, if tie Bidders are found to be having the same production capacity, then the Bidder having higher average annual turnover as per the eligibility criterion shall be taken into consideration and would be given first preference. Such Bidder shall execute necessary Contract as specified in the Tender Document. On depositing the required amount as Performance Security and on execution of the agreement, such Bidder will be eligible for the placement of Purchase Orders.

3.20.8. This tender is governed under the provisions of the Revised Manual of Office Procedures for Procurement by the Government Departments" issued by Department of Industries and Labour, government of Maharashtra vide GR dated 1.12.2016 or any subsequent amendment thereto. The purchase preference shall be in full adherence to the guidelines specified under the aforementioned manual. In case of any inconsistency between the purchase preference mentioned in this Tender Document, the same shall be resolved in accordance with provision of Revised Manual of Office Procedures for Procurement by the Government Departments and the same shall prevail.

3.20.9. Subject to clause 3.20.8 above, the Bidders from Maharashtra and / or MSME and / or SC/ST MSME, as the case may be, who have qualified for Price Bid (Envelope 2) opening, will be informed by the Purchaser of the lowest rate received for the drugs quoted by such Bidder and inviting their consent to match with the lowest rate for those drug(s). The Bidders who agree to match L1 Price Bid, will be considered as L1 Bidder. For the purpose of this Tender, the Bidders from Maharashtra would have the meaning as ascribed in Clause 3.1.2.8 of the Revised Manual of Office Procedures for Procurement by the Government Departments or any subsequent amendment thereto. On depositing the required amount as Performance Security and on execution of the Contract, such Bidder will be eligible for the placement of Purchase Orders for the quantities determined as per the provisions of "Revised Manual of Office Procedures for Procurement by the Government Departments.

3.20.10. The Bidder mentioned at clause 3.20.9 above, who matches the L1 Price Bid, on placement of Purchase Order, will be deemed as L1 Bidder for the purpose of the tender and all provisions of the Tender Documents applicable to L1 Bidder will apply mutatis mutandis to the Supplier who matches the L1 Price Bid.

3.20.11. Purchaser will issue Notification of Award to the L1 Bidder (L1) specifying the quantity for which the Tender is awarded and requiring the Bidder to execute a contract in the prescribed format and to furnish the Performance Security within 15 days from the issuance of Notification of Award, so as to become a Supplier.

3.20.12. The L1 bidder shall within 2 (two) days from the receipt of NOA submit to Purchaser its acceptance to Notification of Award.

3.20.13. The L1 Bidder on submission of acceptance to Notification of Award and Performance Security to the satisfaction of Purchaser, shall execute necessary Contract as per the format specified in Schedule-1 for the supply of the tendered quantity of such drug(s) as specified in the Tender Document.

3.21. Unethical Practices

3.21.1. The Purchaser as well as Bidders shall observe the highest standard of ethics during the procurement and execution of such contracts. For the purpose of this Tender Document Unethical Practices shall mean the following:

i. "Corrupt practice" means the offering, giving, receiving or soliciting of anything of value to influence the action of a public official in the procurement process or in contract execution;

ii. "Fraudulent practice" means a misrepresentation or omission of facts in order to influence a procurement process or the execution of a Contract to the detriment of Purchaser and includes collusive practice among bidders (prior to or after bid submission) designed to establish bid prices at artificial non-competitive levels and to deprive the Purchaser of the benefits of free and open competition;

iii. "Collusive practice" means a scheme or arrangement between two or more bidders, with or without the knowledge of the Purchaser, designed to establish bid prices at artificial, non-competitive level; and

iv. "Coercive practice" means harming or threatening to harm, directly or indirectly, persons or their property to influence their participation in the procurement process or effect the execution of the Contract.

3.21.2. The Purchaser will reject a bid for award if it determines that the bidder recommended for award and/or execution of Contract has directly or through an agent has engaged in the abovementioned unethical practices at any point of time during bidding process or after execution of Contract. The Purchaser reserves the right to terminate the Contract, forfeit EMD/ Performance Security (as applicable) and debar/blacklist the Supplier from participating in any future Tender published by the Purchaser.

3.22. Code of Integrity

3.22.1. Any person participating in a procurement process shall-

i. Not offer any bribe, reward or gift or any material benefit either directly or indirectly in exchange for an unfair advantage in procurement process or to otherwise influence the procurement process.

ii. Not misrepresent or omit or mislead or attempts to mislead so as to obtain a financial or other benefit or avoid an obligation.

iii. Not indulge in any collusion, bid rigging or anti-competitive behavior to impair the transparency, fairness and progress of the procurement process.

iv. Not misuse any information shared between the Purchaser and the Bidders with an intent to gain unfair advantage in the procurement process.

v. Not obstruct any investigation or audit of a procurement process.

vi. Disclose conflict of interest, if any; and

vii. Disclose any previous transgressions with any Entity in India or any other country during the last three years or any debarment by any other procuring entity.

3.22.2. The Purchaser will reject a bid for award if it determines that the Bidder recommended for award and/or execution of Contract has directly or through an agent has breached the above Code of Integrity at any point of time during bidding process or after execution of Contract. The Purchaser reserves the right to terminate the Contract, forfeit EMD/ Performance Security (as applicable) and debar/blacklist the Supplier from participating in any future Tender published by the Purchaser.

3.23. Payment Provisions

3.23.1. Payment against supply order issued under this bid will be made by Chief Account & Finance officer, Maharashtra Medical Goods Procurement Authority, Mumbai. 100% Payment shall be made on fulfilling the below mentioned conditions:

i. upon submission of following documents by the Supplier:

a. 3 copies of Supplier's invoice,
b. Receipt and acceptance certificates issued by the consignees on E-Aushadhi, and
c. Batch wise in-house Lab Report.

ii. Purchaser shall make payments of the quantity supplied for drugs which are declared to be of standard quality (SQ) by Purchaser empaneled labs.

3.23.2. Payments towards the supply of Drugs will be made strictly as per the rules of Purchaser. The payment will be made through RTGS/ NEFT. The Bidder shall furnish the relevant details in original to make the payment through RTGS/NEFT and the change of bank account during the validity of the bid will not be entertained normally.

3.23.3. The Purchaser shall have every right to deduct the pending dues on account of loss, compensation, or any remedial action in monetary terms from the said payment. The Supplier shall not agitate the said issue in future.

3.24. Termination of Contract

3.24.1. The Purchaser reserves the right to terminate the Contract on the below mentioned grounds:

A. In case the Drugs are declared "Misbranded" 'Adulterated' & Spurious' as per the applicable laws:
   i. The contract of the Bidder for the said item will be cancelled.
   ii. The extra expenditure incurred if any because of Risk Purchase shall be recovered from the Supplier.
   iii. EMD or Performance Security, as applicable, of the Supplier will be forfeited.
   iv. Purchase cost of full order if paid, irrespective of its consumed quantity shall be recovered from the Supplier from the outstanding bills or Performance Security .
   v. The drugs which are not used but belong to the said substandard batch shall be destroyed by the concerned DDO in the presence of/or under intimation to Food and Drug Administration officials. The necessary expenditure incurred for this shall be recovered from the Supplier.
   vi. The Supplier will be debarred from participating in any future Tender published by the Purchaser as per the terms of this Tender Document.

B. In case the Drugs are declared "Not of Standard Quality" as per the Applicable Laws:
   I. The cancellation of Contract for the specified item shall be decided by the Chief Executive Officer, Maharashtra Medical Goods Procurement Authority, Mumbai, after reviewing the severity of sub-standard quality of item with the FDA Maharashtra. The testing report issued by FDA approved laboratory regarding quality shall be final & binding on the Supplier.
   II. The extra expenditure incurred if any because of Risk Purchase shall be recovered from the Supplier.
   III. Purchase cost, if paid, of full order irrespective of its consumed quantity shall be recovered from the Supplier from the outstanding bills or Performance Security.
   IV. The goods which are not used but belong to the said substandard batch shall be destroyed by the concerned DDO in the presence of/or under intimation to Food and Drug Administration officials. The necessary expenditure incurred for this shall be recovered from the Supplier.

C. In case it is determined, post award of Tender, that the Supplier has charged prices higher than allowed as per DPCO, NPPA for the quoted drug or higher than MRP (only in cases where DPCO, NPPA rates are not available), or has failed to supply the drugs consistently, the Supplier will be declared as fraudulent and defaulter and in such case: -
   I. The extra expenditure incurred due to higher prices charged over and above ceiling price as per DPCO, NPPA / MRP (as applicable) or in case of Risk Purchase shall be recovered from the Supplier.
   II. The Contract shall be terminated, Supplier's EMD/Performance Security, as applicable, will be forfeited and the Supplier will be debarred for next three years from participating in any future Tender published by the Purchaser.

D. In case if found that the Bidder has submitted forged documents the following actions will be taken against the Bidder: -
   I. A police case will be filed against the bidder.
   II. The Bidder's EMD or Performance Security, as applicable, will be forfeited.
   III. The bidder will be debarred for next three years from participating in any future Tender published by the Purchaser.
   IV. The Contract already entered into will be liable for termination.

E. In case if found that the drugs & other item supplied by the Supplier have been declared "Not of Standard Quality" as per the Applicable Law the actions will be taken as per Maharashtra Medical Goods Procurement Authority Regulations, 2025 and terms outlined in this Tender Document.

F. In case, the Supplier becomes bankrupt or otherwise insolvent, the Purchaser reserves the right to terminate the contract at any time, by serving written notice to the Supplier without any compensation, whatsoever, to the Supplier, subject to

further condition that such termination will not prejudice or affect the rights and remedies which have accrued and/or will accrue thereafter to the Purchaser.

G. Termination for convenience: - The Purchaser reserves the right to terminate the contract, in whole or in part for its (Purchaser's) convenience, by serving written notice on the Supplier at any time during the currency of the Contract. The notice shall specify that the termination is for the convenience of the Purchaser. The notice shall also indicate inter alia, the extent to which the Supplier's performance under the Contract is terminated, and the date with effect from which such termination will become effective.
The Purchaser will be at liberty to terminate the contract either wholly or in part on 30-day notice. The Supplier will not be entitled for any compensation whatsoever in respect of such termination.

3.25. Dispute Resolution

3.25.1. In the event of any question, dispute or differences in respect of Contract or terms and conditions of the Contract or interpretation of the terms and conditions or part of the terms and conditions of the Contract arises, the parties shall make every effort to resolve, amicably by direct informal negotiation.

3.25.2. In the event of failure to settle the dispute amicably between the parties, the same shall be referred to the sole arbitrator as mutually appointed by the parties. In case, the parties fail to appoint the sole arbitrator mutually, in such case, board of three arbitrators, of whom each Party shall appoint one, and the third arbitrator shall be appointed by the two arbitrators so selected, and in the event of disagreement between the two arbitrators, the appointment shall be made in accordance with the Indian Arbitration and Conciliation Act, 1996 and the rules made thereunder.

3.25.3. The arbitrators shall make a reasoned award (the "Award"). Any Award made in any arbitration held pursuant to this Clause 3.25 shall be final and binding on the parties as from the date it is made, and the Supplier and the Purchaser agree and undertake to carry out such Award without delay.

3.25.4. The arbitration proceedings shall be carried out as per the Indian Arbitration and Conciliation Act, 1996 and the rules made thereunder.

3.26. Governing law and jurisdiction

3.26.1. This Contract shall be construed and interpreted in accordance with and governed by the laws of India, and the courts at Mumbai shall have exclusive jurisdiction over matters arising out of or relating to this Contract.

3.27. Indemnification

3.27.1. The Supplier shall indemnify the Purchaser against all actions, suit, claims and demand or in respect of anything done or omitted to be done by Supplier in connection with the Contract and against any losses or damages to the Purchaser in consequence of any action or suit being brought against the Supplier for anything done or omitted to be done by the Supplier in the execution of the Contract. .

3.28. Saving clause:

3.28.1. No suits, prosecution or any legal proceedings shall lie against the Purchaser, or any person for anything that is done in good faith or intended to be done in pursuance of this tender.

3.29. Force Majeure

3.29.1. For purpose of this clause, Force Majeure means an event beyond the control of successful Purchaser and not involving the successful tenderers fault or negligence and which is not foreseeable and not brought about at the instance of, the party claiming to be affected by such event and which has caused the non-performance or delay in performance. Such events may include, but are not restricted to, acts of the Purchaser either in its sovereign or contractual capacity, wars or revolutions, hostility, acts of public enemy, civil commotion, sabotage, fires, floods, explosions, epidemics, quadrant quarantine restrictions, strikes excluding by its employees, lockouts excluding by its management, and freight embargoes. Scarcity of raw materials/increase in the cost of raw material/shifting/up gradation of manufacturing facilities and power cut are not considered as Force Majeure.

3.29.2. If a Force Majeure situation arises, the successful tenderer shall promptly notify the Purchaser in writing of such conditions and the cause thereof with satisfactory documentary proof, within ten days of occurrence of such event. The time for making supply may be extended by the Purchaser as its discretion for such period as may be considered reasonable.

3.29.3. In case due to a Force Majeure event the MMGPA is unable to fulfil its contractual commitment and responsibility, the MMGPA will notify the successful tenderer accordingly and subsequent actions taken on similar lines described in above sub-paragraphs.

Section 4: Specific Terms and Conditions

This section deals with the specific conditions of contract and contains the following terms & conditions governing the tender.

4.1. Eligibility Criteria and Supporting Documents to be Submitted

Sr. No.	Basic Requirement	Specific Requirement	Documents required
1	**Registered Legal Entity**	The Bidder may be a natural person, private entity, government-owned entity. registered under applicable laws in India ("**Bidder**"). The Bidder shall be – a. Registered with the GST Authorities.	Copy of certificate of incorporation/registration along with charter documents like copy of Memorandum and Articles of Association, and other registration documents according to the nature of entity.

Sr. No.	Basic Requirement	Specific Requirement	Documents required
		b. Should have a valid PAN number.	Copy of GST Registration certificate issued by GSTN authorities. Copy of PAN Card.
2	**Licenses**	The Bidder must have valid manufacturing license/ import license for the drugs quoted as per technical specifications in the Tender Documents: a. Only manufacturer/ importer (i.e., authorized agent/subsidiary of the foreign manufacturer) will be allowed as Bidder. b. Loan Licensee / third party licensee are not permitted to participate under this Tender Document.	Self-attested copies of original manufacturing license in Form 25, 28, 28-D, 28-E, MD-5, MD-9 etc. approved by the Licensing authority along with retention Licenses. Or Self-attested copies of original import license in Form-10 or Form 10-A (as applicable), Form-41, MD-15 etc., and licenses in Form 20B/21B approved by the corresponding licensing authority with retention licenses. Or Self-attested copies of licenses in Form CT-20, Form CT-23 in case of new drugs. Further, during supply of drugs, if the drugs are manufactured at more than one premises, the Bidder shall submit the applicable license such as the manufacturing license, for each such premises mandatorily. Authority letter of the original manufacturer for importing the product for which bid is offered or agreement between foreign manufacturer and importer. The drugs quoted shall be highlighted in the product permission with their respective drug code as mentioned in the

Sr. No.	Basic Requirement	Specific Requirement	Documents required
			Appendix-A (Schedule of Requirement)
3	**Certifications/ Registration**	WHO-GMP (WHO - Good Manufacturing Practices Certificate) Certificate issued by the licensing authority. The WHO-GMP certificate must not be older than one year from the Bid Due Date in case where validity is not mentioned in the certificate. The WHO-GMP certificate of all the manufacturing plants, of which products have been quoted, should be submitted. The Importer should produce WHO-GMP / COPP of the manufacturing firm or a certificate which is at par with WHO-GMP issued by exporting countries like US-FDA approval, etc. In the case of imported drugs, labels and product literature of all quoted products must be submitted.	For manufacturers, WHO-GMP certificate with product list OR COPP, Quality management System (QMS) as per Medical Devices Rules, 2017 issued by the licensing authority wherever applicable. For importers, labels and product literature of all quoted drug(s) must be uploaded with WHO-GMP or certificate which is at par with WHO-GMP issued by the authorities of exporting countries of their principal manufacturing company or firm. Authority letter from OEM for the offered drug and valid import license issued by licensing authority. Import Export Certificate (IEC Code) for importer.
4	**Past Experience**	The Bidder must submit particulars of quantity of the past supplies of drugs made as per Annexure 3. **Note: At least 25% quantity** for **similar drug as specified in the Annexure 1- Technical Specification and**	Certificate issued by a statutory auditor/chartered accountant (as attached Annexure-3)

Sr. No.	Basic Requirement	Specific Requirement	Documents required
		in the Schedule of Requirements' must have been supplied for any of the last 3 (three) financial years preceding the Bid Due Date, i.e., 2022-23 ,2023-24,2024-25.	
5	**Average Annual Turnover**	Average Annual Turnover (in last three financial years 2022-23,2023-24,2024-25 shall be Rs. -------/-	Certificate issued by a statutory auditor/chartered accountant (as attached Annexure-6) along with audited financial statements confirming the average annual Turnover of the Bidder during the stated financial years must be submitted. The turnover should be as certified by the chartered accountant/statutory auditor (specifying UDIN) and having valid registration. Note: In case the annual accounts for the latest financial year are not audited and therefore the Bidder cannot make it available, the Bidder shall give an undertaking to this effect and the chartered accountant/statutory auditor shall certify the same. In such a case, the Bidder shall provide the audited financial statements for the financial year preceding the latest financial year for which the audited annual report is not being provided.
6	**Net Worth**	The net worth of the bidder in the financial year immediately preceding the Bid Due Date should be **positive**.	Certificate issued by a statutory auditor/chartered accountant (as attached **Annexure-6).** The Net Worth should be as certified by the chartered accountant/ statutory auditor (specifying UDIN) and having valid registration.

Sr. No.	Basic Requirement	Specific Requirement	Documents required
7	**Production Capacity**	Production capacity of the original drug manufacturer must be minimum 1.5 times of the quoted order quantity in last one financial year.	Certificate of Statutory Auditor/Chartered Accountant. As per Annexure 4.
8	**Market Standing Certificate**	Bidder should mandatorily possess 3 years Market Standing Certificate (i.e., for financial year 2022-23 and 2023-24 and 2024-25) as a manufacturer/importer for each drug(s) quoted in the tender as on Bid Due Date. The period of Market Standing will be reckoned from the date of issue of product/drug permission. In case of an importer, their principal manufacturer located overseas should have 3 years market standing in India and the importer shall have 3 years market standing in the pharmaceutical field. In cases involving new drugs/ drugs out of patent period it is sufficient to possess relevant market standing as applicable.	Market Standing Certificate as issued by Central or State Licensing Authority under the Applicable Law. Bill of landing of a foreign manufacturer and bill of entry of the importer, mentioning the country of origin. Notarized/ certified copy of Drug Controller General of India, new Delhi, for permission for Items coming under, "New Drug and Fixed Dose Combinations" in form 45/46 as per Drugs & Cosmetic Act and Rules. Relevant period Market standing certificate for new drug/drugs out of patent period issued by licensing authority.
9	**Proof of distribution network**	Bidders, if not having their registered office, manufacturing unit, or distribution facility within Maharashtra State, must have an established and operational distribution network in Maharashtra State at the time of bid submission.	Proof of distribution network—such as a valid drug selling/distribution license issued by the state's licensing authority, along with details of authorized distributors (names, addresses, contact details) — must be submitted as part of the bid documentation **Annexure 4 (A) and Copy of License od Sale / Distribution issued by State's Licensing Authority**

Sr. No.	Basic Requirement	Specific Requirement	Documents required
10	**Blacklisting or banned**	On the Bid Due Date, the Bidder should not be blacklisted or debarred by any ministry/department /attached offices/sub-ordinate offices under Government of India and any State government, Autonomous bodies (established by Central/State govt), any Central/State PSUs for unsatisfactory past performance, corrupt, fraudulent or any other unethical business practices. The bidder, whose drug has been declared as misbranded, spurious or adulterated or any criminal case in respect of the above is pending in any court, as on Bid Due Date shall not be eligible to participate for that particular drug, in the bid. Similarly, a Bidder convicted by court of law shall not be eligible to participate in the bid. The Bidder(s) quoting for this Tender Document should not have been convicted as on Bid Due Date by any court of law in India/overseas in lieu of deficiency noticed in the any of the quoted drug(s) in the tender and tender should not be submitted for such drugs for which conviction was pronounced by any court of law).	Affidavit as per **Annexure 8** Non-Conviction Certificate issued by licensing authority/ State FDA

Sr. No.	Basic Requirement	Specific Requirement	Documents required
11	**Litigation**	The Bidder should not be involved in any major litigation such as fraud, FEMA violations and any other civil or criminal proceedings that may have an impact of affecting or compromising the delivery of services as required under this contract.	Affidavit as per Annexure 9.
12	**EMD/Bid Security**	The EMD indicated under Clause 3.4 unless exempted under Clause 3.4.7, shall be the Rs. 25,000/- per item of drug quoted subject to minimum of Rs.2.00 lacs and maximum of Rs. 5.00 lacs.	EMD payment shall be done as per the Clause 3.4.
	EMD Exemption	If a Bidder is a Micro and Small Enterprise ("MSEs") / Small Scale Industry ("SSI") then subject to submission of relevant documents as provided in this table, such Bidder may be exempted from submitting EMD in accordance with Appendix-8 of Revised Manual of Office Procedures for Procurement by Government Departments.	Requisite Certificate of Micro and Small-scale manufacturing industries registered under Micro, Small and Medium Enterprises Development Act, 2006.
13	**Conflict of Interest**	On the date of submission of the Bid, the Bidder should not have any conflict-of-interest situation.	Undertaking by the authorized signatory as per Annexure 2

4.1.1. **Conflict of Interest:** The Bidder participating in a bidding process must not have a Conflict of Interest. A Conflict of interest is considered to be a situation in which a party has interests that could improperly influence that party's performance of official duties or responsibilities, contractual obligations, or compliance with Applicable Laws and regulations.

A Bidder may be considered to be in Conflict of interest with one or more parties in bidding process if, including but not limited to:

a. Have controlling partners/shareholders in common; or

b. Receive or have received any direct or indirect subsidy from any of them; or

c. Have the same legal representative for purposes of the Bid; or

d. Have a relationship with each other, directly or through common third parties, that puts them in a position to have access to information about or influence on the Bid of another Bidder, or influence the decisions of the Purchaser regarding the bidding process; or

e. The Bidder participates in more than one Bid in the same bidding process. Participation by a Bidder in more than one Bid for the same drug, will result in the disqualification of all Bids in which the Bidder is involved;

f. has a close business or family relationship with a staff with the Purchaser who: (i) are directly or indirectly involved in the preparation of the Tender document or specifications of the Tender Process, and/or the evaluation of bids; or (ii) would be involved in the implementation or supervision of resulting Contract unless the conflict stemming from such relationship has been resolved in a manner acceptable to the Purchaser throughout the tender process and execution of the Contract; and

g. The Bidder or any of its affiliates participated as a consultant in the preparation of the design or technical specification of the procurement of the drugs that are the subject of the Bid.

4.1.2. Bid should not be submitted for drug(s) for which the Bidder has been blacklisted/debarred either by Purchaser or by any other State/Central Government's organization/procurement agencies on the grounds of quality failure until completion of the penal period, and the bar subsists as on Bid Due Date.

4.1.3. Bid should not be submitted by any Bidder as a whole or for the specified drug(s) who have been blacklisted/debarred either by Purchaser or by any other State/Central Government's organization/procurement agencies/ autonomous bodies (established by Central/State govt), any Central/State PSUs on the grounds of unsatisfactory past performance, unethical practices such as fraudulent/corrupt practices etc., and the bar subsists as on Bid Due Date.

4.1.4. If any of the drug(s) of a Bidder have been blacklisted, during last 2 years from the Bid Due Date, such Bidder shall not be eligible to participate in this Tender Document for such drug(s). If it is found that the Bidder has quoted for any such drug as per the terms of this Tender Document, the Bidder shall be blacklisted for such particular drug for 2 (two) years and damages equivalent to EMD shall also be levied on the Bidder. In such situation, the Bid for remaining drugs (if quoted) will be considered further only if the damages are deposited before the completion of technical evaluation.

4.1.5. The Bidder, whose drug has been declared as of misbranded or spurious or adulterated quality and any criminal case is filed and pending in any court and subsists as on Bid Due Date, shall not be eligible to participate for that particular drug, under this Tender Document. Similarly convicted bidder shall also not be eligible to participate in the Bid.

4.1.6. If a Bidder has two or more separate manufacturing units at different sites/states, the Bidder will be allowed to submit only one Bid for all units but necessary document regarding separate manufacturing units will be submitted along with the Technical Bid. The Bidder will be allowed to submit only one Bid for one drug.

4.1.7. Any Bidder from a country which shares a land border with India will be eligible to Bid in this tender only if the Bidder is registered with the Competent Authority as provided in the Order (Public Procurement No. 1) dated 23rd July 2020 issued by the Ministry of Finance, Department of Expenditure Public Procurement Division. Provided further that the selected Bidder shall not be allowed to sub-contract works to any contractor from a country which shares a land border with India unless such contractor is registered with the Competent Authority as provided in the aforesaid Order. "Competent Authority" for the purpose of this clause means the Authority defined in Annex 1 of the Order (Public Procurement No. 1) dated 23rd July 2020 issued by the Ministry of Finance, Department of Expenditure Public Procurement Division.

4.1.8. This Tender Document is not transferable.

4.1.9. Any award of the Contract pursuant to this Tender Document shall be subject to the terms of Tender Documents.

4.2. Manufacturing/Importing and Product Permissions

4.2.1. Bidder should be a manufacturer duly licensed in Form 25/Form 28/ Form 28D/Form 28E/Form MD5 and Form MD9 (as per drugs quoted) with current validity/ retention issued by the State Licensing Authority (SLA)/Central Licensing Authority (CLA) as the case may be or a direct importer holding valid import license in Form 10 or Form 10-A as applicable, with Form 41/Form MD 15 issued by the Drugs Controller General of India (DCGI) accompanied with Licenses in Form 20B/21B with validity retention.

4.2.2. Bidder should have obtained permission to manufacture the drug(s) quoted strictly as per specification indicated in the Tender Document and in accordance with the standards specified in the Drugs and Cosmetics Act, 1940 from the competent authority such as state and/or central licencing authority.

4.2.3. In case of new drugs, import permission in Form CT-20 and manufacturing permission in Form CT-23 should be furnished in accordance with Rule 76/81 of the New Drugs and Clinical Trials Rules 2019 and Drugs and Cosmetics Act, 1940.

4.2.4. To ensure timely and smooth distribution of medicines, bidder, if not having their registered office, manufacturing unit, or distribution facility within Maharashtra State, must have an established and operational distribution network in Maharashtra State at the time of bid submission. Proof of such distribution network—such as a valid drug selling/distribution license issued by the state's licensing authority, along with details of authorized distributors (names, addresses, contact details) —must be submitted as part of the bid documentation

4.3. Minimum Tender Quantity

4.3.1. The details of the required drugs, etc., are shown in Appendix A. The Tender Quantity mentioned herein is not a fixed procurement quantity and it is only a tentative requirement and may be increased up to 50% or decreased by the Purchaser, at its discretion, depending on the actual need.

4.3.2. Though the tentative quantity is indicated in the Appendix A, the Purchaser, will confirm the actual requirement then and there only through Purchase Order(s). The Supplier shall supply the drugs only on the basis of the Purchase Order issued by the Purchaser. Any supply without a valid Purchase Order will not be accepted by MMGPA, for payment and the Purchaser, shall not be responsible for any loss on this account.

4.3.3. However, once the Purchase Order(s) are issued by the Purchaser, the Supplier should not renege from the commitment of supplying the quantity mentioned in the Purchase Order. The rates quoted shall also not be varied with the ordered quantity or the destination during the Contract Period.

4.4. Market Standing

4.4.1. Bidder should mandatorily possess 3 years Market Standing Certificate as a manufacturer/importer for each drug(s) quoted in the tender within the Bid Due date. The period of Market Standing will be reckoned from the date of issue of product/drug permission. In case of an importer, their principal manufacturer located overseas should have 3 years market standing in India and the importer shall have 3 years market standing in the pharmaceutical field. Also, the importer shall have due authorization for quoting drugs from the principal manufacturer along with relevant import licenses & marketing agreements as applicable. In the case of a new drug, bidder should possess relevant market standing as a manufacturer / importer from date of permission from DCGI and products (both of Plasma derived & recombinant categories) with USFDA certification, shall be considered with one-year global market standing. In cases involving any drugs out of patent period, it is sufficient to possess relevant market standing as applicable.

4.4.2. In cases of drug(s) with similar formulation but with varied strengths, market standing for 3 years for any strength of similar formulation shall be considered for all quoted drugs as equivalent, subject to possession of manufacturing license for the quoted drug(s) for a period not less than 3 years.

4.4.3. In case of imported drugs, market standing for the drug in international market would be considered for establishing eligibility regarding this particular clause of the bidding document. Also, if a bidder is manufacturing a drug abroad at various locations/countries and participating in the bid quoting a drug being manufactured at a particular place, market standing of the drug manufactured at other than particular place would be considered.

4.4.4. Bidder should have obtained permission to manufacture the drug(s) quoted as per specification in the tender and in accordance with the standards specified in the Drugs and Cosmetics Act, 1940 from the competent authority. The imported drug(s) should have valid import license by the competent authority. In both cases as indicated above, the permission provided by the Drug Controller General of India (DCGI) shall be in possession as applicable.

4.5. Inspection of Manufacturing Facilities

4.5.1. Purchaser may, at its discretion, conduct a inspection with the Drug Inspector of the manufacturing premise.

4.5.2. Inspections of the production and related facilities of Bidders/ Suppliers will be at the discretion of the Purchaser. Such inspection may be at any stage after the Bidder is technically qualified for opening of Price Bid.

4.5.3. Where inspections are conducted as above, all parts of the manufacturing units including the quality control section will be subjected to rigorous inspection/auditing, irrespective of the items quoted. The Bidder/Supplier shall provide necessary co-operation for inspection of all the sections of the manufacturing unit. The denial of permission to inspect the manufacturing unit or failure to co-operate with the inspection of the different facilities or in providing information as per the details sought, will lead to disqualification.

4.5.4. The availability of plant & machinery, technical experts, analytical facilities of quality control lab etc., along with the compliance of WHO GMP regulations adopted for the production of quality assured products, all other parameters mentioned in the regulations shall be evaluated by the team for considering the eligibility of the firm. Claim of holding the valid certification/valid license will be of no avail for eligibility, if the procedures as stipulated in the standard operating procedures are not duly complied with, or if the available plant/ machinery are not in working condition at the time of inspection. Tender offer will be rejected/contract will be terminated with due notice in such cases.

4.5.5. Originals of all the documents uploaded/submitted in the Technical Bid as mentioned in Annexure-4 should be produced for verification during inspection. Failure to produce any of the original documents will result in the rejection of the tender offer deeming that the Supplier had made false statement at the time of the bid.

4.5.6. Key manufacturing areas may be photographed by the inspection team as a part of transparency and cross verification. Denial of permission for photographing may result in the rejection of Bid deeming that the Supplier had made false statement at the time of the Bid, if applicable, and/or the Purchaser may proceed with any actions available to it under the terms of this Tender Document.

4.5.7. Failure to observe any of the conditions of the licenses issued by competent authority, if reported by the inspection team will result in the rejection of the Bid deeming that the Bidder/Supplier had made false statement at the time of the Bid, if applicable, and/or the Purchaser may proceed with any actions available to it under the terms of this Tender Document.

4.5.8. The entire EMD or equivalent amount from the Performance Security shall be enchased, as the case maybe, paid by the Bidder(s) shall be forfeited whose manufacturing facilities were rejected on the grounds of non-compliance to statutory requirements. For the Bidder/Supplier claiming EMD exemption, the Bidder/Supplier shall be liable to pay damages to the Purchaser of an amount equivalent to the EMD for the drugs quoted by the said Bidder. In the event, the Bidder fails to pay the damages specified in this clause, the Purchaser reserves the

right to debar/blacklist the Supplier/Bidder for next three years from participating in any future Tender published by the Purchaser.

4.5.9. The Purchaser, or its authorized representative(s) shall have the right to inspect the factories of Bidders, before releasing any Purchase Order(s) or at any point of time after the Bid Due Date till the completion of the obligations as per the terms of this Tender Document/Contract, and also has the right to reject the Bid or terminate / cancel the Purchase Orders issued and/or not re-order, based on adverse reports brought out during such inspections.

4.6. Shelf Life of the Drugs

4.6.1. The supplied medicines and drugs should have the prescribed potency throughout the life period of drugs as prescribed in the Drugs and Cosmetics Act, 1940 (as amended) and rules there under and in relevant Pharmacopoeias. The "Life period of drugs" should be as per the Schedule P of the Drugs and Cosmetic Rules, 1945 (as amended).

4.6.2. Supplier(s) should supply the drugs to consignee within 30 days from the date of manufacture of that product. (Tablet, Capsule, Pessaries Ointment, Oral and Liquid preparation, Laboratory Chemicals, Kits, Injection and I.V Fluids etc.)

4.7. Method of Placing Purchase Orders

4.7.1. Subject to Clause 3.20, the following procedures will be adopted:

i. After the conclusion of Price Bid opening (Envelope 2), the lowest offer of the Bidder for the respective drug(s) is considered.

ii. The Bidder, who has been declared as Supplier for respective drug(s), shall execute necessary Contract for the supply of the tendered quantity of such drug(s) as specified in the Tender Document. On depositing the required amount as Performance Security and on execution of the Contract, such Bidder(s) shall be eligible for the placement of Purchase Orders.

4.8. Execution of Contract

4.8.1. The lowest/matched Supplier shall execute a contract as per the form provided in Schedule-1 on a non-judicial stamp paper of value of as per The Maharashtra Stamp Act 1958 (stamp duty to be paid by the Supplier) within 15 days from the date issuance of the NOA from Purchaser. The cost of the stamp duty shall be borne by the Bidder. The Bidder shall not, at any time, assign, sub-let or make over the contract or the benefit thereof or any part thereof to any person or persons whatsoever.

4.8.2. All notices or communications relating to and arising out of this contract or any of the terms thereof shall be considered duly served on or given to the Bidder if delivered to him or left at the premises, places of business or abode as provided by the bidder.

4.9. Performance Security

4.9.1. The successful Bidder shall furnish Performance Security to the Purchaser at the time of execution of the Contract, for an amount of 3 % of the contract value for Bidders who are not MSE. In case the Bidder is MSE, the Bidders is required to provide Performance Security as per Clause 4.6 of Revised Manual of Office Procedures for Procurement of Goods by the Government Departments and any subsequent

amendment thereto. The Performance Security shall be valid for a period of 2 years from the date of signing of the Contract.

4.9.2. Performance Security can be in the form of ***Demand Draft or irrevocable Bank Guarantee in favour of the Maharashtra Medical Goods Procurement Authority, Mumbai from any Nationalized or Scheduled bank (Schedule-2).***

4.9.3. The Performance Security will be discharged by the Purchaser and returned to the Supplier not later than 60 days following the date of completion of the Supplier's performance obligations under the Contract.

4.9.4. The Performance Security shall be forfeited as a compensation for any loss resulting from the failure to perform the obligations under the Contract or in the event of termination of the Contract or in any event as the Purchaser thinks fit and proper, as the terms of this Tender Document.

4.10. Supply Conditions

4.10.1. Purchase Orders along with the place(s) of supply (consignee destinations) will be issued to the Supplier(s). The supplier should supply drugs within 30 days from the date of manufacturing at consignee destinations. No drugs will be accepted whose manufacturing date is beyond 30 days.

4.10.2. Within 2 days from the receipt of Purchase Orders, the Supplier(s) should provide the confirmation for the receipt with signed copy of Purchase Order and supply schedule as specified in Schedule-3 via email (maha.mmgpa2023@gmail.com).

4.10.3. The Supplier shall supply the entire ordered quantity within the timeline as specified in Maharashtra Medical Goods Procurement Authority Regulations 2025 dt: 21-03-2025, and subsequent amendments thereto. The supply period as per the said regulations is as below:

Category	**Supply Period starting from the date of Purchase Order** (in days)
Medicines and Medical supplies (Manufacturer)	45
Medicines and Medical supplies (Importer)	60
Essential Vaccines and highly specialized medicines	90

4.10.4. The Supplier shall supply the quantity specified in Purchase Order as per the timelines mentioned in the table above. If the Supplier fails to deliver any or all of the goods within the period(s) specified herein, the Purchaser shall, without prejudice to its other remedies under the Tender Document, shall recover from the Supplier as liquidated damages, a sum equivalent to 0.5% of the Contract price of the unsupplied drugs at the stipulated rate for each week or part thereof during which the delivery of such drugs may be delayed, as under:-

i. In case of an order not exceeding Rs. 2.00 lakh in value –damage amount –at the rate of 0.5% per week (i.e., 0.0714% per day) subject to maximum limit of 10 %.

ii. In Case of an order of Rs 2.00 lakh and above –damage amount –at the rate of 0.5% per week (i.e., 0.0714% per day) subject to maximum limit of 5 %.

4.10.5. If the Supplier fails to commence delivery as scheduled or to deliver the quantities ordered to him within the delivery period stipulated in the Contract, it shall be discretion of the Purchaser either (a) To extend the delivery period or (b) To cancel the Contract in whole or in part for the unsupplied quantities without any show cause notice.

4.10.6. All supplies will be scheduled for the period from the date of Purchase Order till the completion of the tender, as may be stipulated in the Purchase Order, subject to various conditions mentioned here under.

4.10.7. The Supplier(s) must submit an analysis report from a NABL accredited laboratory for every batch of drug along with invoice. In cases of Vaccines and Sera, the certificate of analysis from Central Drugs Laboratory, Kasauli shall be provided. In case of failure on part of the Supplier to furnish such report, the batch of drugs will be returned back to the Supplier and Supplier is bound to replenish the same with Govt. approved lab test report. The drugs supplied by the Supplier shall be of the best quality and shall comply with the specifications, stipulations and conditions specified in the tender.

4.10.8. Consignee shall not accept any shortages/damage in drug(s) at the time of receipt. It is Supplier's responsibility to fulfil or replace shortages/damage in drug(s) recorded at the time of receipt, as the case may be, within timelines as applicable as per the terms of the Purchase Order. Purchaser is not responsible for the excess stock of drug received, for which no order is placed.

4.10.9. If the Supplier fails to supply the drug(s) within the stipulated time, either fully or partly, Purchaser, is at liberty to place Purchase Orders either with other Bidders at the price offered by them or with alternate sources and in such cases the defaulted Supplier is liable to indemnify Purchaser, without any protest or demur, for the difference in cost incurred by Purchaser, and the Purchaser is entitled to recover the difference in cost from any amount due/payable to the defaulted Supplier.

4.10.10. Notwithstanding anything contained in Clause 4.10.9 above, the Supplier, after committing the default in supply either partly or fully, can inform the Purchaser, about its willingness to execute the Purchase Order. The Purchaser, at discretion, may consider the willingness of the Supplier on merit. However, such supplies will be subjected to the levy of liquidated damages and other penalties as stipulated in the Tender Document/ Contract and Purchase Order, at the discretion of the Purchaser.

4.11. Packing and Labeling

A. Packing

4.11.1. The drugs shall be supplied in the package specified in tender document and the packing and labelling shall be as mentioned in Schedule-4. Affixing of labels in smaller size will be treated as violation of tender conditions and fine will be deducted from the amount payable as per condition in Clause 4.12.2

4.11.2. 2D bar coding as per GS1 standard should be done on tertiary packing of the supplies as per the specifications given under Schedule-4.

4.11.3. 2D bar coding should be done on secondary packing for fixed variables as per the specifications given under Schedule-4.

4.11.4. The packing in each carton shall be strictly as per the specification mentioned in Schedule-4. Failure to comply with this shall lead to non-acceptance of the goods besides imposition of damages as per Clause 4.12 (ii). However, in case of poor / damaged packing, necessary replacement should be provided for damaged goods as notified by the Purchaser in such cases.

4.11.5. The caps of bottle preparations should not carry the name of the Supplier. The labels in the case of injectable preparations should clearly indicate whether the preparations are meant for Intravenous (IV), Intramuscular (IM), Intra Dermal (ID), Subcutaneous (SC) administration etc. The capsule shell should have the name of the drug.

4.11.6. It should be ensured that only first-hand fresh packaging material of uniform size, including bottle and vial, is used for packing. All primary packing containers should be strictly conforming to the specifications included in the relevant pharmacopoeia.

4.11.7. Packing should be able to prevent damage or deterioration during transit and storage. In the event of drugs supplied found to be not as per specifications in respect of their packing, the Purchaser, is at liberty to make alternative purchase of the drugs for which the Purchase Orders have been placed from any other sources or in the open market or from any other bidder who might have quoted higher rates, at the risk and the cost of the Supplier. In such cases the Purchaser, has every right to recover the cost and damages as mentioned in Clause 4.12.

B. Labelling

4.11.8. Labelling of the Drugs/Medical device shall be in strict compliance with Part-IX of the Drugs Rules, 1945/Chapter VI of Medical Device Rules, 2017 and other rules for the time being in force as approved by the appropriate Statutory authorities.

4.12. Schedule for packaging of essential drugs

(A) GENERAL SPECIFICATIONS:

1. No corrugated package should weigh more than 15 kilograms (i.e; product + inner carton + corrugated box).

2. All Corrugated boxes should be of "A" grade material i.e., Virgin

quality.

3.All Essential Drugs should be packed only in first hand boxes.

FLUTE:

4. The corrugated boxes should be of narrow flute.

JOINT:

5. Every box should be preferably single joint and not more than two

joints.

STITCHING:

6. Every box should be stitched using pairs of metal pins with an interval of two inches between each pair. The boxes should be stitched and not joined using calico at the corners.

FLAP:

7. The flaps should uniformly meet and should not overlap each other. The flap when turned by 45 - 60° should not crack.

TAPE:

8. Every box should be sealed with Gum Tape/BoPP (Biaxially Oriented Polypropylene) tape running along the Top and lower opening.

CARRY STRAP:

9. Every box should be strapped with two parallel nylon carry straps (they should intersect).

LABEL:

10. Every corrugated box should carry a large outer label clearly indicating that the product is for "Maharashtra Govt. Supply - Not for Sale".

11. The product label on the carton should be large at least 15cms x 10cms dimension. It should carry the correct technical name, strength of the product, date of manufacturing, date of expiry, quantity packed and net weight of the box.

OTHERS:

12. No box should contain mixed products or mixed batches of the same product.

(B)SPECIFICATION FOR CORRUGATED BOXES HOLDING TABLETS / CAPSULES / PESSARIES

1. The box should not weigh more than 7-8 Kilograms. The grammage of outer box should be 150 GSM and inside partition / lining should

be 120GSM.

2. The box should be of 5 ply with bursting strength of 9 Kg/ Cm2

(C) SPECIFICATIONS FOR OINTMENT / CREAM / GELS PACKED IN TUBES:

1. No corrugate box should weigh more than 7-8 Kgs.

2. Every Ointment tube should be individually packed in carton and then packed in 20's in a White board box, which may be packed in a corrugated box.

3. The grammage of outer box should be 150 GSM and inside partition / lining should be 120GSM.

(D) SPECIFICATIONS FOR INJECTABLE (IN VIALS AND AMPOULES):

1. Vials may be packed in corrugated boxes weighing upto 15 Kilograms. Ampoules should be packed in C.B weighing not more than 8 Kilograms.

2. Corrugated box for vials should be of 150 GSM (outer box should be 150 GSM and inside partition / lining should be 120 GSM) and 7 ply, while corrugated box for ampoules should be of 150 GSM (outer box should be 150 GSM and inside partition / lining should be 120 GSM) and 5 ply.

3. Bursting strength for CB boxes for

a. Vials: Note less than 13 Kg/Cm2

b. Amp: Note less than 9 Kg/Cm2

4. In the case of 10 ml Ampoules, 100 or 50 ampoules may be packed in a White board box. Multiples of White board boxes packed in corrugated box. In case of Ampoules larger than 10 ml, only 25 ampoules may be packed in a White board box with partition.

5. If the vial is packed in individual carton, there is no necessity for White board box packing. The individual carton may be packed as such in the corrugated box with center pad.

6. In case of ampoules, every White board box should carry 5 amps.

Cutters placed in a polythene bag.

7. Vials of Eye and Ear drops should be packed in an individual carton with a dispensing device. If the vial is of FFS/BFS technology, they should be packed in 50's in a White board box.

2D Bar Coding on Secondary Packing

DRUG CODE :
DRUG NAME :
BATCH NO :
SUPPLIER CODE:
SUPPLIER NAME:
MFG DATE:
EXPIRY DATE:

2D Bar Coding on Tertiary Packing

BOX NO:
PO NUMBER:
SUPPLIER CODE:
SUPPLIER NAME:
DRUG CODE:
DRUG NAME:
BATCH NO:
MFG DATE:
EXPIRY DATE:
BATCH QUANTITY:
INVOICE NO:



4.13. Aggregation and “parent-child” relationship serialisation

When the QR code or barcode on a **tertiary package** (like a shipping case or pallet) is scanned, the serial numbers of the **blister packs** inside (primary packaging) can be identified **without opening the package** due to a process called **aggregation** in pharma serialization.

- **Parent-Child Relationship:** During packaging, each blister (primary) receives a unique serial number and QR/DataMatrix code (the "child"). When these blisters are packed into cartons (secondary) and further into cases/pallets (tertiary), software systems link the serial numbers at each level by recording a "parent-child" relationship.
- **Central Database:** All this linking data (which blisters/serials are inside which carton, which cartons are inside which case) is uploaded to a secure database or the manufacturer's digital traceability system.
- **Tertiary Code Lookup:** When the tertiary-level code (unique QR code) is scanned, the system retrieves from the database the **complete list of serial numbers** for all individual blisters contained within that package—based on the links established during aggregation.
- **No Need to Unpack:** This allows supply chain operators or warehouses to quickly know exactly which blisters (their unique serial numbers) are inside any shipping case or pallet just by scanning the outside label.
- The identification is indirect: the tertiary code itself is not a "container" for all serial numbers, but is a reference that unlocks a digital "tree" of all linked codes for the inner packs.
- To ensure this facility the Bidder/Supplier shall ensure the aggregation process in packaging and provide the complete data of 'Parent-Child' linkage of the medical goods supplied and the access to its database to the same extent.

4.14. Deduction & Damages on Quality Failure

4.14.1. As soon as the drugs are received at the consignee location from the Suppliers, the details of the same shall be fed into the computer system (e-Aushadhi). Samples shall be drawn randomly from the Supplies from each batch. The samples drawn will be sent to the Quality Assurance (QA) cell of Purchaser.

4.14.2. After the samples are received at QA cell of Purchaser from randomly selected consignees, they will be segregated drug wise and batch number wise. The common batch of an item shall be mixed, and sample shall be drawn from pooled batch. Steps shall be taken to remove or hide the identity of the manufacturer and encode the formulations secretly. Encoded stickers shall be affixed on the blisters/strips/bottles/vials, as the case may be, so that the name and identity of the manufacturer gets hide but the contents of the sample are visible (Printed on the Sticker). The formulations / items assigned with secret unique codes will be sent to empaneled laboratories for analysis. Such sample should randomly be sent to laboratory. Within twenty-four hours of the receipt of samples, the information in appropriate format shall be uploaded by the empaneled laboratories on the e-Aushadhi portal. If any sample is received in a damaged condition by the laboratory, it shall not be analyzed, and the information thereof shall be sent immediately to the QA cell of Purchaser.

4.14.3. The empaneled laboratories shall analyze the drugs as per specifications and prescribed test protocols and submit its report to QA cell of Purchaser on e- Aushadhi

portal. The empaneled laboratory shall not disclose any of its information or report to anyone except the Purchaser. Every test report must have remark (i.e.) "Standard Quality" or "Not of Standard Quality". Reports should have serial no., description of tests, specifications and results obtained as enumerated in relevant Acts and Rules. Reports shall be attached along with spectra/chromatography datasheets, if applicable.

4.14.4. If any sample sent to the empaneled laboratories fails in quality, the result may be confirmed with the other empaneled laboratories or Government Analyst before taking final decision.

4.14.5. If the drug fails in assay or any other parameters action shall be taken by the QA Cell immediately. The stock shall be frozen and kept separately until it is cleared. If the empaneled laboratories or government analyst confirm the failure of the drug to meet the standards, steps shall be taken to destroy or incinerate the stocks at the cost of the Supplier.

4.14.6. The report of the laboratory shall be communicated to the Supplier. The Supplier shall compensate for the substandard drug by supplying new batch of the same quantity within thirty days of the letter for information. If the Supplier fails to deliver the same within the stipulated timeline, then the Purchase Order for the item will be cancelled and no payment shall be made against that supply. For avoidance of doubt, it is clarified that the Damages shall be levied as per Clause 4.10.4 of this Tender Document.

4.14.7. If any of the drug/medicines supplied by the Supplier has been partially or wholly used or consumed after supply and are subsequently found to be in bad odour, unsound, inferior in quality or description or otherwise faulty or unfit for consumption, then the contract price for the quantity not consumed and informed to take back, will be recovered from the Supplier, if payment has already been made.

4.14.8. The Supplier shall furnish the source of procurement of raw material utilized in the formulations, if required by the Purchaser. The Purchaser reserves the right to cancel the Purchase Orders, if the source of supply is not furnished.

4.14.9. The decision of the Purchaser, or any officer authorized by it, as to the quality of the supplied drugs, medicines etc., shall be final and binding.

4.14.10. In the event of making alternative purchase, as specified in Clause 4.10 (ix) damage will be imposed on the Supplier. The excess expenditure over and above contracted prices incurred by Purchaser, in making such purchases from any other sources or in the open market or from any other bidder who has quoted higher rates and other losses sustained in the process, shall be recovered from the Supplier including through encashment of Performance Security or adjustment from any money payable to the Supplier under this Contract. Upon encashment and appropriation of the Performance Security, the Supplier shall, within [15 (fifteen)] days thereof, replenish, in case of partial appropriation, the Performance Security to its original level, and in case of appropriation of the entire Performance Security provide a fresh Performance Security, as the case may be, failing which the Purchaser shall be entitled to terminate the Contract. In all the above conditions, the decision of the Purchaser, shall be final and binding.

4.15. Blacklisting of Product/Tenderer on withdrawal of Tender:

4.15.1. If the Tenderer(s) fails to execute the agreement / to deposit performance security / to perform the obligations under the tender conditions / commits default in the performance of the contract, such Tenderers will be blacklisted for a period of 2 years by MMGPA., from the date of intimation besides forfeiture of Earnest Money Deposit (EMD) / Performance Security.

4.15.2. The Tenderers who have withdrawn after submitting their bids and before MMGPA finalizes and places the purchase orders either fully or partially, will be blacklisted for a period of 2 years from the date of intimation by MMGPA, apart from forfeiture of the Performance Security /EMD.

4.16. Blacklisting for Non-Supply of purchase Order(s):

4.16.1. If the supplier fails to execute at least 70% of the ordered quantity as mentioned in a single Purchase order and such part supply for any three purchase orders of the same drug, then the product of the supplier will be blacklisted and becomes ineligible to participate in any of the tenders for that particular drug(s) by MMGPA, for a period of 2 years from the date of intimation for blacklisting besides forfeiture of performance security of that product(s).

4.16.2. If the supplier supplies more than one drug and 50% of such drugs are blacklisted, the firm/company is liable to be blacklisted for a period of 2 years from the date of intimation besides forfeiture of performance security in full.

4.16.3. Purchase orders, if any, already issued before taking any blacklisting action or orders given in past will not be affected in view of action taken as per above guidelines but all strict quality checks shall be observed for each supply of products.

4.16.4. The blacklisting of particular product or company/firm will be done without prejudice to other penalties which may be imposed as per the conditions of Tender documents and also to other actions which may be initiated under Drugs and Cosmetics Act 1940 or any other law of MMGPA, will display names of such blacklisted product(s) and company/firm on its website and also circulate the same among other state Government / Central Government and its Drug procurement agencies including respective State Drugs Control Department where the company or firm is located.

4.17. Blacklisting of Product(s) based on Quality Test by the Empanelled Laboratories

4.17.1. Each and every batch of Drug/Medicines supplied by the supplier shall be subjected to quality test by the Empanelled laboratories.

4.17.2. The samples are collected from the Warehouses/consignees from each batch of supply of the same drugs and after eliminating the common batch, samples shall be taken in random, decoded and will be sent to the empanelled testing laboratories for testing the quality of drugs.

4.17.3. If such sample passes quality test in all aspects, MMGPA, will instruct its Warehouses/consignees to issue such drugs to various hospitals/Institutions for use.

4.17.4. Such quality passed batches if received after declaration of result of the earlier supply, the same will be again subjected to testing and the latest report of that particular batch will prevail upon the earlier results and binding on the entire quantity of the batch supplied and recovery will be made for the entire quantity of that batch irrespective of purchase order date or date of supply etc.

4.17.5. If the sample fails in quality test and report is received certifying that sample is not of standard quality, one more sample shall be drawn from the same batch and will be sent to Government Drugs Testing Laboratory for quality testing.

i If such sample passes the quality test as per the report of Government Analyst, the drugs representing the sample shall be qualified for issue to various Institutions.

ii If such sample fails in the quality test, as per the report of the Government Analyst, the drugs of the batch are not qualified for issue and the supplier shall take back the drugs supplied in that batch, besides taking other actions as per the Tender conditions by MMGPA.

iii If such Sample fails in quality test for ASSAY content of less than 50% as per the Government Analyst report, such product of the tenderer will be blacklisted for two years beside forfeiture of Performance security of that product.

iv However, MMGPA, reserves the right to reject the drugs based on reports from empanelled laboratories with the applicable penal provisions.

4.17.6. If 3 batches of a particular drug supplied by the supplier is reported to be failing in Assay content (above 50% but below prescribed limit) / Sterility / BET / Toxicity / and or other parameters, then the particular drug of the firm shall be blacklisted and forfeiture of Performance Security of that particular product(s).

4.17.7. In all the cases the reports received from the Government Drug Testing Laboratory/ decision of MMGPA will be conclusive and final and binding on the suppliers.

4.18. Blacklisting of Product(s) based on Quality Test by Statutory Authorities

4.18.1. On intimation from Drugs Inspector(s) during their statutory sampling, that the particular drug has been reported to be of not of standard quality, the issue of available stock of the particular drug will be stopped. Further, the available stock of the product in hospitals will be retrieved. If the sample is reported to have less than 50% of content, the particular product will be blacklisted for 2 years from the date of intimation of blacklisting

4.18.2. If 3 batches of a particular drug supplied by the supplier is reported to be failing in assay content (above 50% but below prescribed limit) and/or other parameters, then the particular drug of the firm shall be blacklisted for a period of 2 years from the date of intimation.

4.18.3. If a single batch of any product(s) supplied by the company/firm declared as Adulterated/spurious/ Misbranded by the Government Authorities during the shelf life of the product supplied irrespective of tender period, the company/firm shall be blacklisted for a period of 5 years from the date of intimation.

4.19. Blacklisting of the Supplier on Quality Failure:

4.19.1. In case of any sample even in one batch, declared as Adulterated/spurious/Misbranded by the Government Authorities, the company/firm shall be blacklisted for a period of 5 years from the date of intimation besides forfeiture of performance security in full.

4.19.2. If the supplier supplied more than one drug and 50% of such drugs are blacklisted, the firm is liable to be blacklisted for a period of 2 years from the date of intimation.

4.20. Procedure for Blacklisting/Debarment:

4.20.1. On receipt of report from Govt. Analyst/Drug Testing Laboratory indicating that a particular Drug/Drugs is Not of Standard Quality/ Adulterated/ Spurious/ Misbranded (as the case may be), a show cause notice shall be issued to the supplier calling for explanation within 7 days from the date of notice. On receipt of explanation from the supplier, the CEO, MMGPA, may take appropriate action on merits of the case and impose penalty @ 25% of the value of the failed batch (or) 7.5% of the total supply value made in the particular purchase order (which ever higher) or blacklist the particular drug(s) of the company or firm as deemed fit besides forfeiture of Performance Security.

4.20.2. If a particular drug has been blacklisted according to the procedure stated above, the supplier is not eligible to participate in any of the tenders for that particular drug floated by the MMGPA, until the period of blacklisting is over.

4.20.3. 3If a supplier company/firm is blacklisted according to the procedure stated above, such supplier is not eligible to participate in any of the tenders floated by MMGPA until the period of blacklisting is over.

Appendix-A: Schedule of Requirements:

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
1	2FDC (Pediatric)-CP Isoniazide 50mg + Rifampicin 75mg	2FDC (Pediatric)-CP Isoniazide 50mg + Rifampicin 75mg	Per Tab	Strip of 28 Tab	15815	1518250
2	3FDC (Pediatric)-IP Isoniazide 50mg + Rifampicin 75mg + Pyrazinamide 150mg	3FDC (Pediatric)-IP Isoniazide 50mg + Rifampicin 75mg + Pyrazinamide 150mg	Per Tab	Strip of 28 Tab	100000	800000
3	4FDC (Adult)-IP Isoniazide 75mg + Rifampicin 150mg +Pyrazinamide 400mg + Ethambutol 275mg	4FDC (Adult)-IP Isoniazide 75mg + Rifampicin 150mg +Pyrazinamide 400mg + Ethambutol 275mg	Per Tab	Strip of 28 Tab	511466	1006564
4	Acetazolamide Tab 250 mg	Tab Acetazolamide 250 mg	Per Tab	strip of 10 tablets	100000	88000
5	Acetyl Salicylic Acid Tab 150 mg	Tab. Aspirin (acetylsalicylic acid) 150 mg Aluminium Blister of 14 Tablets	Per Tab	strip of 14tablets	699080	2350504
6	Acetyl Salicylic Acid Tab 150 mg effervescent/ dsipersable/ enteric coated	Tab. Aspirin (acetylsalicylic acid) 150 mg Aluminium Blister of 14 Tablets effervescent/ dsipersable/ enteric coated	Per Tab	strip of 14tablets	6247400	1849230
7	Acetyl Salicylic Acid Tab 75 mg	Tab. Aspirin (acetylsalicylic acid) 75 mg Aluminium Blister of 14 Tablets	Per Tab	strip of 14tablets	50029032	10048884
8	Acetyl Salicylic Acid Tab.300mg I.P	Tab Aspirin (Acetyl Salicylic Acid) 300mg Alumminium Blister of 14 tab	Per Tab	strip of 14tablets	946256	393642
9	Acyclovir DT Tab 200 mg	Tab. Acyclovir 200 mg D T	Per Tab	strip of 10 tablets	72000	130749
10	Acyclovir ointment 3%	ACYCLOVIR EYE OINTMENT 3% W/V Tube	Per Tube	5gm tube	120000	854400
11	Acyclovir Ointment Cream 5 gm	Cream. Acyclovir 5% w/w 5 gm tube	Per Tube	5 gm Tube	35000	156257
12	Acyclovir Tab 400 mg	Tab. Acyclovir 400 mg	Per Tab	strip of 10 tablets	514000	982464
13	Adrenaline Inj. 1mg/ml	Inj. Epinephrine hydrochloride or hydrogen tartarate in 1 mg / 1 ml ampoule/ Inj. Adrenaline Bitartarate 1 : 1000 w/v 1 ml.	per ampl	1ml ampl	322000	1139328

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
14	Albendazole Susp 200 mg 10 ml	Sy. Albendazole - 200 mg/5 ml in Bottle of 10 ml	per bottle	10 ml Bottle	780000	3178640
15	Albendazole Tab 400 mg	Tab. Albendazole 400 mg Aluminium Blister - Strip of 10 Tablets	Per Tab	strip of 10 tablets	76705000	85399680
16	Albumin Human 20% Inj 100ml bottle	Albumin Human 20% Inj 100ml bottle	per bottle	100 ml bottle	4690	14375600
17	Alcohol based surgical hand antiseptic Solution 500 ml bottle with dispenser	Active Ingredient in 100 gm- 2- propanol- 45.0 g , 1 Propanol - 30.0 g Alcohol based surgical hand antiseptic containing macetronium ethyl sulphate 0.2 gm / 100 gm or 0.5 % to 1 % chlorhexidine gluconate with suitable emollient & moisturizer 500 ml Container To be accompanied with following valid test reports: 1) EN 1500 (Hygenic Handrub) 2) EN 12791 (surgical Hand Disinfection) 3) EN 14348 (Mycobactericidal activity) 4) EN 14476 (Virucidal activity) 5) ISO 10993-10 (skin Irritation Test)	per bottle	500ml bottle	34615	6923000
18	Alprazolam Tab 0.25 mg	Tab. Alprazolam 0.25mg	Per Tab	strip of 10 tablets	151000	20136
19	Alprazolam Tab 0.5 mg	Alprazolam Tab 0.5 mg	Per Tab	strip of 10 tablets	105000	37800
20	Alteplase powder for inj 20mg	1 vial with powder contains: 20 mg alteplase (corresponding to 11,600,000 IU)	per vial	1ml vial	100	1297167
21	Alteplase powder for inj 50mg	1 vial with powder contains: 50 mg alteplase (corresponding to 29,000,000 IU)	per vial	1ml vial	100	2708400
22	Amidarone 100mg tab	Amidarone 100mg tab	Per Tab	strip of 10 tablets	2000	20096

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
23	Amidarone Inj 150 mg/3ml 3 ml Amp	Inj. Amidarone 150mg/3ml ampoules i.e. 50 mg per ml	per ampl	3 ml Amp	1000	22848
24	Amikacin Inj 100 mg 2 ml	Inj. Amikacine sulphate100 mg - 2 ml	per ampl	2 ml amp	923000	5631616
25	Amikacin Inj 250 mg 2 ml	Inj. Amikacine sulphate250 mg - 2 ml	per ampl	2 ml amp	771400	9382496
26	Amikacin Inj 500 mg 2 ml	Inj. Amikacine sulphate 500 mg - 2 ml	per ampl	2 ml amp	908725	13011885
27	Amino Acid 10% 500 ml Bot.	Amino Acid 10% Essential and Non Essential for Parenteral nutrition OR Equivalent 500 ml Bot.	per bottle	500ml bottle	5052	1593360
28	Amino Acid IV 200 ml	Liquid Amino Acids and Vitamins Liquid Each 15ml contains: DL-Methionine BP 100mg, Choline Dihydrogen Citrate NFXII 100mg L-Leucine USP 19mg, L-Isoleucine USP 10mg L-Valine USP 11mg, Pyridoxine Hydrochloride IP 1.5mg Nicotinamide IP 22.5mg, Biotin USP 0.1mg Folic Acid IP 0.5mg, Cyanocobalamin IP 3.0mcg, Inositol BP 50mg	per bottle	200 ml bottle	28100	8582736
29	Amino Acids Cap	Capsule Amino Acids Each Contains : Isoleucine 67mg, Leucine 101mg, Phenylalanine 68mg, Valine 86mg, Methionine 59mg, L-lysine 105mg, L-threonine 53mg, L-tryptophan 23mg, L-histidine 38mg, L-tyrosine 30mg, Nitrogen 36mg	per Cap	strip of 10 capsules	118125	963899
30	Aminophylline Inj 25 mg/ml 10 ml	Inj. Aminophyllin - 25 mg per ml i.e. 250 mg/10 ml w/v	per ampl	10 ml ampl	215000	1496936
31	Amiodarone Inj 150 mg/3ml 3 ml Amp	Inj. Aminodarone 150mg/3ml ampoules i.e. 50 mg per ml	per ampl	3 ml Amp	1500	31200
32	Amisulpride 100 mg Tab	Each tablet contains; Amisulpride 100mg	Per Tab	strip of 10 tablets	299920	1086910

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
33	Amitryptillin Hydrochloride Tab 25 mg	Tab. Amitryptillin hydrochloride 25 mg	Per Tab	strip of 10 tablets	1342000	332816
34	Amlodipine Besylate 10 mg Tab	Tab. Amlodipin besylate 5 mg Aluminium Blister - Strip of 10 Tablets	Per Tab	strip of 10 tablets	1971313	9935418
35	Amlodipine Tab 2.5 mg	Tab. Amlodipine besylate 2.5 mg Aluminium Blister - Strip of 10 Tablets	Per Tab	strip of 10 tablets	100000	11200
36	Amlodipine Tab 5 mg	Tab. Amlodipin besylate 5 mg Aluminium Blister - Strip of 10 Tablets	Per Tab	strip of 10 tablets	945758520	104607627
37	Amoxycillin (875mg) + Clavulanic acid(125mg)Tablet	Tab. Amoxycillin I P 875 mg + Clavulanic acid I P 125 mg - Strip of 10 Tablets	Per Tab	strip of 10 tablets	1050000	4991200
38	Amoxycillin + Clavulanic acid dry Syrup 200 mg + 28.5 mg/5ml	Sy. Amoxycillin 200 mg + Clavulanic acid 28.5 mg / 5 ml dry Syrup - Bottle of 60 ml	per bottle	60 ml bottle	520000	10402240
39	Amoxycillin + Clavulanic Acid Inj 1000 mg + 200 mg Vial	Inj. Amoxycillin Sodium 1000 mg + Clavulanic acid as Potasium Salt 200 mg i.e. 1.2 gm (1.2 gm) in Vial	per vial	per vial	362550	8580005
40	Amoxycillin + Clavulanic Acid Inj 250 mg + 50 mg Vial	Inj. Amoxycillin + Clavulanic acid 300mg Inj. Amoxycillin Sodium 250 mg + Clavulanic acid as Potasium salt 50 mg i.e. 300 mg (0.3 gm) in Vial	per vial	Vial	101000	1189184
41	Amoxycillin + Clavulanic acid inj. 600mg ie. 500mg + 100mg)	Inj. Amoxycillin + Clavulanic acid 600 mg Inj. Amoxycillin Sodium 500mg + Clavulanic acid as Potasium Salt 100 mg i.e. 600 mg (0.6 gm) in Vial	per vial	Vial	500000	6688000
42	Amoxycillin + Clavulanic acid Tab 250 mg + 125 mg	Tab. Amoxycillin 250 mg + Clavulanic acid 125 mg	Per Tab	strip of 10 tablets	15001000	42669184
43	Amoxycillin + Clavulanic acid Tab 500 mg +125 mg	Tab. Amoxycillin I P 500 mg + Clavulanic acid I P 125 mg - Strip of 6 Tablets	Per Tab	strip of 6 tablets	24124000	111620960

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
44	Amoxycillin 125mg + Clavulanic acid 31.25mg/5ml Dry syrup)	Each reconstituted suspension contains Amoxycillin (125mg) + Clavulanic Acid (31.25mg)/5ml	per bottle	30 ml bottle	300000	6417600
45	Amoxycillin Cap 250 mg	Cap. Amoxycillin Trihydrate 250 mg	per Cap	strip of 10 capsules	33400000	58796000
46	Amoxycillin Cap 500 mg	Cap. Amoxycillin Trihydrate 500 mg	per Cap	strip of 10 capsules	20514706	65664713
47	Amoxycillin DT Tab 125 mg	Tab. Amoxycillin D T 125 mg	Per Tab	strip of 10 tablets	4000000	2496000
48	Amoxycillin DT Tablet 250 mg	Tab. Amoxycillin D T 250 mg	Per Tab	strip of 10 tablets	965961	2086476
49	Amoxycillin powder for suspension 125 mg/5ml	Each reconstituted suspension contains amoxycillin trihydrate 125 mg/5ml, .	per bottle	60 ml bottle	800000	12313600
50	Amoxycillin Syrup 125 mg 60 ml Bottle	Sy. Amoxycillin Trihydrate 125 mg / 5 ml- Bottle of 60 ml	per bottle	60 ml bottle	2448500	29039160
51	Amoxycillin Trihydrate 250 mg / 5 ml- Bottle of 60 ml	Sy. Amoxycillin Trihydrate 250 mg / 5 ml- Bottle of 60 ml	per bottle	60 ml bottle	580000	10747200
52	Amoxycilln 250 mg + Clavulanic acid 125mg Tab	Amoxycilln 250 mg + Clavulanic acid 125mg Tab	Per Tab	strip of 10 tablets	238250	808144
53	Amoxycilln 500 mg + Clavulanic acid 125mg Tab	Amoxycilln 500 mg + Clavulanic acid 125mg Tab	Per Tab	strip of 10 tablets	2371000	11089452
54	Amphotericin B 50mg/10 ml Lyposomal Inj	Amphotericin B 50mg/10 ml Lyposomal Inj	per vial	10ml vial	1580	1589859
55	Ampicillin 125mg + cloxacillin 125 mg Syp	Powder for preparing suspension. When dispensed as directed each 5 mL of the suspension contains the equivalent of 125 mg ampicillin and 125 mg cloxacillin. The powder contains 0,13% m/m of sodium benzoate B.P. as a preservative.	per bottle	30 ml bottle	112280	6287697
56	Ampicillin capsule 500 mg	Ampicillin capsule 500 mg	per Cap	strip of 10 capsules	2000000	4768000

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
57	Ampicillin inj. 500 mg/ml	Each vial of Ampicillin for Injection, USP contains 500 mg, ampicillin as the sodium salt. Each gram of ampicillin sodium contains approximately 60 mg or approximately 6% sodium.	per vial	10 ml Vial	100000	1082400
58	Antacid Syp	Sy. Antacid Each 5 ml contains Aluminium Hydroxide 250 mg + Magnesium Hydroxide 250 mg + Dimethicone 50 mg	per bottle	170 ml bottle	210000	7188480
59	Anti D (Rho D) Immunoglobulin recombinant 300mcg Inj vial/pfs	Anti D (Rho D) Human Immunoglobulin Polyclonal/monoclonol 300mcg Inj	per vial	per vial	1482	2642465
60	Anti Rabies Vaccine ID (Human Tissue culture) 0.5 ml	Anti Rabies vaccine Tissue culture 2.5 I U per Vial or amp or Purified vero cell Rabies vaccine 2.5 IU per Vial or amp or purified chick embryo vaccine 2.5 I U per Vial or amp & Sterile water for injection as diluents, Label should indicate for ID / IM use Ampoule/Vial of 1 ml or 0.5ml	Per Vial	1 ml vial	600000	88704000
61	Anti-D Immunoglobulin Inj Monoclonal / Polyclonal 150 mcg	Anti D (Rho (D) Immunoglobulin (Human) Polyclonal / Monoclonal - 150 mcg in pfs/ single dose Vial	per pfs	pfs/ single dose Vial	19990	23080426
62	Anti-D Immunoglobulin Inj Mono/Polyclonal 300 mcg PFS	Anti D (Rho-D) immunoglobulin (Human) Polyclonal / Monoclonal - 300mcg in single dose Vial	per pfs	pfs/ single dose Vial	27300	41697600
63	Anti-Rabies Immunoglobulin	Human Rabies Immunoglobulin (750IU)	per pfs	per pfs	2500	937000
64	Anti-Rabies Immunoglobulin-300ml /2ml	Anti-Rabies Immunoglobulin-300ml /2ml	per ampl	2ml ampoule	3500	13571040

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
65	Antitetanus Human Immunoglobulin Injection	each vial contains human tetanus immunoglobulin equivalent to tetanus antitoxin 250 I.U. stabiliser glycin 0.3M, preservative thiomersal 0.01% w/v- 1 ml	per ampl	1ml ampl	10000	12706400
66	Aripiprazole 10mg tab	Each tablet contains; Aripiprazole 10mg	Per Tab	strip of 10 tablets	256000	1126400
67	Artemether (A) + Lumefantrine (B) 80mg+480mg Tab	Each Tab contains Artemether 80mg (A) + Lumefantrine 480mg (B)	Per Tab	6 Tab Strip	25000	920000
68	Artesunate Inj 60mg vial	Artesunate Inj 60mg vial	per vial	10ml vial	100	3652
69	Artesunate powder for injection 120 mg	Each vial contains: artesunate powder 120 mg	per vial	10 ml Vial	5000	960000
70	Artesunate tab 200mg	Artesunate tab 200mg	Per Tab	strip of 10 tablets	100	541
71	Artesunate tab 50mg	Artesunate tab 50mg	Per Tab	strip of 10 tablets	100	372
72	Artesunate with Normal Saline & Sodium bicarbonate for dilution Inj. 60mg	Artesunate with Normal Saline & Sodium bicarbonate for dilution Inj. 60mg	per vial	2ml vial	150000	1521600
73	Ascorbic acid (Vitamin C) 100 mg tab	Tab. Ascorbic acid 100 mg	Per Tab	strip of 10 tablets	5000	3920
74	Ascorbic acid (Vitamin C) 500 mg	Tab. Ascorbic acid 500 mg	Per Tab	strip of 10 tablets	44103052	21466250
75	Atazanavir 300mg / Ritonavir 100mg (FDC)	Atazanavir 300mg / Ritonavir 100mg (FDC)	Per Tab	strip of 10 tablets	32520	1014624
76	Atenolol Tab 100mg	Tab. Atenolol 100 mg Aluminium Blister - Strip of 14 Tablets	Per Tab	strip of 14tablets	75199	1203184
77	Atenolol Tab 25 mg	Tab. Atenolol 25 mg Aluminium Blister - Strip of 14 Tablets	Per Tab	strip of 14tablets	1000000	160000
78	Atenolol Tab 50 mg	Tab. Atenolol 50 mg Aluminium Blister - Strip of 14 Tablets	Per Tab	strip of 14tablets	10605000	1448640
79	Atorvastatin 20 mg Tab	Atorvastatin 20 mg Tab	Per Tab	strip of 10 tablets	2799000	912698
80	Atorvastatin Tab 10 mg	Tab. Atorvastatin 10 mg	Per Tab	strip of 10 tablets	47476490	11471346

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
81	Atorvastatin Tablet 40mg	Tab. Atorvastatin 40 mg	Per Tab	strip of 10 tablets	110000	1744960
82	Atracurium Besylate Inj 10 mg 2.5 ml	Inj. Atracurium Besylate 10 mg/ml	per ampl	2.5 ml Ampoule	75	6720
83	Atropine Inj 1mg/ml	1 mg/mL: containing 1 mg atropine sulfate monohydrate equivalent to 0.83 mg of atropine.	per ampl	10ml ampl	50000	3000000
84	Atropine Inj. 0.6mg/ml 1ml	Inj. Atropine sulphate0.6 mg/ml - 1 ml amp	per ampl	1 ml Ampoule	30000	58800
85	Azelastine HCL 0.14% + Fluticasone Proprionate 0.05% Nasal Spray	Each Spray Contains Azelastine HCL IP 0.14% w/v Fluticasone Propionate IP 0.05% w/v Benzalkonium Chloride IP 0.01% w/v Phenylethyl Alcohol IP 0.25%w/v Excipients q.s.	per bottle	9.8ml bottle	65781	905140
86	Azithromycin 500mg Tab	Azithromycin 500mg Tab	Per Tab	strip of 10 tablets	586716	3059560
87	Azithromycin Syrup 100mg/5ml-15ml bottle	Azithromycin Syrup 100mg/5ml-15ml bottle	per bottle	15ml bottle	5000	155800
88	Azithromycin Syrup 200 mg/5ml 15ml	Sy. Azithromycin 200 mg per 5 ml	per bottle	15ml bottle	975000	11448000
89	Azithromycin Tab 500 mg	Tab. Azithromycin 500 mgAluminium Blister - Strip	Per Tab	strip of 10 tablets	10200000	55438400
90	B complex Inj 10 ml vial	Each ml contains: Thiamine Hydrochloride 100 mg, Riboflavin 5' Phosphate Sodium 2 mg, Pyridoxine Hydrochloride 2 mg, Dexpanthenol 2 mg, Niacinamide 100 mg, with Benzyl Alcohol 2% as preservative, in Water for Injection. Sodium Hydroxide and/or Hydrochloric Acid may have been used to adjust pH	per vial	10 ml Vial	300500	2731800
91	B1 B6 B12 Inj	Each 2ml Ampoule Contains- Thaiamine (B1) 100mg+ Pyridoxime (B6)	per ampl	2ml ampoule	149130	16447514

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
		100mg+ Cyanocobalamine 100mcg				
92	Bedaquiline - 100mg Tab	Tab. Bedaquiline - 100mg	Per Tab	188 tab in 1 bottle	18632	1059788
93	Benzalkonium Chloride solution I.P 20% w/v 500ml bottle	Benzalkonium Chloride solution I.P 20% w/v (equivalent to Benzalkonium Chloride 10 % w/v). Required item wise WHO GMP 500ml bottle	per bottle	500ml bottle	92200	9884240
94	Benzoyl Peroxide Gel 5%	Tube Conatins Benzoyl Peroxide 5%	Per Tube	20 gm Tube	80000	956800
95	Benzyl Benzoate Lotion 100 ml	Benzyl Benzoate Application 25 % w/w 100 ml	per bottle	100 ml bottle	301000	4271200
96	Betahistine tab 16mg	Tab. Betahistine hcl 16 mg	Per Tab	strip of 10 tablets	5000	29280
97	Betamethasone cream 0.1%	Tube contains Betamethasone 0.1%	Per Tube	20 gm Tube	180000	1638720
98	Betamethasone Valerate + Fusidic Acid Cream 15gm	Betamethasone Valerate 1mg + Fusidic Acid 20mg , 15gm Cream	Per Tube	15gm tube	200000	904000
99	Bisacodyl suppository Tab 5 mg	Tab Bisacodyl 5mg Suppository	Per Tab	strip of 10 tablets	1000	10120
100	Bisacodyl Tab 5 mg	Tab. Bisacodyl 5 mg	Per Tab	strip of 10 tablets	4501000	830760
101	Black coal tar Disinfectant Fluid R.W.C. not less than 10 Gr -II A I.S.I. mark Latest 5 Litre can	Black coal tar Disinfectant Fluid R.W.C. not less than 10 Gr -II A I.S.I. mark Latest 5 Litre can	per can	5 litre can	2005	802000
102	Black coal tar Disinfectant Fluid R.W.C. not less than 5 Gr. III I.S.I mark Latest 5 Litre can	Black coal tar Disinfectant Fluid R.W.C. not less than 5 Gr. III I.S.I mark Latest 5 Litre can	per can	5 litre can	2850	962160
103	Boro-Spirit Ear Drops- 0.183gm Boric Acid in 2.08 ml of Alcohol	Ear Drop Contains 0.183gm boric acid in 2.08ml of Alcohol 10 ml bottle	per bottle	10ml Ear Drop in Bottle	50000	739200
104	Bromhexine Hydrochloride Syp	each bottle containsBromhexine Hydrochloride 4mg/5ml	per bottle	100 ml bottle	100000	1540000
105	Budesonide 0.5mg Respules 2ml	Budesonide 0.5mg Respules 2ml	per respules	2ml respules	207300	927046

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
106	Budesonide Nebulisation solution	Each 1 Respules Contains Budesonide 0.5mg	per bottle	5 respules in 1 packet	100000	1584000
107	Budesonide Resp. Solution 0.5mg / 1mg	Budesonide Resp. Solution 0.5mg/ 2ml Respule	per respules	2ml respules	302000	963744
108	Budesonide respirator solution for use in nebuliser 1mg/ml	Each 1 Respules Contains Budesonide 1 mg	per respules	5 respules in 1 packet	85000	829600
109	Bupivacaine 0.5mg/ml Inj	Inj. Bupivacaine HCL USP 0.5 %, 5mg/ml	per vial	20 ml Vial	19345	851963
110	Bupivacaine Heavy mixed with glucose solution Inj.0.5% + 7.5% 4ml amp ANAWIN	Bupivacaine Heavy mixed with glucose solution Inj.0.5% + 7.5% 4ml amp ANAWIN	per ampl	4ml ampoule	2000	55920
111	Bupivacaine Low Molecular Weight 0.5% 20 ml Vial Inj	Inj Bupivacaine Hydrochloride 50mg/10ml	per vial	20 ml Vial	100000	6240000
112	Caffeine Citrate 20mg/ml, Inj	Caffeine Citrate 20mg Inj. Contains Caffeine Citrate 20 mg/ ml (equivalent to 10 mg caffeine base/ ml).	per ampl	3ml Amp	40300	5620320
113	Caffeine Citrate 20mg/ml, syp	Caffeine Citrate 20mg/ml, syp	per bottle	per bottle	19182	5668429
114	Calamine Lotion Bottle 50 ml	Calamine 8% w/v, Diphenhydramine hcl 1% w/v, Camphor 0.1% w/v, specially Denatured Spirit 2.37% v/v	per bottle	50 ml bottle	350500	6186000
115	Calcium carbonate 650 mg equivalent to elemental calcium 250 mg and cholecalciferol usp 125mg Tab	Each Tab contains calcium carbonate 650 mg equivalent to elemental calcium 250 mg and cholecalciferol usp 125mg	Per Tab	15 Tab Strip	1000000	4000000
116	Calcium Carbonate Tab + vit D3 1.25 gm	Tab Calcium Carbonate-1.25 gmi.e.1250 mg Vit D3- 250 iu,	Per Tab	stripe of 15 Tab	524475385	105497895
117	Calcium carbonate tablet 250mg	Tab Calcium Carbonate 250mg	Per Tab	strip of 10 tablets	6000000	960000
118	Calcium carbonate tablet 500 mg	Tab Calcium Carbonate 500mg	Per Tab	strip of 10 tablets	20000000	4000000
119	Calcium gluconate injection 1 gm, IV	Inj. Calcium Gluconate 100 mg/ml(w/v) 10 ml	per ampl	10ml ampl	550700	2567584

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
120	Calcium with phosphate Syp	Each 5 ml contains: Vitamin D3 (cholecalciferol)I.P. 200 IU,Vitamin B12 (Cynocobalamin)I.P.2. 5mcg, Calcium phosphate 82mg	per bottle	200 ml bottle	1730000	29623520
121	Calcium with Vitamin & Minerals Tab	Calcium Carbonate I.P. 1000mg + Magnesium Hydroxide I.P. 240mg + Zinc Sulphate I.P. 17.61mg + Vitamin D3 I.P. 200 IU + Vit. C I.P. 25mg	Per Tab	15 Tab Strip	7983996	9261435
122	Calcium with Vitamin D3 Granules	Sachet Elemental Calcium with Vitamin D3 Granules Each Sachet contains : From an organic soure (Oyster shell) Equivalent to Elemental Calcium 500mg + Vitamin D3 IP 250 IU OR EQUIVALENT	per sachet	per sachet	100105	840882
123	Capreomycin 500 mg Inj	Inj. Capreomycin - 500mg	per vial	10 ml Vial	5750	896988
124	Carbamazepine CR Tab 400mg	Carbamazepine CR Tab 400mg	Per Tab	strip of 10 tablets	300000	76800
125	Carbamazepine Tab 100 mg	Tab. Carbamezapine 100 mg	Per Tab	strip of 10 tablets	280000	212800
126	Carbamazepine Tab 200 mg	Tab. Carbamezapine 200 mg	Per Tab	strip of 10 tablets	6080000	4615360
127	Carbimazole Tab 5 mg	Tab Carbimazole 5 mg	Per Tab	strip of 10 tablets	25000	930000
128	Carboprost Inj. 250mcg/ml	Inj Carboprost tromethamine 250mcg/ml	per ampl	1ml ampl	196500	10180720
129	Carboxy Methyl Cellulose Sodium Lubricant eye drops 0.5% w/v 10 ml	Carboxy Methyl Cellulose Sodium Lubricant eye drops 0.5% w/v 10 ml bottle	per bottle	10ml bottle	73900	1271671
130	Carboxymethyl Cellulose Opthalmic Eye Drop 0.5%	Carboxymethyl Cellulose Opthalmic Eye Drop 0.5%, 5ml	per bottle	5 ml bottle	190000	1807280
131	Cefixime 200 mg Tab	Cefixime 200 mg Tab	Per Tab	strip of 10 tablets	8575000	27539200
132	Cefixime Oral Liquid 100 mg/5 ml	Each of reconstituted suspension contains Cefixime as Trihydrate 100mg/5ml,	per bottle	30 ml Bottle	401000	4332200

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
133	Cefixime oral liquid 50 mg/5ml	Each reconstituted suspension contains Cefixime as Trihydrate 50mg/5ml,	per bottle	30 ml Bottle	200000	5376000
134	Cefixime Tab 400 mg	Cefixime Tab 400 mg	Per Tab	strip of 10 tablets	1500000	18240000
135	Cefoperazone and Sulbactum for Inj 1 gm + 1 gm Vial	Inj. Cefoperazone+Sulbactum 2gm Inj. Cefoperazone sodium 1 gm + Sulbactum Sodium 1 gm USP i.e. 2 gm	per vial	Vial	176070	5527475
136	Cefoperazone and Sulbactum for Inj 500 mg+ 500 mg Vial	Inj. Cefoperazone+Sulbactum1gm Inj. Cefoperazone sodium 500 mg + Sulbactum Sodium 500 mg USP i.e. 1gm	per vial	Vial	855000	10098800
137	Cefotaxime Inj 1 gm Vial	Inj. Cefotaxime Sodium sterile powder 1 gm /Vial	per vial	per Vial	6005180	66469400
138	Cefotaxime Inj 250 mg Vial	Inj. Cefotaxime Sodium sterile powder 250 mg/Vial	per vial	per Vial	201000	1703560
139	Cefotaxime Inj 500 mg Vial	Inj. Cefotaxime Sodium sterile powder 500 mg/Vial	per vial	per Vial	1102000	18480720
140	Cefpodoxime Proxetil Tab 100mg	Cefpodoxime Proxetil Tab 100mg	Per Tab	(blank)	10000	66560
141	Ceftazidime powder for injection 250 mg	Inj. Ceftazidime Sodium sterile powder 250mg/Vial	per vial	Vial	40000	2851200
142	Ceftazidime powder for injection 500 mg	Ceftazidime powder for injection 500 mg	per vial	Vial	100000	1436000
143	Ceftriaxone Inj. 250mg	Inj. Ceftriaxone Sodium sterile powder 250 mg/Vial	per vial	Vial	200000	2876800
144	Ceftriaxone Inj 500 mg Vial	Inj. Ceftriaxone 500 mg	per vial	per Vial	1460000	11920400
145	Ceftriaxone Inj. 1gm	Inj. Ceftriaxone 1000 mg	per vial	Vial	3450500	37566853
146	Cefuroxime 1 gm injection	Inj.cefuroximeSodium sterile powder 1000 mg/Vial	per vial	per Vial	100000	4000000

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
147	Cefuroxime 250 mg tablet	Tablet Contains Cefuroxime 250 mg	Per Tab	strip of 10 tablets	1005000	5454600
148	Cefuroxime DT 125mg tablet	Cefuroxime DT 125 mg tablet	Per Tab	strip of 10 tablets	1000000	1200000
149	Cetrimide + Chlorhexidine Solution 5 ltr Jar	Antiseptic solution containing = Cetrimide 3% w/v Chlorohexidine 1.5% w/v = 5 ltr jar	per jar	5 litre jar	25000	6200000
150	Cetrizine Hydrochloride Tab 10 mg	Tab. Cetrizine Di Hydrochloride 10 mg Aluminium Blister - Strip of 10 Tablets	Per Tab	strip of 10 tablets	100500000	12136000
151	Cetrizine Syrup 5 mg/5 ml 30 ml	Cetrizine Syrup 5 mg/5 ml	per bottle	30 ml bottle	2030000	9038880
152	Cetrizine Tablet 5mg	Each Tablet Contains Cetrizine 5mg	Per Tab	strip of 10 tablets	20000000	2400000
153	Chlorhexidine Gluconate 500 ml bottle Surgical scrub	Surgical scrub containing : Chlorhexidine Gluconate 20 % v/v equivalent to Chlorhexidine Gluconate 4 % w/v in Non-Ionic surfactant base (EN Tests required from International Laboratories in Europe / USA) EN1499 Hygenic Hand wash & EN13727 Bactericidal activity Required item wise WHO GMP 500 ml bottle with dispenser	Per dispenser	500 ml bottle with dispenser	26200	4590240
154	Chlorhexidine gluconate Mouthwash 100 ml	Chlorhexidine Gluconate Oral Rinse 0.12%	per bottle	100 ml bottle	66000	615200
155	Chlorine Tab 25 mg	Tab. Chlorine 25 mg (Tab. Sodium Dichloroisocyanurate Available chlorine 25 mg)	Per Tab	strip of 10 tablets	6000	59232
156	Chlorine Tab 250 mg	Tab. Chlorine 250 mg (Tab. Sodium Dichloroisocyanurate Available chlorine 250 mg)	Per Tab	strip of 10 tablets	2500	68240
157	Chloroquine base Tab 600mg	Tab Chloroquine 600 mg	Per Tab	10 Tab	200	2024

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
158	Chloroquine Tab 150mg	Chloroquine Phosphate base Tab 250mg (250mg of chloroquine phosphte equivalet to 155mg)	Per Tab	strip of 10 tablets	366894	2048709
159	Chlorpheniramine Maleate Tab 4 mg	Tab. Chlorpheniramine maleate 4 mg Aluminium Blister - Strip of 10 Tablets	Per Tab	strip of 10 tablets	15020000	3244640
160	Chlorpheniramine oral liquid 5mg/5ml	Each bottle Contains Chlorpheniramine Maleate 5mg/5ml	per bottle	60 ml bottle	500000	3576000
161	Chlorpromazine Tab 100 mg	Chlorpromazine Tab 100 mg	Per Tab	strip of 10 tablets	55000	105600
162	Chlorpromazine Tab 50 mg	Tab. Chlorpromazine Hydrochloride 50 mg	Per Tab	strip of 10 tablets	261000	204624
163	Chlorthalidone 25mg Tab	Tab. Chlorthalidone 25mg Strip of 10 Tablets	Per Tab	strip of 10 tablets	3659337	966065
164	Chlorthalidone 6.25mg Tab	Tab. Chlorthalidone 6.25mg Strip of 10 Tablets	Per Tab	strip of 10 tablets	8050000	2290000
165	Chlorthalidone Tab 12.5 mg	Tab. Chlorthalidone 12.5mg Strip of 10 Tablets	Per Tab	strip of 10 tablets	2030000	940800
166	Cholecalciferol 1000 IU Tab	Tab. Cholecalciferol 1000 IU	Per Tab	strip of 10 tablets	590789	1995661
167	Cholecalciferol Granules sachet 60000 IU 1 gm	Vitamin D3 (Cholecalciferol) 60,000 IU / g Granules	per sachet	1 gm Sachet	1620000	7848800
168	Cholecalciferol injection of 600000 IU	Each ml Contains Cholecalciferol IP 600000 IU	per ampl	1ml ampl	150000	801600
169	Ciprofloxacin + Dexamethasone Eye Drops 5 ml	Ciprofloxacin 0.3% w/v Dexamethasone 0.1% w/v E/D (5ml.Vial)	per vial	5 ml vial	1000000	6560000
170	Ciprofloxacin Eye Ointment 5 gm	Ciprofloxacin Eye ointment (Ciprofloxacin Hydrocloride equivalent to 3 mg/g, Ciprofloxacin in an anhydrous Ophthalmic Oint base)	Per Tube	5 gm Tube	150000	960000
171	Ciprofloxacin Eye/Ear drop 5 ml	Ciprofloxacin 0.3% w/v Eye Drop 5ml	per bottle	5 ml	2002000	14412096

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
172	Ciprofloxacin I.V Inj 200 mg 100 ml Bottle	I. V. Ciprofloxacin : Each 100 ml contains : Ciprofloxacin HCL eq. to Ciprofloxacin 200 mg , Water for Injection Q.S. AFFS/BFS/FFS Technology	per bottle	100 ml bottle	1458500	8957120
173	Ciprofloxacin oral liquid 250 mg/5ml	Each 10 ml contains Ciprofloxacin 250mg	per bottle	60 ml bottle	50000	1040000
174	Ciprofloxacin Tab 250 mg	Tab. Ciprofloxacin 250 mg	Per Tab	strip of 10 tablets	23255000	14361160
175	Ciprofloxacin Tab 500 mg	Tab. Ciprofloxacin 500 mg	Per Tab	strip of 10 tablets	15972500	20209885
176	Cisatracurium Inj 2mg/ml 5ml vial	Cisatracurium 2 mg as cisatracurium besylate 2.68 mg per 1 ml	per vial	5 ml vial	1500000	4056000
177	Clarithromycin 250 mg Tab	Each Tab Clarithromycin Contains 250mg	Per Tab	6 Tab Strip	6000	991920
178	Clindamycin Cap 150 mg	Cap. Clindamycin 150 mg	per Cap	strip of 8 capsules	382596	951830
179	Clindamycin Cap 300mg	Each Capsule Contains Clindamycin 300mg	per Cap	strip of 10 capsules	250000	800000
180	Clobazam Tab 10 mg	Tab Clobazam 10 mg	Per Tab	strip of 10 tablets	2446000	1021104
181	Clobetasol Oint Propionate 0.05% w/w	Oint / Cream Clobetasol Propionate 0.05% w/w, 30gm	Per Tube	30 gm Tube	602000	4768720
182	Clonazepam Tab 0.25mg	Each tablet Contains Clonazepam 0.25mg	Per Tab	strip of 10 tablets	275000	4070000
183	Clonazepam Tab 0.5mg	Tab. Clonazepam 0.5mg	Per Tab	strip of 10 tablets	16780000	2867200
184	Clonazepam Tab 2 mg	Tab. Clonazepam 2 mg	Per Tab	strip of 10 tablets	611724	1296699
185	Clonidine 75mcg Inj.	Inj. Clonidine 75mcg/ml	per vial	per Vial	200	14240
186	Clopidogrel Tab 75 mg	Tab Clopidrogel 75 mg	Per Tab	strip of 10 tablets	5820000	2878080
187	Clotrimazole Cream 1% 15 gm	Clotrimazole Cream : Cream Clortimazole 1% w/w- 15 gm	Per Tube	15 gm Tube	2903000	20322400
188	Clotrimazole Dusting Powder 1 % 30 gm	Clotrimazole Dusting Powder 1% w/w - 30 gm	per bottle	30 gm bottle	802000	9156800

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
189	Clotrimazole Ear Drops 10 ml	Gentamycin 0.300%, Clotrimazole 1%, Betamethasone Dipropionate 0.025%, Lignocaine Hcl 2% Chloramphenicol 5%, Beclomethasone Dipropionate 0.25%, Clotrimazole 1%, Lignocaine 2%-10 ml	per bottle	10 ml bottle	1000	6936
190	Clotrimazole Mouth Paint 1 % 15 ml	Clotrimazole Mouth Paint 1% w/v - 15 ml	per bottle	15 ml Bottle	104172	951719
191	Clotrimazole tablet 100 mg	Each tablet Contains Clotrimazole 100mg	Per Tab	6 Tab Strip	950000	934800
192	Clotrimazole vaginal Pessaries with applicator 100 mg	Tab Clotrimazole 100mg Vaginal with applicator	Per Tab	strip of 10 tablets	1764984	2470333
193	Cloxacillin capsule 250 mg	Each capsule Contains cloxacillin 250 mg	per Cap	strip of 10 capsules	90000	864000
194	Clozapine Tab 100mg	Clozapine Tab 100mg	Per Tab	strip of 10 tablets	850000	2039200
195	Clozapine Tab 25 mg	Clozapine Tab 25 mg	Per Tab	strip of 10 tablets	550000	308000
196	Clozapine Tab 50mg	Clozapine Tab 50mg	Per Tab	strip of 10 tablets	4691852	4115892
197	Colistimethate Sodium 1 million IU Inj	Each Vial Contains Colistimethate Sodium IP1000000 IU (Powder for Injection)	per vial	10 ml Vial	8086	1261478
198	Combipack of mifepristone+Misoprostol (1 tab of Mifepristone 200mg and 4 tab of misoprostol 200mcg)	Combipack of mifepristone+Misoprostol (1 tab of Mifepristone 200mg and 4 tab of misoprostol 200mcg)	per combipack	per combipack	1000	276000
199	Contrast Non Ionic monomer 370mg/ml or 350mg/ml or 300mg/ml Iohexol 100ml bottle	Contrast Non Ionic monomer 370mg/ml or 350mg/ml or 300mg/ml Iohexol	per bottle	100ml bottle	2552	2245760
200	Contrast Non Ionic monomer 370mg/ml or 350mg/ml or 300mg/ml Iohexol 50ml vial	Contrast Non Ionic monomer 370mg/ml or 350mg/ml or 300mg/ml Iohexol	per vial	50ml vial	4730	2270400
201	Contrast Non Ionic monomer 370mg/ml or 350mg/ml or 300mg/ml Ioversol 100ml vial	Contrast Non Ionic monomer 370mg/ml or 350mg/ml or 300mg/ml Ioversol	per vial	100ml vial	1500	1020000

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
202	Cotrimoxazole DS (Trimethoprim + Sulphamethoxazole) Tab 160 mg + 800 mg	Tab. Cotrimoxazole DS Tab. Cotrimoxazole (Trimethoprim 160 mg + Sulphametaxazole 800 mg) DS	Per Tab	strip of 10 tablets	12760400	19962653
203	Cotrimoxazole SS (Trimethoprim + Sulphamethoxazole) Tab 80 mg + 400 mg	Tab. Cotrimoxazole (Trimethoprim + Sulphametaxazole) S S Tab. Cotrimoxazole (Trimethoprim 80 mg + Sulphametaxazole 400 mg) S S	Per Tab	strip of 10 tablets	10821800	8923218
204	Cotrimoxazole Syrup (Trimethoprim + Sulphamethoxazole) 40 mg + 200 mg 50 ml Bottle	Sy. Cotrimoxazole - Each 5 ml contains Trimethoprim 40 mg + Sulphamethoxazole 200 mg	per bottle	50 ml bottle	1333200	8261056
205	Cough Expectorant with Dextromethorphan Hydrobromide 100ml Bottle	Cough Expectorant with Dextromethorphan Hydrobromide Each 10ml Contains Dextromethorphan Hydrobromide I.P. 10mg, Chlorpheniramine Maleate I.P.4mg, Guiafenesin I.P. 100mg, Alcohol (95%) 0.2ml, OR Equivalent 100ml Bottle	per bottle	100ml bottle	142416	2839205
206	Cough Suppresent with Diphenhydramine & Guaiphenesin 100 ml Bottle	Cough Suppresent with Diphenhydramine & Guaiphenesin Each 5 ml contains Diphenhydraimine HCL IP 8 mg, Guaiphenesin IP 50 mg, Bromhexine HCL IP 4mg, OR Equivalent 100ml Bottle	per bottle	100ml bottle	84320	800028
207	Cyanocobalamine Inj 1000 mcg/ml 10 ml Vial	Inj. Cyanocobalamin (Vitamine B 12) 1000mcg/mL; soln for IM or SC inj; contains Benzyl alcohol.- 10 ml	per vial	10 ml Vial	400500	6437380
208	Cycloserine capsule 250 mg	Each capsule Contains Cycloserine 250 mg	per Cap	strip of 10 capsules	50000	936320
209	Deferasirox 500mg Tab	Deferasirox 500mg Tab	Per Tab	strip of 10 tablets	906000	5660688

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
210	Deferasirox Tab 250 mg	Tab Deferasirox 250 mg	Per Tab	strip of 10 tablets	600000	1915200
211	Deferiprone 500mg Tab	Deferiprone 500 mg Tab	Per Tab	strip of 10 Tab	200000	928000
212	Deriphyllin Tablet SR	Each Film Coated Sustained Release Tab contains Etophylline 115 mg + Theophylline 35 mg	Per Tab	30 Tab Strip	12000	33120
213	Deriphyllin Tablet SR 150mg	Each Film Coated Sustained Release Tab contains Etophylline 115 mg + Theophylline 35 mg	Per Tab	30 Tab Strip	1100000	880000
214	Desensitising Paste Containing Stronium Chloride + Potassium Nitrate 10 % + 5 % 50 gm	Desensitising paste containing stronium chloride 10 % + Potasium Nitrate 5% - 50 gm	Per Tube	50 gm Tube	35334	1272024
215	Desflurane 240ml	Desflurane Liquid for inhalation 240ml Bottle	per bottle	240ml bottle	1125	7923665
216	Dexamethasone Inj 4 mg 2 ml	Inj. Dexamethasone Sodium Phosphate 4 mg/ml - 2 ml Vial IM/IV -	per ampl	2 ml amp	3003000	7947424
217	Dexmedetomidine 100mcg/ml Inj 1ml amp	Dexmedetomidine hydrochloride 100mcg/ml Inj 1ml amp	per ampl	1ml ampoule	6050	1635984
218	Dextrose 25% I V 100 ml Bottle	Dextrose 25% w/v I. P.100 ml Bottle I V	per bottle	100 ml bottle	343050	3375890
219	Dextrose 5% with Sodium Chloride 0.9 % W/V I.P. (DNS) I V 500 ml Bottle	Dextrose 5% with Sodium Chloride 0.9 % W/V I.P. (DNS) 500 ml Bottle I V	per bottle	500ml bottle	433100	6166235
220	Dextrose I.V 10 % 500 ml Bottle	I. V. . Dextrose Anhydrous 10%, water for inj. qs. 500 ml - AFFS/BFS/FFS Technology	per bottle	500 ml bottle	100200	1444320
221	Dextrose I.V 5 % 500 ml Bottle	I. V. Dextrose 5% Isotonic w/v AFFS/BFS/FFS Technology	per bottle	500 ml bottle	1997525	25509340

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
222	Dextrose with Normal Saline I.V 5% 500 ml Bottle	I. V. Dextrose 5% in Normal saline 0.9% (I. E. Glucose with sodium chloride 5% glucose, 0.9% sodium chloride (equivalent to 150 mmol/L Na+ and 150 mmol/L Cl-); 5% glucose, 0.45% sodium chloride (equivalent to 75 mmol/L Na+ and 75mmol/L Cl- w/v) AFFS/BFS/FFS Technology	per bottle	500 ml bottle	2103000	29973600
223	Diazepam Inj 5 mg 2 ml Amp	Inj. Diazepam 5 mg/ml	per ampl	2 ml amp	238487	824191
224	Diazepam Tab 5mg	Tab. Diazepam 5 mg	Per Tab	strip of 10 tablets	3584000	1211808
225	Diclofenac Gel 1 % 30 gm	Gel Diclofenac Diethylammonium Salt 1.16 %w/w/2.32% w/w (equivalent to Diclofenac Sodium 1% w/w)-30 gm	Per Tube	30 gm Tube	4220000	25450400
226	Diclofenac sodium 75 mg/ml Inj. Pack size - 1 ml I V Bolus Injection	Diclofenac Sodium Inj. I.P.Contains Each ml contains Diclofenac Sodium I.P. 75, Benzyl Alcohol 4% v/v, water for injection q.s. 1ml Ampoule (I V Bolus Injection)	per ampl	1ml Amp	551000	8741600
227	Diclofenac Sodium Inj 25 mg/ml 3 ml Amp	Inj. Diclofenac sodium 25 mg/ml - 3 ml Amp	per ampl	3 ml Amp	8525000	14007000
228	Diclofenac Sodium Tab 50 mg	Tab. Diclofenac Sodium 50 mg Aluminium Blister - Strip of 10 Tablets	Per Tab	strip of 10 tablets	77717500	11355070
229	Diclofenac Suppository 100 mg single	Diclofenac sodium 100 mg Suppository	Per suppository	5 Suppository in 1 Packet	81182	1309295
230	Dicyclomine 10 mg / ml - 2 ml Inj	Dicyclomine Hydrochloride Inj 10 mg/ml 2 ml	per ampl	2 ml amp	410000	1028320
231	Dicyclomine 500 mg tablet	Each Tab Contains Dicyclomine 500 mg	Per Tab	strip of 10 tablets	738629	827265
232	Dicyclomine Hydrochloride Tab 10 mg	Dicyclomine Hydrochloride Tab 10 mg	Per Tab	strip of 10 tablets	17858829	3721036
233	Dihydrogen Sodium Citrate Syp	Syp. Dihydrogen Sodium Citrate	per bottle	100 ml bottle	457000	4600384

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
		contains Dihydrogen Sodium Citrate 1.37gm				
234	Dinoprostone Gel 0.5 mg	Dinoprostone 0.5mg gel	Per Tube	3 gm Tube	222500	34614496
235	Dioctyl sulfosuccinate sodium 100mg	Each Tab Contains Dioctyl sulfosuccinate sodium 100mg	per bottle	1 Bottle of 100 Tab	5000	892000
236	Distilled Water 5 Ltr Jar	Distilled Water 5 Ltr Jar (DEIONOIZED WATER)	per jar	5 Ltr Jar	7110	1703856
237	Divalproex Sodium tab 500 mg	Divalproex Sodium tab 500 mg	Per Tab	strip of 10 tablets	6355000	13975600
238	Dobutamine 50mg/ml-5mlAmpoule(i.e.250mg) Inj	Inj. Dobutamine 50 mg/ml - 5 ml Ampoule(i.e.250mg)	per ampl	5 ml	500	18224
239	Dobutamine50mg/ml-5mlAmpoule(i.e.250mg) Inj	Inj. Dobutamine 50 mg/ml - 5 ml Ampoule(i.e.250mg)	per ampl	5 ml	14000	282240
240	Domperidone Mouth Dissolving Tab 10mg	Tab Domperidone 10 mg M D Aluminium Blister - Strip of 10 Tablets	Per Tab	strip of 10 tablets	13600000	2284800
241	Domperidone syrup 30ml	Syrup Domperidone : each ml contain 1mg domperidone	per bottle	30ml bottle	1694600	7049558
242	Domperidone Tab 10mg	Tab Domperidone 10 mg Aluminium Blister - Strip of 10 Tablets	Per Tab	strip of 10 tablets	31267000	4679456
243	Donepezil Tab 5mg	Tab. Donepezil HCL 5 mg	Per Tab	strip of 10 tablets	386000	327328
244	Dopamine Inj 40 mg/ml 5 ml	Inj. Dopamine Hcl 200mg/5ml (40mg/ml)	per vial	5 ml vial	291974	2549114
245	Doxycycline Cap 100 mg	Capsule Doxycycline 100 mg	per Cap	strip of 10 capsules	38038411	29644966
246	Doxycycline syrup 50 mg/5ml	Each reconstituted suspension contains Doxycycline 50 mg/5ml,	per bottle	60 ml bottle	113486	953286
247	Doxylamine succinate	Combination of 10 mg of Doxylamine Succinate + 10 mg of Pyridoxine hydrochloride (Vitamin B 6)	Per Tab	strip of 10 tablets	2000	3408
248	Doxylamine succinate 50mg tab	Doxylamine succinate 50mg tab	Per Tab	strip of 10 tablets	600000	374400
249	Drotaverine 40mg, 2ml Inj	Inj. Drotaverine 40mg, 2ml Each 2ml contains Drotaverine HCL IP 40mg, Absolute	per ampl	2 ml amp	164298	1019819

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
		Alcohol IP 8.0% w/v, Water for Injection q.s.				
250	Drotaverine tab 500mg	Each Tablet Contains Drotaverine 500mg	Per Tab	strip of 10 tablets	87871	984155
251	Enalapril Tab 10 mg	Each Tablet Contains Enalapril 10mg	Per Tab	strip of 10 tablets	1000000	992000
252	Enalapril Tab 5 mg	Tab. Enalaprile Maleate 5 mg	Per Tab	strip of 10 tablets	11272157	3465196
253	Erythromycin 0.5% ointment	Erythromycin ophthalmic ointment USP, 0.5%	Per Tube	3.5gram Tube	40000	1371200
254	Erythromycin Susp 125 mg/5ml 60 ml	Sy. Erythromycin 125 mg/5 ml as Estolate or Sterrate - Bottle of 60 ml	per bottle	60 ml bottle	74212	1060936
255	Erythropoetin Injection10000 IU	Each Prefilled Syringe of 1 ml contains Erythropoetin concentration solution IP 10000IU	per pfs	PFS of 1ml	50000	1800000
256	Erythropoetin Recombinant Inj 2000 IU Vial	Inj. Recombinant Erythropoietin 2000 iu per Vial	per vial	10 ml Vial	78000	5730816
257	Escitalopram Tab 10 mg	Tab. Escitalopram Oxalate 10 mg	Per Tab	strip of 10 tablets	9710000	3167440
258	Escitalopram tablet 5 mg	Each tablet Contains Escitalopram 5 mg	Per Tab	strip of 10 tablets	59432	2424834
259	Esmolol Inj 10mg/ml	Each ml Contains Esmolol 10mg	per vial	10 ml Vial	4000	944000
260	Ethamsylate Inj 125 mg/ml 2 ml	Inj. Ethamsylate 125 mg/ml - i.e. 250 mg in 2 ml Ampoule	per ampl	2 ml ampl	1000	36184
261	Ethamsylate Tab 250 mg	Tab. Ethamsylate 250 mg	Per Tab	10 Tab	2000	22016
262	Etomidate 2mg Inj	Inj. Etomidate USP 2mg Propylene Glycol 35% v/v, pH is 6.0	per vial	per Vial	20	2016
263	Etophylin + Theophyillin SR Tab 231 mg + 69 mg	Tab. Etophyllin 231 mg + Theophyllin 69 mg S R Aluminium Blister - Strip of 10 Tabs	Per Tab	strip of 10 tablets	3005000	2960520
264	Etophylin + Theophylline Inj 169.4 mg + 50.6 mg 2 ml	Inj. Etophyllin 169.4 mg + Theophyllin 50.6 mg in 2 ml - 2 ml	per ampl	2 ml amp	1602000	2077872

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
265	Factor VIII Recombinant 250 IU	Factor VIII Recombinant 250 IU 1. Recombinant Factor VIII-Plasma free, Human Albumin free inj. 2. Reconstitute in 2 or 4 ml dilution 3. Expiry date should not be less than one Year. 4. No human and animal derived protines should have been used during manufacture or formulation of recombination products. 5. Safety and Efficacy standards as per WFH guidelines for clotting factors Concentrates (CFC) Assesment. 6. Packege shall contain the sterile water for injection.	Single Unit	250 IU per vial	25934	45441010
266	Factor VIII Recombinant 500 IU	Factor VIII Recombinant 500 IU 1. Recombinant Factor VIII-Plasma free, Human Albumin free inj. 2. Reconstitute in 2 or 4 ml dilution 3. Expiry date should not be less than one Year. 4. No human and animal derived protines should have been used during manufacture or formulation of recombination products. 5. Safety and Efficacy standards as per WFH guidelines for clotting factors Concentrates (CFC) Assesment. 6. Packege shall contain the sterile water for injection.	Single Unit	500 IU per vial	17968	54140503

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
267	Fat Emulsion I.V. 20% 250 ml Bot.	Fat Emulsion I.V. 20% w/v I.V. fat emulsion for Parenteral nutrition Soyabean oil – 20 gm USP Egg Phopholipid/Lecithin – 1.2gm IP Glyceral unhydrous- 2.25gm IPWater fluid – 9 – 250 ml / OR Equivalent 250 ml Bot.	per bottle	250ml bottle	1500	921360
268	Feracrylum 1% Gel 15gm Tube	Feracrylum 1% Gel Each Gram contains 1% w/w Feracrylum Pack Size : 15gm Tube	Per Tube	15 gm Tube	25000	800000
269	Feracrylum 1% Gel 50gm Tube	Feracrylum 1% Gel Each Gram contains 1% w/w Feracrylum Pack Size : 50gm Tube	Per Tube	50 gm Tube	24792	1289194
270	Ferric Carboxy Maltose 500mg/10 ML Inj	Inj. Ferric Carboxy Maltose 500mg/10 ML Vial	per vial	10 ml Vial	387449	43380268
271	Ferrous Fumarate 200 mg + Cyanocobalamine 15 mcg + Folic Acid 1.5 mg. Sustained release OR EQUIVALENT Cap	Ferrous Fumarate 200 mg + Cyanocobalamine 15 mcg + Folic Acid 1.5 mg. Sustained release OR EQUIVALENT Cap	per Cap	strip of 10 capsules	2035000	1256979
272	Ferrous fumarate Tab 210 mg	Tab Ferrous fumarate 210 mg Strip of 10 Tablets	Per Tab	strip of 10 tablets	3612666	1473968
273	Flucanazole Tab 150 mg	Tab. Flucanazole 150 mg	Per Tab	strip of 10 tablets	2510000	3156480
274	Flucionolone Acetonide Cream 0.1% w/w	Flucionolone Acetonide Cream 0.1% w/w	Per Tube	30gm tube	11150	802800
275	Flunarizine Tab 10 mg	Each Flunarizine Tab contains 10mg	Per Tab	strip of 10 tablets	70000	862400
276	Fluocinolone Ointment 15 gm	Fluocinolone Acetonide Topical ointment 0.025% ointment - 15 gm	Per Tube	15 gm Tube	2000	104000
277	Fluoxetine Cap 20 mg	Cap. Fluoxetine Hydrochloride equivalent to 20 mg (64.7 µmol) of fluoxetine. The Pulvules also contain dimethicone, FD&C Blue No. 1, FD&C Red No. 3, FD&C Yellow No. 6, gelatin, sodium	per Cap	strip of 10 capsules	860000	516688

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
		lauryl sulfate, starch, and titanium dioxide				
278	Fluphenazine Decanoate Inj 25 mg/ml	Inj. Fluphenazine HCL Decanoate 25 mg/ml	per ampl	1ml ampl	1680	29541
279	Fluticasone Nasal Spray	Fluticasone Nasal Spray Contains: Microcrystalline Cellulose & Carboxy Methyl Cellulose Sodium, Dextrose 0.02% w/w Bezalkonium Chloride, Polysorbate 80, and 0.25% w/w Phenylethyl Alcohol, with pH between 5 to 7.	per bottle	10 ml Bottle	151672	995236
280	Folic Acid 400mcg Tab	Tab. Folic Acid 400 mcg. Strip of 10 Tablets	Per Tab	strip of 10 tablets	53684182	7368692
281	Folic acid inj 1mg/ml	Each ml of contains Folic Acid 1mg	per vial	10 ml Vial	35000	840000
282	Folic acid Tab 5 mg	Tab Folic Acid 5 mg. Strip of 10 Tablets	Per Tab	strip of 10 tablets	20500000	6064000
283	Formaldehyde Solution 500 ml	Formaldehyde 500 ml Solution	per bottle	500ml bottle	14400	875664
284	Formaldehyde Tab 1 gm	Tab Formaldehyde - 91% Paraformaldehyde 96% Paraformaldehyde-paraformaldehyde 96% Tablets. (A single Tablet consists of paraformaldehyde 1. 04 gm. Eq. To paraformaldehyde 1 gm.) = available strengths 1 gm	Per Tab	strip of 10 tablets	167632	1740687
285	Formoterol,Salmeterolol/Fluticasone MDI,DPI Combination of LABA+ICS	Each Actuation Delivers Salmeterolol Xinafoate 25mcg +Fluticasone Proprionate 250mcg + Formoterol q.s.	Per Packet	120 MDI In 1 Packet	5143	1040984
286	Fradiomycin 1% w/w Skin Cream 30gm	Fradiomycin Skin Cream 0.5 % w/w, 30gm	Per Tube	30 gm Tube	47453	1442562

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
287	Framycetin Cream 0.5%	Oint. Framycetin skin 0.5 % w/w 30 gm	Per Tube	30 gm Tube	100000	2800000
288	Framycetin Sulphate Cream 30 gm	Oint. Framycetin skin 1 % w/w 30 gm	Per Tube	30gm tube	351000	9164800
289	Frusemide Inj 10 mg/ml 2 ml	Frusemide 10mg/ml Inj 2ml amp	per ampl	2ml ampoule	1117072	2501474
290	Frusemide Inj. 2mg/ml	Inj. Frusemide - 2 mg Each 1 mL contains 10 mg furosemide	per ampl	2 ml ampl	1100000	1751200
291	Frusemide Tab 40 mg	Tab. Frusemide 40 mg Aluminium Blister - Strip of 10 Tab	Per Tab	strip of 10 tablets	2205000	1410240
292	Furazolidone 25 mg/5 ml 60 ml Bottle Syp	Sy. Furazolidine 25 mg / 5 ml : 60 ml.	per bottle	60 ml bottle	252000	1324992
293	Furazolidone Tab 100 mg	Tab. Furazolidine 100 mg	Per Tab	strip of 10 tablets	43652637	11030072
294	Furesamide 10mg/ml Syp	Syp. Furesamide 10mg/ml	per bottle	10ml bottle	12718	857064
295	Fusidic acid Cream 2%	Fusidic acid 2% w/w - 10 gm (Fusidic acid 20mg per gm)	Per Tube	30 gm Tube	102675	2792749
296	Fusidic acid Cream 5%	Fusidic acid 5% w/w - 10 gm (Fusidic acid 20mg per gm)	Per Tube	10 gm Tube	75000	1414800
297	Gabapentine Tablet 400mg	Each Gabapentine Tablet Contains 400mg	Per Tab	strip of 10 tablets	50000	943200
298	Gamma Benzene hexachloride Lotion 100 ml	Gammabenzene Hexachloride 1% w/v, Bottle of 100ml	per bottle	100 ml bottle	612000	10262720
299	Gelatin based material with Thrombin 8-10ml pfs	Hemostatic Gelatin Thrombin Matrix - Containing Human Thrombin, 8-10 ml Prefilled syringe containing Gelatin matrix, One Vial of Calcium Chloride 10 ml , Syringe with luer connector, Plastic Bowl of Thrombin Solution 8-10ml	per pfs	per pfs	50	834000
300	Gentamicin drops 0.3%	Gentamicin Eye/Ear drops0.3%	per bottle	10 ml Bottle	100000	2000000
301	Gentamycin 10mg/ml Inj	Inj. Gentamycin 10 mg/ml - 1ml ampoule	per ampl	1ml ampl	446037	1648207
302	Gentamycine Inj 40 mg/ml 2 ml	Inj. Gentamycin 40 mg/ml - 2 ml amp	per ampl	2ml ampoule	1605000	6732200

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
303	Glibenclamide Tab 5 mg	Tab. Glibenclamide 5 mg Aluminium Blister - Strip of 10 Tab	Per Tab	strip of 10 tablets	4000000	1024000
304	Gliclazide Tab 80 mg	Tab. Gliclazide 80mg	Per Tab	strip of 10 tablets	2260259	886022
305	Gliclazide tablet 40 mg	Each Tab Gliclazide tablet Contains 40 mg	Per Tab	strip of 10 tablets	2626880	945677
306	Glimiperide 1mg Tab	Tab Glimepiride 1mg	Per Tab	strip of 10 tablets	45347930	6446702
307	Glimiperide Tab 2 mg	Tab Glimepiride 2mg	Per Tab	strip of 10 tablets	165736024	24325693
308	Glucagon Inj 1 mg/ml Vial	Inj Glucagon 1mg/ml - Vial	per vial	10 ml Vial	2634	817715
309	Glucose Injection 5%	Each 100 ml Bottle Contains Glucose Injection 5%	per bottle	100 ml bottle	5000	960000
310	Glucose Powder 75gm	Indian Standard IS 874:1992 Dextrose Monohydrate (3rd Revision) Sachet of 75 gm	per sachet	75gm Sachet	6417668	64483075
311	Gluteraldehyde Solution 2 % 5 Ltr	Gluteraldehyde solution 2% activation non staining non restoring 5 ltr jar	per jar	5 Ltr Jar	24945	5538176
312	Glycerine 500 ml Glass Bottle	Glycerin 500 ml Glass Bottle	per bottle	500 ml bottle	50100	897920
313	Glyceryl trinitrate 125mg/5ml	Each ml Glyceryl trinitrate Contains 25mg	per vial	5 ml Vial	50000	2000000
314	Glyceryl Trinitrate Patech 10 mg patch	Glyceryl Trinitrate Patech 10 mg patch	Per patch	Per patch	100	2036
315	Glyceryl Trinitrate Sublingual Tabs 0.5 mg	Tab. Glyceryl Trinitrate 0.5 mg	Per Tab	strip of 10 tablets	101000	816880
316	Glycopyrolate Inj. 1ml	Inj. Glycopyrrolate 0.2mg/ml	per ampl	1 ml Ampoule	500	13024
317	Griseofulvin Tab 125 mg	Tab. Griseofulvin 125 mg	Per Tab	strip of 10 tablets	1050296	1201539
318	Gum Paint (Tannic Acid)	Each Bottle contains Tannic acid 2 % W/V	per bottle	15 ml Bottle	15000	864000
319	Haloethane with Vaporiser 250ml	Haloethane with Vaporiser 250ml	per bottle	250ml bottle	10	9960
320	Haloperidol 1.5mg Tab	Each Tab Haloperidol Contains 1.5mg	Per Tab	strip of 10 tablets	300000	998400

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
321	Haloperidol Deconoate Depot Inj 50mg/ml	Each mL of Haloperidol Decanoate Injection, 50 mg/ml contains 50 mg haloperidol (present as haloperidol decanoate 70.5 mg) in a sesame oil vehicle, with 1.2% (w/v) benzyl alcohol as a preservative.	per ampl	1ml ampl	24208	1641302
322	Haloperidol Inj 5mg/ml	Inj. Haloperidol 5 mg/ml	per ampl	1ml ampl	26100	1864375
323	Haloperidol Tab 5 mg	Tab. Haloperidol 5 mg	Per Tab	strip of 10 tablets	7246038	1763797
324	Hemodialysis solution B.P. with soda bicarbonate (to be used with Dialysis Machine) 10 Ltr. Jar	Hemodialysis solution B.P. with soda bicarbonate (to be used with Dialysis Machine) 10 Ltr. Jar	per jar	10 litres jar	3674	1066577
325	Heparin Gel 20 gm	Heparine jelly 200 iu per gm - 20 gm	Per Tube	20 gm Tube	20200	1350240
326	Heparin Low molecular weight 40mg/ 0.4ml Inj PFS	Heparin Low molecular weight 40mg/ 0.4ml Inj PFS	per pfs	0.4 ml PFS	19800	1920600
327	Heparin Sodium 5000 I.U./ml Inj 5ml Vial	Heparin Sodium 5000 I.U./ml Inj 5ml Vial	per vial	5ml vial	51900	3064211
328	Heparin Topical sodium Inj 1000 IU/ml - 5 ml vial	Inj. Heparin sodium 1000 I U/ml - 5 ml Vial	per vial	5 ml vial	10100	820560
329	Hepatitis B Immunoglobulin 100 IU	Hepatitis B Immunoglobulin 100 i. u. IM Single Dose	per vial	10 ml Vial	4100	6956880
330	Homatropine Drops 5 ml	Isopto homatropine Methylbromide 2% Drop - 5 ml	per bottle	5 ml bottle	25000	820000
331	Human Albumin 20% (Low Salt) 50 ml Inj	Inj. Human Albumin 20% (Low Salt) 50 ml infusion bottle	per bottle	50 ml bottle	612	1875081
332	Hyaluronidase Inj 2 ml	Inj. Hyaluronidase (2 ml Vial, each Vial contain 1500 International Units of Hyluronidase)	per vial	2 ml Vial	35000	3032960
333	Hydrochlorothiazide 12.5mg Tab	Tab Hycdrochlorothiazide 12.5mg	Per Tab	10 Tab	500	9200
334	Hydrochlorthiazide 50 mg Tab	Each Tab Hydrochlorthiazide Contains 50mg	Per Tab	strip of 10 tablets	100000	5288800
335	Hydrocortisone Cream/Gel/Oinment 0.5%	Each Tube contains Hydrocortisone Cream 0.5%	Per Tube	15 gm Tube	50000	1662000

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
336	Hydrocortisone Sodium Succinate Inj 100 mg Vial	Inj. Hydrocortisone Sodium Succinate 100mg;	per vial	per Vial	1591205	12302641
337	Hydrocortisone sodium succinate injection 200 mg	Each Reconstituted vial Contains Hydrocortisone sodium succinate 200mg	per vial	10 ml Vial	100000	1876000
338	Hydrogen Peroxide 11 % + Silver Nitrate 1%	Hydrogen Peroxide 11% with Silver Nitrate 1 %	per jar	1 lit Jar	9473	4088645
339	Hydrogen Peroxide IP 500 ml	Hydrogen Peroxide 20 volume 6% w/v 500 ml	per bottle	500 ml bottle	300100	2758640
340	Hydroxy Chloroquine Tab 200 mg	Hydroxychloroquine sulphate 200mg	Per Tab	strip of 10 tablets	32682	4627771
341	Hydroxy Propyl Methyl Cellulose USP 2 % In Sterile Isonic Base PFS 2 ml PFS Inj	Pre filled preferably in glass syringes in double pouch packing . Inj. Hydroxy Propyl Methyl Cellulose USP 2% w/v, in sterile isonic base 2ml PFS , For introcular use	per pfs	2 ml PFS	105000	8484000
342	Hydroxy Urea Tab 500 mg	Tab Hydroxyurea 500 mg	Per Tab	strip of 10 tablets	1241800	2555642
343	Hydroxyethyl Starch (Hetastarch) Inj 6 % 500 ml Bottle	I.V. Hydroxyethyl starch 6% IPHydroxyethyl starch 130/ 04, 6% saline solution Plasma Volume Expander IV 1) 6% Hydroxy Ethyl Starch 2) Low mean molecular wt. From 1,00,000- 1,50,000 daltons 3) High dose flexibility up to 50mls/ kg. b.w./day 4) Minimal interference in coagulation mechanism, grouping cross matching. 5) Low risk of anaphylaxis 6) Bottle of 500ml.	per bottle	500 ml bottle	70100	9344987
344	Hydroxyzine syrup 10 mg/5ml	Each bottle contains Hydroxyzine Hydrochloride 10 mg/5ml	per bottle	100 ml bottle	25000	3136000

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
345	Hydroxyzine Tablet 25 mg	Each Tab Hydroxyzine contains 25 mg	Per Tab	strip of 10 tablets	120000	940800
346	Hyoscin Butyl Bromide Inj. 20mg/ml 1ml ampoule	Hyoscin Butyl Bromide Inj. 20mg/ml 1ml ampoule	per ampl	1ml ampl	1000	11808
347	Hyoscinebutylbromide Tablet 10 mg	Each Tab Hyoscine butylbromide contains 10 mg	Per Tab	strip of 10 tablets	220152	1229329
348	Ibuprofen Tab 400 mg	Tab. Ibuprofen 400 mg F/c Aluminium Blister - Strip of 10 Tablets	Per Tab	10 Tab	50000	66000
349	IFA (Iron 60mg + Folic Acid 500mcg) - blue Coloured tablet	Ferrous Sulphate I P equivalent to 60 mg of elemental iron + Folic Acid 500 mcg	Per Tab	strip of 10 tablets	447000000	64368000
350	IFA (Iron 60mg + Folic Acid 500mcg) - Red Coloured tablet	Ferrous Sulphate I P equivalent to 60 mg of elemental iron + Folic Acid 500 mcg	Per Tab	strip of 10 tablets	463000000	65340000
351	IFA Syrup with Auto Dispenser 50 ml Bottle	IFA Syrup with Auto Dispenser 50 ml Bottle	per bottle	50 ml bottle	18105000	104855000
352	Imipramine Tab 25 mg	Tab. Imipramine HCL 25 mg	Per Tab	strip of 10 tablets	3511000	1819824
353	Imipramine Tab 75 mg	Imipramine Tab 75 mg	Per Tab	strip of 10 tablets	5000	4920
354	Immunoglobulin Human Normal 5% for Intravenous use 5gm (IVIG) 100ml vial	Human Normal Immunoglobulin 5% for Intravenous use 5gm (IVIG) 100ml vial	per vial	100ml vial	2040	12337920
355	Indinavir Cap 400 mg	Indinavir Cap 400mg	per Cap	strip of 10 capsules	50000	1032000
356	Indomethacine 100mg Cap	Cap. Indomethacine Extended Release Cpsule 100mg	per Cap	strip of 10 capsules	421968	816929
357	Infliximab 100 mg Inj	Inj. Infliximab 100mg , Vial 10ml	per vial	10 ml Vial	5000	67899600
358	Influenza Vaccine (Quadrivalent) 0.5 ml PFS	Influenza Vaccine (Quadrivalent) Northern Hemisphere 2023-24.*anA/Victoria/4897/2022 *an/A Darwin/9/2021 (H3N2) - like virus: *aB/Austria/1359417/2021(B/Victoria lineage) = Like Virus; And *aB/Phuket/3073/2013	per vial	per Vial	37524	15760080

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
		(B/Yamagata lineage) - Like Virus Packaging should be as; 0.5ml Single Dose Prefilled Syringe (0.5 ml PFS)				
359	Insulin Lispro Mix 25/75 pen with needle Pack size 1 pen	25% Insulin Lispro (rDNA origin) and 75% Insulin Lispro protamine suspension 100 IU/ml - ml Pen with needle or 30% Insulin Lispro (rDNA origin) and 70% Insulin Lispro protamine suspension 100 IU/ml - ml Pen with needle	per vial	10 ml Vial	100	31440
360	Insulin Soluble plain (Human) 40 IU/ml 10 ml Vial	Highly purified human neutral insulin 40 IU/ml - 10 ml	per vial	10 ml Vial	72100	4063760
361	Insulin Soluble Zinc (Human) 40 IU /ml 10 ml Vial	Human Insulin Protamine Zinc Insulin (PZI) 40 IU /ml	per vial	10 ml Vial	8000	1344000
362	Ipratropium Inhalation (MDI/DPI) 20mcg	Each Actuation Delivers Ipratropium Bromide contains 20mcg	Per Packet	120 MDI In 1 Packet	50000	1040000
363	Ipratropium Respiratory Solution 250 mcg	Ipratropium bromide 250mcg/ml - 15 ml	per ampl	15 ml amp	32000	1967200
364	Ipravet/Levoline Nebulisation solution	Ipravet/Levoline Nebulisation solution	per bottle	per bottle	5000	19040
365	Iron + Folic Acid (100 mg + 0.5 mg) (WIFS) Tab	Feerous Sulphate 333-335 mg (Equivalent to 100 mg of elemental iron) + Folic Acid I P 0.5 mg	Per Tab	strip of 10 tablets	40000000	4467200
366	Iron 45 mg + Folic Acid 400 mcg Sugar Coated (Junior) Tab	Tab. IFA containing 45 mg Elemetal Iron & 400 mcg Folic Acid	Per Tab	strip of 10 tablets	390050000	54395200

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
367	Iron and Vitamin Drops (Paediatric) 15ml	Iron and Vitamin Drops (Paediatric) 15ml Each 1 ml Contains: Colloidal Iron equivalent to Elemental Iron 80mg Folic Acid IP 200mcg, Vitamin B 12 IP 2mcg	per bottle	15 ml Bottle	451000	6474048
368	Iron Folic Acid Liquid 15ml	Each 1 ml of liquid formulation of Ferrous sulphate should contain 20 mg of elemental Iron & 100 mcg of Folic Acid - 15ml bottle with Dropper	per bottle	15 ml Bottle	450000	6840000
369	Iron Folic Acid Liquid 15ml (Paediatric)	Iron and Vitamin Drops (Paediatric) 15ml Each 1 ml Contains: Colloidal Iron equivalent to Elemental Iron 80mg Folic Acid IP 200mcg, Vitamin B 12 IP 2mcg	per bottle	15ml bottle	1000000	19200000
370	Iron Folic Acid Liquid 200ml	Each 15 ml contains; Protein Hydrosylate (Nitrogen content 20%) 1gm, Carbohydrate 6 gm, Elemental Iron (as Choline Citrate) 13 mg, Thiamine Hydrochloride IP 1 mg, Riboflavin Sodium Phosphate IP, equivalent to Riboflavin 0.5 mg, Pyridoxine Hydrochloride IP 0.5 mg, Cyanocobalamine IP 0.5 mcg, D-Panthenol IP 2.5 mg, Magnesium Chloride IP 10 mg, Manganese Chloride 0.1 mg, Niacinamide IP 10 mg, flavoured syrup base q.s.	per bottle	200 ml bottle	670000	34780000
371	Iron Sucrose (Parenteral Iron) Inj 50 mg in 2.5ml Amp	Inj. Iron Sucrose 50 mg in 2.5ml Ampoule Iron Sucrose - Ferric hydroxide Complex with sucrose equivalent to elemental irons Inj. 50mg in 2.5ml	per ampl	2.5 ml amp	1755000	12876000

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
372	Iron Sucrose Inj 200mg, 10ml Amp (20mg/ml)	injection iron sucrose, each ml contains 20 mg elemental iron as iron sucrose water for injection	per vial	10 ml Vial	100000	2319200
373	Isoflurane 100 ml Bottle	Isoflurane Amber Colour Bottle 100ml	per bottle	100 ml bottle	6550	2784360
374	Isosorbide Dinitrate 10 mg tab	Isosorbide Dinitrate 10 mg tab	Per Tab	10 Tab	10000	12480
375	Isosorbide Mono Nitrate SR Tab 30mg	Each Tab Contains Isosorbide Mono Nitrate SR 30mg	Per Tab	strip of 10 tablets	100000	4796800
376	Isosorbide-5-mononitrate 5 mg Tablet	Each Tab Contains Isosorbide-5-mononitrate 5mg	Per Tab	strip of 10 tablets	505000	1976600
377	Isoxsuprine Inj 5 mg/ml 2 ml	Inj Isoxsuprine Hcl 5 mg/ml	per ampl	2 ml Ampoule	1000	18400
378	Isoxsuprine Tab 10 mg	Tab Isoxsuprine Hcl 10 mg	Per Tab	strip of 10 tablets	1480490	1148736
379	Itraconazole cap 100mg	Itraconazole cap 100mg	Per Tab	10 Tab	10000	55120
380	IV 0.45 % DNS (500 ml)	IV 0.45 % DNS (500 ml)	per bottle	500ml Bottle	73781	1239517
381	IV 0.67 % DNS (500 ml)	IV 0.67 % DNS (500 ml)	per bottle	500ml Bottle	42893	800207
382	IV 0.9% DNS (500ml)	IV 0.9% DNS (500ml)	per bottle	500ml Bottle	48156	834832
383	IvIg (For MSI-C)5mg/I00 ml Bottle	IvIg (for MSI-C) 5mg/ 100 ml Bottle	per bottle	100 ml bottle	619	3659760
384	Ketamine HCL 50 mg/ml Inj	Ketamine Hydrochloride Inj 50 mg 10 ml Vial	per vial	10 ml Vial	21344	1108218
385	Ketorolac Tromethymene Eye Drop 5 ml	Ketoraloc Eye Drop 5 ml Vial (Ketoraloc tromethymene 0.5% solution)	per bottle	5 ml bottle	57000	889200
386	Labetalol Inj 20 mg 4ml	Inj. Labetalol HCL 20 mg	per ampl	4 ml ampoule	10000	259280
387	Labetalol Inj. 5mg/ml	Labetalol 5mg/ml 4ml Amp	per ampl	4ml ampoule	32030	2025739
388	Labetalol Tab 100 mg	Tab. Labetlol HCL 100 mg	Per Tab	strip of 10 tablets	2550000	2666800
389	Lactulose Syrup 250ml bottle	Lactulose Syrup Each 15 ml contains:- Lactulose Concentrate equivalent to Lactulose	per bottle	250ml bottle	24750	1943964

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
		U.S.P. 10 gm 250ml bottle				
390	Lactulose Syrup 667 mg/ml 100 ml	Lactulose Solution contains lactulose 667 mg/mL (10 g/15 mL).	per bottle	100 ml bottle	4000	436928
391	Lamotrigine Tab 50 mg	Tab. Lamotrigine 50 mg	Per Tab	strip of 10 tablets	447000	178800
392	Lansoprazole DT 15 mg Tab	Each uncoated tablet contains; Lansoprazole IP 15 mg	Per Tab	strip of 10 tablets	38902	1431594
393	Levetiracetam 500mg Inj	Inj. Levetiracetam 500mg contains: Levetiracetam 500mg Sodium Chloride 45mg, pH – 5.5 with glacial acetic acid, 8.2 mg sodium acetate trihydrate with Water for Injection	per vial	5ml vial	122716	6974691
394	Levetiracetam 500mg Tab	Each Tab levetiracetam contains 500 mg	Per Tab	strip of 10 tablets	1284100	12457671
395	Levetiracetam Tab 250 mg	Tab Levetiracetam 250mg	Per Tab	strip of 10 tablets	1932000	1530144
396	Levo Salbutamol Respiratory Solution 0.0625 mg/ml 10ml	Levo Salbutamol Respiratory Solution 0.0625 mg/ml 10ml	per bottle	10ml bottle	1000	20624
397	Levo salbutamol Syrup 1 mg/5ml 100 ml	Levosalbutamol sulphate INN equivalent to 1mg/5ml Syrup	per bottle	per bottle	107601	1627983
398	Levocetrizine 10 mg Tab	Each tablet contains; Levocetrizine Dihydrochloride IP 10 mg	Per Tab	strip of 10 tablets	2681146	2188535
399	Levocetrizine 2.5mg Oral Liquid	Each 5 ml contains: Levocetrizine Dihydrochloride 2.5 mg, 60 ml Bottle	per bottle	60 ml bottle	1000	16096
400	Levocetrizine 5 mg Tab	Each tablet contains; Levocetrizine Dihydrochloride IP 5 mg	Per Tab	strip of 10 tablets	10005000	803920
401	Levofloxacin Tab 500 mg	Tab. Levofloxacin 500 mg	Per Tab	strip of 10 tablets	400000	1174400
402	Levofloxacine I V Inj. 500mg 100ml bottle	I. V, Levofloxacin 5 mg/mL (500 mg) (as hemihydrate)., 100 mL flexible container, 100 mL fill (Inj. Levofloxacin 500	per bottle	100ml bottle	15000	247320

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
		mg/100 ml) AFFS/BFS/FFS Technology				
403	Levonorgestrel tablet 1.5 mg	Each Tab Levonorgestrel contains 1.5 mg	Per Tab	1 Tablet Strip	400000	1200000
404	Levosalbutamol 1.25mg + Ipratropium 500mcg Respules 3ml	Levosalbutamol 1.25mg + Ipratropium 500mcg Respules 3ml	per respules	pack of 5 respules	181500	829092
405	Levosalbutamol 50 mcg	Each Actuation Delivers Levosalbutamol 50 mcg	Per Packet	200 MDI in Packet	70000	6384000
406	Lignocaine 2 % 30 gm Topical (oint.)	Oint Lignocaine Or Lidocaine HCL Ointment 30 gm	Per Tube	30 gm Tube	163277	1202716
407	Lignocaine HCI I.P Inj 2 % 30 ml Vial	Inj. Lignocaine or Lidocaine HCL 0.02 (2%) 30 ml	per vial	30 ml vial	532000	5297568
408	Lignocaine Ointment 2%	Each Tube contains Lignocaine Ointment 2%	Per Tube	30 gram tube	40000	2000000
409	Lignocaine Spray 10%	Lignocaine Spray 10% Contains Lignocaine / Xylocaine 10%, Spray 10mg/Puff	per bottle	100 ml bottle	11540	1384800
410	Lignocaine with Adrenaline inj. 20mg + 0.01 mg 30ml vial	Lignocaine with Adrenaline inj. 20mg + 0.01 mg 30ml vial	per vial	30ml vial	200	3677
411	Lignocaine with hydrocortisone, zinc oxide (Aovate/pilorute)	Lignocaine with hydrocortisone, zinc oxide (Aovate/pilorute) cream	Per Tube	10gm tube	508407	4087592
412	Lignocaine+Adrenalin inj 1%+1:200000(5 mcg/ml)	Each ml contains lignocaine+Adrenalin inj 1%+1:200000(5 mcg/ml)	per vial	30 ml vial	15000	1032000
413	Lignocaine+Adrenalin inj 2%+1:200000(5 mcg/ml)	Each ml contains lignocaine+Adrenalin inj 2%+1:200000(5 mcg/ml)	per vial	30 ml vial	12000	1078560
414	Linezolid 100 mg Inj	Linezolid inj 1 mg/ ml Each - 100 ml contains Linezolid 100 mg Water for injection q.s.	per bottle	100 ml bottle	25100	880040
415	Linezolid Tab 600 mg	Tab Linezolid 600 mg, Strip of 4 Tablets	Per Tab	stripe of 4 Tab	245100	1322320
416	Linezolide I V 300ml Bottle	Linezolide 2mg/ml 300ml Bottle I V	per bottle	300ml bottle	25465	1324180
417	Liquid Paraffin Bottle 500 ml Bottle	Liquid paraffin 500 ml	per bottle	500 ml bottle	63813	2276283

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
418	Liquid Paraffin-Menthol Drops: Menthol 10gm+Eucalyptus 2ml+Camphor 10mg+Liquid paraffin to 100ml	Liquid Paraffin-Menthol Drops: Menthol 10gm+Eucalyptus 2ml+Camphor 10mg+Liquid paraffin to 100ml	per bottle	100 ml bottle	50000	852800
419	Lithium Carbonate Tab 300 mg	Tab. Lithium Carbonate 300mg	Per Tab	strip of 10 tablets	4020000	12777760
420	Loperamide Tab 2mg	Each Tab Contains Loperamide 2mg	Per Tab	strip of 10 tablets	1705000	875320
421	Loratadine Tab 5 mg	Loratadine Tab 5mg	Per Tab	strip of 10 tablets	700000	834400
422	Lorazepam 2mg Inj	Inj. Lorazepam 2 mg	per ampl	1ml Amp	110000	889008
423	Lorazepam Tab 1 mg	Tab. Lorazepam 1 mg	Per Tab	strip of 10 tablets	880000	633600
424	Lorazepam Tab 2 mg	Tab. Lorazepam 2 mg	Per Tab	strip of 10 tablets	9636351	6222761
425	Losartan Potassium Tab 50 mg	Tab Losartan potassium 50 mg	Per Tab	strip of 10 tablets	4620810	1911167
426	Low molecular weight heparin (Enoxaparin) 0.4 IU PFS	Low molecular weight heparin (Enoxaparin) 0.4 IU PFS	per pfs	0.4 ml PFS	21000	1937000
427	Low molecular weight heparin (Enoxaparin) 0.6 IU PFS	Low Molecular weight heparin (Enoxaparin) 0.6 IU PFS	per pfs	0.6 ml PFS	101303	11249502
428	Lung Surfactant 5ml Inj	Inj. Lung Surfactant Contains Surfactant Bovine 27mg/ml, 5 ml Vial	per vial	5 ml vial	3300	16992000
429	Magnesium Hydroxide liquid	Each bottle Contains of Magnesium Hydroxide liquid 300mg/5ml	per bottle	100 ml bottle	43330	1005247
430	Magnesium sulphate Inj 50 % w/v - 2 ml	Inj. Magnesium sulphate50 % w/v - 2 ml i.e. Each ml contain 500 mg magnesium sulphate	per ampl	2 ml ampl	1725000	10266196
431	Magnesium Sulphate inj 500mg/ml	Magnesium Sulphate inj 500mg/ml	per ampl	per ampl	5000	13800
432	Magnesium sulphate powder Sachet 500 gm	Magnesium Sulphate Powder 500 gm	per sachet	500 gm Sachet	12677	1121068
433	Mannitol Inj 100 ml	I.V. Mannitol 20% 100 ml bottle AFFS Technology I.V. Mannitol 20%	per bottle	100 ml bottle	433800	7201059

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
		100 ml (20 mg / ml) AFFS/BFS/FFS Technology				
434	Mannitol Inj.10%	Each 100ml contains 10gram Mannitol	per bottle	100 ml bottle	53007	902384
435	Mebendazole Tab 100 mg	Tab Mebendazole 100 mg	Per Tab	6 Tab Strip	1089072	1054222
436	Mecetronium and Alchohol Dry Hand Rub 500ml	Mecetronium and Alchohol Dry Hand Rub 500ml	per bottle	500 ml Bottle	12582	1669910
437	Medroxy Progesterone Tab 10 mg	Medroxy Progesterone Tab 10 mg	Per Tab	strip of 10 tablets	1000	4360
438	Medroxy Progesterone Tab 5 mg	Medroxy Progesterone Tab 5 mg	Per Tab	strip of 10 tablets	2000	11832
439	Medroxyprogesterone Acetate Injection 150 mg	Each prefiiled syringe containsMedroxyprogesterone Acetate Injection 150 mg	per pfs	1ml prefiiled syringe	10200	1837760
440	Mefenamic Acid 250mg Cap	Cap. Mefenamic Acid 250mg	per Cap	strip of 10 capsules	956752	949098
441	Mefenamic Acid 500mg Cap	Cap. Mefenamic Acid 500mg	per Cap	strip of 10 capsules	635226	1600769
442	Mephenteramine Inj 30mg/ml	Inj.Mephentermine sulphate 30mg /ml	per vial	10 ml Vial	8100	461900
443	Meropenam Inj 1 gm Vial	Meropenam 1 gm Inj	per vial	per vial	946450	76614568
444	Meropenam Inj 500 mg Vial	Inj. Meropenam 500 mg Each 500 mg I.V. Vial will deliver 500 mg meropenem and 45.1 mg of sodium as sodium carbonate (1.96 mEq).	per vial	per vial	200500	9496272
445	Metformin 1000mg Tab	Tab. Metformin 1000 mg	Per Tab	strip of 10 tablets	1821224	1092734
446	Metformin SR 500 mg Tab	Tab. Metformin SR 500 mg	Per Tab	strip of 10 tablets	17655600	5791037
447	Methyl Dopa Tab 250 mg	Tab. Methyl Dopa 250 mg Aluminium Blister - Strip of 10 Tablets	Per Tab	strip of 10 tablets	504907	1312031
448	Methyl Ergometrine Inj 0.2 mg/ml 1 ml	Inj Methylergometrine maleate 0.2mg/ml	per ampl	1ml ampl	549000	5591248

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
449	Methyl Prednisolone Inj 125 mg/2 ml	Inj. Methylprednisolone sodium succinate -125 mg Each 2 mL (when mixed) contains methylprednisolone sodium succinate equivalent to 125 mg methylprednisolone;	per vial	2 ml Vial	200	23200
450	Methyl Prednisolone Inj 40 mg/ml 1 ml	Inj Methyl prednisolone acetate 40mg/ml - 1 ml	per ampl	1ml ampl	26500	497200
451	Methyl Prednisolone Sodium succinate 1gm/vial Inj	Methyl Prednisolone Sodium succinate 1gm/vial Inj	per vial	per vial	5310	851686
452	Methyl Prednisolone Sodium succinate 500mg/vial Inj	Methyl Prednisolone Sodium succinate 500mg/vial Inj	per vial	10ml vial	31898	2511926
453	Methyl Prednisolone Tab 4 mg	Tab Methyl Prednesolone 4 mg	Per Tab	strip of 10 tablets	150556	843114
454	Methylcellulose Eye drops	each 15 ml contains Methylcellulose 5mg	per bottle	15 ml Bottle	65851	937721
455	Methyldopa Tab. 500mg	Each Tab Methyldopa Contains 500mg	Per Tab	strip of 10 tablets	81864	1135617
456	Metoclopramide Inj 5 mg/ml 2 ml Amp	Metoclopramide Hcl 5 mg/2ml	per ampl	2 ml ampl	72000	649888
457	Metoclopramide Tab 10 mg	Metoclopramide Hcl 10 mg	Per Tab	strip of 10 tablets	1100000	8562400
458	Metoprolol Inj 1 mg 5 ml	Injection Metoprolol Tartrate - each Vial contain Metoprolol Tartrate 1 mg per ml i.e. 5 mg/5 ml	per ampl	5 ml	5000	49328
459	Metoprolol Tab 100mg	Each Tab Metoprolol Contains 100mg	Per Tab	strip of 10 tablets	105880	888545
460	Metoprolol Tab 25mg	Each Tab Metoprolol Contains 25mg	Per Tab	strip of 10 tablets	2200000	862400
461	Metoprolol Tab 50mg	Each Tab Metoprolol Contains 50mg	Per Tab	10 Tab	5000	8720
462	Metronidazole I.V 100 ml Bottle	I V.Metronidazole - 5mg / ml I. V. Metronidazole 500 mg in 100 ml AFFS/BFS/FFS Technology	per bottle	100 ml bottle	4444000	31524496
463	Metronidazole Susp 200 mg/5ml 60 ml Bottle	Metronidazole Suspension 200mg/ 5ml	per bottle	60 ml bottle	1095000	10235440

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
464	Metronidazole Tab 200 mg	Tab. Metronidazole 200 mg	Per Tab	strip of 10 tablets	20015500	5709788
465	Metronidazole Tab 400 mg	Tab. Metronidazole 400 mg	Per Tab	strip of 10 tablets	43150000	19604000
466	Miconazole 2% w/w Cream 15gm tube	Miconazole cream: Miconazole Nitrate 2% w/w 15 gm	Per Tube	15 gm Tube	1716250	8568108
467	Miconazole Tablet 100mg	Each Tab Miconazole Contains 100mg	Per Tab	6 Tab Strip	150000	940800
468	Midazolam Inj 1 mg 10 ml	Inj. Midazolam hydrochloride 1 mg / ml	per vial	10 ml Vial	80300	1169948
469	Milk of Magnessia with Liquid Paraffin 100ml Syp	Syp. Milk of Magnessia with Liquid Paraffin contains Milk Of Magnesia 3.75 ml + Liquid Paraffin 1.25 ml + Sodium Picosulfate 3.33 mg per 5 ml	per bottle	100 ml bottle	69313	1796598
470	Mirtazapine Tab 15 mg	Tab Mirtazapine 15 mg	Per Tab	strip of 10 tablets	261000	208800
471	Misoprostol Tab 200 mcg	Tab Misoprostol 200 mcg	Per Tab	stripe of 4 Tab	1648000	3830880
472	Misoprostol Tab 25 mcg	Tab Misoprostol 25mcg	Per Tab	stripe of 4 Tab	25000	980000
473	Montelukast 10 mg Tab	Each Tablet contains; Motelukast Sodium 10 mg	Per Tab	strip of 10 tablets	1094900	1778118
474	Montelukast 4 mg Tab	Each Tablet contains; Montelukast Sodium 4 mg	Per Tab	strip of 10 tablets	3505000	7563800
475	Montelukast 5 mg Tab	Each Tablet contains; Montelukast Sodium 5 mg	Per Tab	strip of 10 tablets	1805000	4037000
476	Montelukast syrup 60ml bottle	each bottle cotains Montelukast sodium 4 mg/5ml	per bottle	60 ml bottle	2000000	36640000
477	Morphine Sulphate 10 mg, 1 ml Amp	Inj. Morphine sulphate 10 mg / ml	per ampl	1 ml Ampoule	100	17120
478	Moxifloxacin + Prednisolone Acetate Eye Drop 5 ml	Moxifloxacin 0.5% with prednisolone 1% Eye Drop 5ml Vial (Moxifloxacin Hydrocloride equivalent to Moxifloxacin 0.5% w/v, prednisolone acetate - usp 1% w/v, Benzalkonium Chloride solution (as preservative) – IP	per bottle	5 ml bottle	240000	4396800

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
		0.02% w/v sterile aqueous base q.s.)				
479	Moxifloxacin Eye Drop 0.5%	Moxifloxacin Eye Drop 0.5%, 5ml	per bottle	5 ml bottle	370000	2373920
480	Moxifloxacin Tab 400 mg	Tab. Moxifloxacin 400 mg	Per Tab	strip of 10 tablets	120000	1546560
481	Multiple Electrolytes and Dextrose Injection Type I IP for Pediatric use 500 ml Bottle	Multiple Electrolytes & Dextrose Injection Type I IP for Maintenance: Maintenance replacement soluation with 5% dextrose Each 100 ml contains: Dextrose anhydrous I.P. 5 gm ,Potassium chloride I.P. 0.13 gm , Magnesium chloride I.P. 0.031 gm , Dipotassium hydrogen phosphate 0.026 gm , water for injection IP Q.S. AFFS/BFS/FFS Technology	per bottle	500 ml bottle	335200	5282650
482	Multiple Electrolytes and Dextrose Injection Type III IP for Maintenance 500 ml Bottle	Multiple Electrolytes & Dextrose Injection Type III IP for Maintenance: Maintenance replacement soluation with 5% dextrose Each 100 ml contains: Dextrose anhydrous I.P. 5 gm ,Potassium chloride I.P. 0.13 gm , Magnesium chloride I.P. 0.031 gm , Dipotassium hydrogen phosphate 0.026 gm , water for injection IP Q.S. AFFS/BFS/FFS Technology	per bottle	500 ml bottle	74200	2459610

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
483	Multivitamin Drop with Zinc, 15 ml Drops	Each 15 ml contains; Cholecalciferol IP 200 IU Pyridoxine Hydrochloride IP 1 mg Niacinamide IP 15 mg Cyanocobalamin IP 1 mcg Zinc (as Zinc Gluconate USP) 3 mg B- Carotene Dispersion 2.5% USP 38 mg Manganese 0.8 mg Molybdenum 8 mcg Selenium (as sodium selenate) 10 mcg Lysine Hydrochloride USP 30 mg Iodine (as potasium iodide) 50 mcg Biotin USP 10 mcg Chromium 10 mcg Inositol 10 mg Lycopen USP (10%) 500 mcg	per bottle	15 ml Bottle	2620000	25159200
484	Multivitamin tablet	Strip contains Multivitamin Tablets	Per Tab	strip of 10 tablets	15050000	24039200
485	Mupirocin 2% Topical Ointment	Mupirocin 2% w/w Topical Ointment	Per Tube	3 gm Tube	151402	1090097
486	MVI (Multivitamin Injection) Inj	Each 10 ml injection contains; Thiamine HCL IP : 50 mg Pyridoxine HCL IP : 20 mg Roboflavin Sodium Phosphate IP : 20 mg D-Panthenol IP : 30 mg Niacinamide IP : 200 mg Benzyl Alcohol IP : 1.5 % v/v (as preservative) Water for Injection IP q.s.	per ampl	10ml ampl	203000	982680
487	N acetyl cystine tablet 600mg	each effervecent tab contains N acetyl cystine 600mg	Per Tab	strip of 10 tablets	21000	966960
488	N- acetylcysteine Inj 200 mg/2ml	Inj. Acetylcysteine-200 mg in 2 ml	per ampl	2 ml amp	12448	897000
489	N-acetylcysteine 200mg - 1 gm Sachet	each effervecent granules contains N acetyl cystine 200mg	per sachet	1 gm Sachet	25000	900000
490	Naloxone 0.4mg Inj.	Inj. Naloxone hcl 0.4mg i.e. 400mcg/ml - 1 ml	per ampl	1 ml Ampoule	1000	29692

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
491	Naltrexone IP 50mg Tab	Tab Naltrexone IP 50mg	Per Tab	strip of 10 tablets	18120	1030666
492	Naproxen Tablet 250 mg	Each Tab Naproxen Contains 250mg	Per Tab	strip of 10 tablets	501000	843808
493	Naproxen Tablet 500 mg	Each Tab Naproxen Contains 500mg	Per Tab	strip of 10 tablets	557564	1293988
494	Neostigmine Inj 0.5 mg 1 ml Amp	Inj. Neostigmine Each ml of the 1:2000 concentration contains Neostigmine Methylsulfate 0.5 mg/ml, Methylparaben 1.8 mg and Propylparaben 0.2 mg (used as preservatives), in Water for Injection q.s.pH (range 5.0 - 6.5) adjusted, when necessary, with Sodium Hydroxide - 1 ml USP	per ampl	1ml ampl	119835	1396988
495	Nicorandil Tab 5 mg	Tab NICORANDIL 5 mg	Per Tab	strip of 10 tablets	105000	2058000
496	Nifedipine Cap (Liquid) 10 mg	Cap.Nifedepine 10 mg Aluminium Blister - Strip of 10 Capsule	per Cap	strip of 10 capsules	10000	69200
497	Nifedipine Cap (Liquid) 5 mg	Cap.Nifedepine 5 mg Aluminium Blister - Strip of 10 Capsule	per Cap	strip of 10 capsules	502000	1436240
498	Nifedipine Tab 10mg	Tab.Nifedepine 10 mg Aluminium Blister - Strip of 10 Tab.	Per Tab	strip of 10 tablets	1200000	864000
499	Nitrazepam Tab 5 mg	Nitrazepam Tab 5 mg	Per Tab	strip of 10 tablets	642358	3247936
500	Nitrofurantoin 100 mg Tab	Each Tab Nitrofurantoin Contains 100 mg	Per Tab	strip of 10 tablets	167548	982501
501	Nitrofurantoin 50 mg Tab	Nitrofurantoin 50 mg Tab	Per Tab	strip of 10 tablets	1000	9600
502	Nitroglycerine Inj 5 mg 5 ml	Inj. Nitroglycerine 5 ml Each ml to contain : Nitroglycerine Trinitrate 5 mg	per ampl	5 ml Ampoule	30500	879580
503	Noradrenaline 2mg/ml Inj 2ml amp	Noradrenaline 2mg/ml Inj 2ml amp	per ampl	2ml ampoule	330770	2500621
504	Norethisterone Tab 5 mg	Tab Norethisterone enantate 5mg	Per Tab	strip of 10 tablets	629194	860190

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
505	Norfloxacin Tab 400 mg	Tab. Norfloxacin 400 mg Aluminium Blister - Strip of 10 Tab	Per Tab	strip of 10 tablets	15795000	17316360
506	Normal Saline Nasal Drops: Sodium Chloride Drops 0.05%w/v	Each 20ml bottle contains Normal Saline Nasal Drops: Sodium Chloride Drops 0.05%w/v	per bottle	20 ml bottle	300000	2968800
507	Octreotide 100mcg/ml Inj 1ml amp	Octreotide 100mcg/ml Inj 1ml amp	per ampl	1ml ampoule	8580	869463
508	Ofloxacin 400 mg Tab	Each Tab Ofloxacin Contains 400 mg	Per Tab	strip of 10 tablets	1000000	7544000
509	Ofloxacin Tab 200 mg	Tab. Ofloxacillin 200 mg Aluminium Blister - Strip of 10 Tab	Per Tab	strip of 10 tablets	11803200	24545929
510	Ofloxacine IV 100ml 100ml bottle	I. V. Ofloxacin - Each 100 ml contain Ofloxacin-200 mg, water for injection-q.s. AFFS/BFS/FFS Technology	per bottle	100ml bottle	100	2392
511	Olanzapine Tab 10 mg	Tab. Olanzapine 10 mg	Per Tab	strip of 10 tablets	13300000	3298400
512	Olanzapine Tab 5 mg	Tab. Olanzapine 5 mg	Per Tab	strip of 10 tablets	14950000	4637834
513	Omeprazole Cap 20 mg	Cap.Omperazole 20 mg Aluminium Blister - Strip of 10 Capsule	per Cap	strip of 10 capsules	81475500	22285178
514	Ondansetron 2 mg Inj	Each ml to contain: Ondansetron 2 mg	per vial	4ml vial	246000	948576
515	Ondansetron Inj 2 mg/ml 2 ml Amp	Ondansetron 2mg/ml Inj 2ml amp	per ampl	2ml ampoule	3129881	5368043
516	Ondansetron Syrup 2 mg/5 ml 30 ml	Syrup Ondansetron 2mg/5ml, Bottle of 30ml	per bottle	30 ml bottle	2493300	11002690
517	Ondansetron Tab 4 mg	Tab. Ondansetron 4 mg	Per Tab	strip of 10 tablets	14300000	3556400
518	Oral Rehydration Salt Powder WHO Formula 20.5 gms Sachet	O R S WHO Formula – O R S Powder 20.5 gm as per WHO formula contains g/l : Sodium Chloride IP 2.60 gm, Potasium Chloride IP 1.50 gm, Sodium citrate IP 2.90 gm , Anhydrous Dextrose IP 13.50 gm The total osmolar concentration of the	per sachet	20.5 gms Sachet	72265500	129934812

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
		solution in terms of mosmol per litre is 245				
519	Ortho Phthaladehyde 0.55 % w/v	Solution containing Ortho- Phthaladehyde 0.55 % w/v Required Compatability report of International Standard Manufacturers for commonly used endoscopes i. e. Karl Storz/ Pentax/Fujinon/ Olympus 5 Lit. Required item wise WHO GMP.5 litre Jar	per can	5 litre can	990	2130480
520	Oseltamivir 30mg Cap	Capsule Oseltamivir 30mg Strip of 10 Capsules	per Cap	strip of 10 capsules	585302	2079765
521	Oseltamivir 45mg Cap	Capsule Oseltamivir 45mg Strip of 10 Capsules	per Cap	strip of 10 capsules	419300	2944130
522	Oseltamivir 75mg Cap	Capsule Oseltamivir 75mg Strip of 10 Capsules	per Cap	strip of 10 capsules	685000	6340824
523	Oseltamivir 75ml Bottle Syp	Each 1 ml of the reconstituted suspension contain:- Oseltamivir Phosphate equivalent to Oseltamivir 12 mg. (75ml Bottle)	per bottle	75ml Bottle	8450	1862594
524	Oxymetazoline Nasal Drop 0.025% 10 ml	Each Spray Contains Oxymetazoline HCl 0.025% in aqueous isotonic solution Purified water IP Benzalkonium Chloride 0.02% (10ml)	per bottle	10 ml Bottle	19016	867148
525	Oxytocin inj 10 IU	Each ml contains Oxytocin inj 10IU	per ampl	1ml ampl	208155	940862
526	Oxytocin Inj 5 IU 1 ml	Inj. Oxytocin Each ml. to contain: Synthetic Oxytocin 5 IU 1 ml. amp.	per ampl	1ml ampl	7286200	27365824
527	Paliperidone Palmitate 100mg Inj	Paliperidone Palmitate Prolonged Release Suspension 100mg. PFS of 1 ml	per pfs	PFS of 1 ml	1000	3820720

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
528	Paliperidone Palmitate 150mg Inj	Paliperidone Palmitate Prolonged Release Suspension 150mg. PFS of 1 ml	per pfs	PFS of 1 ml	3523	13849312
529	Pantoprazole 40 mg Tab	Pantoprazole 40 mg Tab	Per Tab	strip of 10 tablets	39454520	13562027
530	Pantoprazole 40mg/10ml Inj 10ml vial	Pantoprazole 40mg/10ml Inj 10ml vial	per vial	10 ml Vial	4791141	24069499
531	Paracetamol 10mg/ml Inj 100ml bottle	Paracetamol 10mg/ml Inj 100ml bottle	per bottle	100 ml bottle	247700	6214298
532	Paracetamol 500mg Tab	Paracetamol 500mg Tab	Per Tab	strip of 10 tablets	180711759	68890958
533	Paracetamol 50ml IV	IV Paracetamol in Freeflex 50 ml Container	per bottle	50 ml bottle	200	7322
534	Paracetamol 650mg Tab	Tab Paracetamol 650 mg	Per Tab	strip of 10 tablets	4520000	5963200
535	Paracetamol Drops 150 mg/ml 15 ml	Paracetamol 150mg/ml	per bottle	15 ml Bottle	710000	3801360
536	Paracetamol Inj 150 mg/ml 2 ml Amp	Inj. Paracetamol 150 mg/ml - 2 ml	per ampl	2 ml amp	351000	4352000
537	Paracetamol IV 1gm, 100ml Inj	Inj. Paracetamol IV 1gm, 100ml	per bottle	100 ml bottle	151000	2933000
538	Paracetamol suppository 80mg	Each Paracetamol suppository contains 80mg	Per Packet	7 Suppository 1 PKT	109674	877389
539	Paracetamol Syrup 250 mg /5 ml 60 ml	Paracetamol Syrup 250 mg /5 ml 60 ml	per bottle	60 ml bottle	3525000	30654600
540	Paradichlorobenzene 2% + chlorbutanol 5% + benzocaine 2.7%+turpentine oil 15% ear Drops-10 ml	Paradichlorobenzene 2% + chlorbutanol 5% + benzocaine 2.7%+turpentine oil 15% ear Drops-10 ml	per bottle	10 ml Bottle	501000	3904448
541	Pediatric solution like Isolyte P	Each 100ml of isolyte P (Multi-Electrolyte Injection) in 5% Dextrose contain Hydrous Dextrose USP 5gm ; Sodiun Acetate Trihydrate USP 0.32gm, Potassium Chloride USP 0.13gm, Magnesium Chloride Hexahydrate USP 0.031gm, Diabasic Potassium Phosphate	per bottle	500ml Bottle	46356	815861

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
		USP 0.026gm, Water for injection USP q.s.				
542	Pentazocine inj I.P 30mg/ml	Inj. Pentazocin Lactate 30 mg/ml - 1 ml Ampoule	per ampl	1ml ampl	542000	3698528
543	Permethrin 1% Lotion	Each bottle Contains Lotion Permentherine 1%	per bottle	50 ml bottle	11294	903520
544	Permethrin Cream 30 gm	Cream Permethrine : Cream Permenthrine 5% w/w 30 gm	Per Tube	30 gm Tube	1000	18400
545	Permethrin Lotion 30 ml	Lotion Permentherine 5% w/w- 30 ml	per bottle	30 ml bottle	185000	1989120
546	Petroleum jelly 100%	Each 100gm bottle contains Petroleum jelly 100%	per bottle	100 gm bottle	25000	2124000
547	Pheniramine Maleate Inj. 22.75mg/2ml	Each Ampoule Contains Pheniramine Maleate IP 22.75mg Water for Injection IP …. Qs 2ml Ampoule	per ampl	2 ml Ampoule	5000	15800
548	Pheniramine Maleate Syp	each bottle contains Pheniramine Maleate 15mg/5ml	per bottle	100 ml bottle	300000	7898400
549	Phenobarbitone Tab 30 mg	Tab.Phenobarbitone Sodium 30 mg	Per Tab	strip of 10 tablets	283000	67920
550	Phenobarbitone Tab 60 mg	Tab.Phenobarbitone Sodium 60 mg	Per Tab	strip of 10 tablets	2659000	1132688
551	Phenytoin Inj 50 mg/ml 2 ml	Inj. Phenytoin Sodium 50 mg/ml - 2 ml (Diphenyl Hadantoin Sodium)	per vial	2 ml Vial	452140	2433970
552	Phenytoin injection 25 mg/ml	each ml contains Phenytoin 25mg	per ampl	1ml ampl	35000	1618400
553	Phenytoin Sodium 300 mg Tab	Tab. Phenytoin Sodium 300 mg	Per Tab	strip of 10 tablets	50000000	6400000
554	Phenytoin Sodium 50 mg Tab	Tab. Phenytoin Sodium 50 mg	Per Tab	strip of 10 tablets	900000	921600
555	Phenytoin Sodium Tab 100 mg	Tab. Phenytoin Sodium 100 mg	Per Tab	strip of 10 tablets	4526000	1158656

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
556	Phenytoin Tablet 500mg	Each Tab Phenytoin Contains 500mg	Per Tab	strip of 10 tablets	170000	854080
557	Phytomenadion inj 10mg/ml	Each 0.5ml Contains Phytomenadion 1mg	per ampl	0.5 ml Amp	150000	1197600
558	Phytomenadione (Vitamin K1) Tablet 10mg	Each Tab phytomenadione (Vitamin K1) Contains 10mg	Per Tab	strip of 10 tablets	120000	958080
559	Piperacilin 4gm + Tazobactum 0.5 mg Inj	Piperacilin 4gm + Tazobactum 0.5 mg Inj	per vial	per vial	259620	11813953
560	Piperacillin + Tazobactum for Injection USP 1gm+125mg	Each 10 ml vial contains Piperacillin (1gm) + Tazobactum(125mg) for Injection USP	per vial	per vial	100000	2316000
561	Piperacillin + Tazobactum for Injection USP 2gm+250mg	Each 10 ml vial contains Piperacillin(2gm) + Tazobactum(250mg) for Injection USP	per vial	per vial	200000	7992000
562	Plasma Volume Expander 500ml FFS Pack	Each 100 ml IV Fluid Contains : Polygeline Polypeptides of degraded gelatin, cross linked via urea bridges 3.5g (Equivalent to 0.63g of notrogen) Sodium Chloride IP 0.85g Potassium Chloride IP 0.038g Calcium Chloride IP 0.070g Water for Injection IP q.s. Electrolytes in m. mol/ Litre Na+ 145, K+ 5.1, Ca++ 6.25, Cl- 145 Mean Molecular Weight 30000 pH of infusion solution 7.3+0.3	per bottle	500ml bottle	50	13840
563	Polymeric Biguanide Hydrochloride Solution 1000 ml Bottle	Polymeric Biguanide Hydrochloride <10%, Alkyl Dimethyl Benzyl Ammonium Chloride & Diethyl Dimethyl Ammonium Chloride <10% (EN tests reports required from International Laboratories Europe/ USA) EN 13697 (Bacterial and	per bottle	1000 ml Bottle	5016	5606942

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
		Fingicidal activity) EN 16616 (Chemical Thermal Textile Disinfection)				
564	Polyvitamin (Therapeutic) NFI Tab	Polyvitamin (Therapeutic) NFI Tab	Per Tab	strip of 10 tablets	1529400	4378122
565	Potassium Chloride 1.5gm, 200ml Syp	Potassium Chloride 1.5gm Oral Suspension Each 15ml contains Potassium Chloride IP 1.5gm, (Correnspondingto 20ml equivalent Elemental Potassium)	per bottle	200 ml bottle	19182	897761
566	Potassium chloride injection 150 mg/ml	Inj. Potasium chloride 150 mg/ml 10 ml	per ampl	10ml ampl	55026	1131818
567	Potassium chloride oral liquid 500 mg/5ml	Each bottle contains Potassium chloride oral liquid 500 mg/5ml	per bottle	200 ml bottle	48258	887940
568	Potassium Magnesium Citrate with Vitamin B6 (200 ml) Syp	Syp. Potassium Magnesium Citrate with Vitamin B6 (200 ml)	per bottle	200 ml bottle	25464	1324128
569	Potassium Peroxomonosulphate 50% w/w 500 gm bottle	Surface Disinfectant cintaining Potassium Peroxomonosulphate 50% w/w EN 14476 Required item wise WHO GMP 500 gm	per bottle	500ml bottle	1402	2984566
570	Povidine- iodine Germicide Gargle 20% w/v	Each bottle contains Povidine- iodine Germicide Garle 20% w/v	per bottle	100 ml bottle	6397	1023584
571	Povidine lodine solution scrub 7.5% 500 ml	Povidone Iodine 7.5% w/v topical solution scrub 500 ml	per bottle	500 ml bottle	286770	20847577
572	Povidone Iodine 10 % Liquid hand scrub 500 ml Bottle	Povidone Iodine 10 % Liquid hand scrub 500 ml Bottle	per bottle	500ml bottle	14635	1522040
573	Povidone Iodine 5 % Liquid hand scrub 500 ml Bottle	Povidone Iodine 5 % Liquid hand scrub 500 ml Bottle	per bottle	500ml bottle	19376	1367016
574	Povidone Iodine Ointment 5 % 15 gm	Oint. Povidone Iodine 5% w/w 15 gm	Per Tube	15 gm Tube	4010000	20406400
575	Povidone Iodine Solution 10% (equivalent to 1% available iodine)	Each bottle contains Povidone Iodine Solution 10%	per bottle	500ml Bottle	50000	5700000

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
		(equivalent to 1% available iodine)				
576	Povidone Iodine Solution 4% to 10%	Each bottle containsPovidone Iodine Solution 4% to 10%	per bottle	500ml Bottle	20000	2280000
577	Povidone Iodine Solution 5 % 500 ml	Povidone-iodine 5% w/v solution	per bottle	500 ml bottle	261960	18668698
578	Povidone Mouth Gargle 2%	povidon iodine 2% w/v gargle solution IP	per bottle	100ml bottle	151000	2775920
579	Pralidoxime Chloride 1gm Inj	Pralidoxime Chloride 1gm Inj	per vial	per vial	284700	17957740
580	Pralidoxime chloride 500 mg Inj	Inj. Pralidoxime chloride 500 mg/ 10 ml	per vial	per vial	87342	3841964
581	Prazosin HCL Tab 2 mg	Tab. Prazocin HCL 2 mg	Per Tab	strip of 10 tablets	246296	1121066
582	Pre and Probiotic Capsules DS	PRE AND PROBIOTIC CAPSULES Each Capsule contains Streptococcus Faecalis T-110JPC 60 million Clostridium Butyricum TO-A 4 Million Bacillus Mesentericus TO-A JPC 2 Million Lactic Acid Bacillus 100 Million (Lactobacillus Sporogenes)	per Cap	strip of 10 capsules	1910000	14934640
583	Prednisolone oral liquid 5mg/5ml	Each Bottle contains Prednisolone oral liquid 5mg/5ml	per bottle	60 ml bottle	20000	816000
584	Prednisolone Tab 10 mg	Tab. Prednisolone 10 mg Aluminium Blister - Strip of 10 Tab	Per Tab	strip of 10 tablets	405000	590200
585	Prednisolone Tab 20 mg	Tab. Prednisolone 20 mg Aluminium Blister - Strip of 10 Tab	Per Tab	strip of 10 tablets	150000	264000
586	Prednisolone Tab 5 mg	Tab. Prednisolone 5 mg Aluminium Blister - Strip of 10 Tab	Per Tab	strip of 10 tablets	2805000	901720
587	Premix Biphasic Insulin Analogue 30:70 Injection 3ml PFS	Premix Biphasic Insulin Analogue 30:70 injection Recombinant Insulin 30%, Regular 70%, 100 IU/ml	per pfs	3 ml PFS	100	17200
588	Premix Insulin 30:70 Inj 10 ml	Recombinant human insulin biphasic 30%, Regular 70% 100 iu/ml	per vial	10 ml Vial	20100	1693440

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
589	Primaquine tab 2.5mg	Primaquine tab 2.5mg	Per Tab	strip of 10 tablets	1000	1784
590	Primaquine tab 7.5mg	Primaquine tab 7.5mg	Per Tab	strip of 10 tablets	200	762
591	Promethazine inj 25mg/ml	Each 1ml contains Promethazine 25mg	per ampl	1ml ampl	740151	2171602
592	Promethazine inj. 25mg/ml	Promethazine inj. 25mg/ml 2ml amp	per ampl	2ml ampoule	2000	10176
593	Promethazine Inj. 50mg	Inj. Promethazine Hydrochloride 25mg/ml IM/IV Each mL contains either 50 mg promethazine hydrochloride with 0.2 mg edetate disodium, 0.08 mg calcium chloride, 0.50 mg sodium meTabisulfite, and 10 mg phenol in water for injection.- 2 ml Ampoules I. M./I. V	per ampl	2 ml ampl	450000	2502000
594	Promethazine syrup 5mg/5ml 60 ml	Promethazine syrup 5mg/5ml 60 ml	per bottle	60 ml bottle	1000	18832
595	Propanalol 80mg Tab	Tab.Propranalol HCL 80 mg	Per Tab	strip of 10 tablets	23888	912522
596	Propofol inj. 1% (10mg) 20ml Vial	Propofol inj. 1% (10mg) 20ml Vial	per vial	20ml vial	600	29544
597	Propranolol Tab 10 mg	Tab.Propranalol HCL 10 mg	Per Tab	strip of 10 tablets	362000	86880
598	Protease Based Enzymatic Cleaner 1 Ltr	Protease based Enzymatic Cleaner. Required compatibility Report from International Standard Manufacturers of commonly used endoscopes. (i.e. Karl Storx / Pentax / Fujinon / Olympus I.P.)	per bottle	1000 ml Bottle	3149	2915184
599	Quetiapine Tab 100 mg	Tab. Quetiapine 100 mg	Per Tab	strip of 10 tablets	930000	327360
600	Quetiapine Tab 50 mg	Tab. Quetiapine 50 mg	Per Tab	strip of 10 tablets	1730000	2186720
601	Rabies Antiserum 1500 IU/5ml Inj IM & SC	Rabies Antiserum 1500IU/5ml Inj IM & SC	per vial	5ml vial	49049	33745712

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
602	Rabies immunoglobin - Anti Rabies Serum Inj 2 ml	Human derived anti-rabies immunoglobulin 150 I U per ml - i.e. 300 IU per 2 ml PFS	per pfs	2 ml PFS	10000	3746400
603	Rabies Immunoglobulin Human 300 IU/ml Inj 5ml Vial	Rabies Immunoglobulin Human 300 IU/ml Inj 5ml Vial	per vial	5ml vial	610	1694336
604	Rabies Vaccines Human (cell Culture) potency of not less than 2.5 Units per vial I.P. For ID Use (Tissue Culture Anti Rabies Vaccines) Inj 1ml vial	Rabies Vaccines Human (cell Culture) potency of not less than 2.5 units per vial I.P. For ID Use (Tissue Culture Anti Rabies Vaccines) Inj 1ml vial	per vial	1ml vial	49500	8898120
605	Rabies Vaccines Human (cell Culture) potency of not less than 2.5 units per vial. I.P. For IM Use (Tissue Culture Anti Rabies Vaccines) Inj 1ml Vial	Rabies Vaccines Human (cell Culture) potency of not less than 2.5 units per vial. I.P. For IM Use (Tissue Culture Anti Rabies Vaccines) Inj 1ml Vial	per vial	1ml vial	21750	3909780
606	Ranitidine Inj 25 mg 2 ml Amp	Inj. Ranitidine HCL 25 mg 2 ml Ampoule	per ampl	2 ml amp	3425000	6783440
607	Ranitidine Tab 150 mg	Tab. Ranitidine Hydrochloride 150 mg Aluminium Blister - Strip of 10 Tablets	Per Tab	strip of 10 tablets	5100000	3261600
608	Recombinant Factor IX 1000 IU	1. Recombinant Factor IX-1000 IU Plasma free, Human Albumin free inj. 2. Expiry date should not be less than one Year.	Single Unit	1000 IU per vial	323	1808800
609	Recombinant Factor IX 250 IU	1. Recombinant Factor IX-250 IU Plasma free, Human Albumin free inj. 2. Expiry date should not be less than one Year.	Single Unit	250 IU per vial	343	823200
610	Recombinant Factor IX 500 IU	1. Recombinant Factor IX-500 IU Plasma free, Human Albumin free inj. 2. Expiry date should not be less than one Year.	Single Unit	500 IU per vial	857	2399600

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
611	Recombinant Factor VIII 1000 IU	Factor VIII Recombinant 1000 IU 1. Recombinant Factor VIII-Plasma free, Human Albumin free inj. 2. Reconstitute in 2 or 4 ml dilution 3. Expiry date should not be less than one Year. 4. No human and animal derived protines should have been used during manufacture or formulation of recombination products. 5. Safety and Efficacy standards as per WFH guidelines for clotting factors Concentrates (CFC) Assesment. 6. Packege shall contain the sterile water for injection.	Single Unit	1000 IU per vial	1767	4947600
612	Remdesivir 100 mg Inj	Inj. Remdesivir 100 mg Vial (Lyophillized Powder)	per vial	10 ml Vial	1898	1017114
613	Retiplase 18mg (Pack of 2 Vials) Inj	Inj. Retiplase 18mg Contains Retiplase Recombinant Tissue Plasminogen Activator 18mg	per vial	Pack of 2 Vials	124	3837956
614	Ringer Lactate I.V 500 ml Bottle	I. V. Ringer's Lactate (Sodium lactate, compound solution) Each 100ml to contain: Lactic Acid 0.24 ml., Sod.Chl. 0.6 gm, Potassium Chloride 0.04 gm, Calcium Chloride 0.027 gm. Water for injection Q.S. Calculated Osmolarity –280 mOs/L(approx) Concentration of Electrolytes (in moles/Lit.) - Sodium 131, Potassium 5, Calcium 2, Bicarbonate (as Lactate) 29, Chloride 111.AFFS/BFS/FFS Technology	per bottle	500 ml bottle	7714300	93505595

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
615	Risperidone Inj 25mg	each single dose vial contains extended release microsphares containing risperidone BP 25mg, each single use PFS contains diluent for reconstitution 2ml	per pfs	2ml PFS	75	207072
616	Risperidone Tab 2 mg	Tab. Resperidone 2 mg	Per Tab	strip of 10 tablets	11850000	1771600
617	Rocuronium 50mg/5ml Inj 5ml amp	Rocuronium 50mg/5ml Inj 5ml amp	per ampl	5ml ampoule	15555	2573419
618	Rotahalers	Beclomethasone dipropionate 50mcg + levosalbutamol 50mcg inhaler with dose counter	per vial	200mdi vial	50000	5360000
619	Salbutamol 100 mcg Inhaler of 200MDI	Salbutamol 200 mcg per Cap - powder puff (60 cap x 6 pack with 1 Dispensing Device)	per 6 pack with dispensing device	60's cap x 6 pack with 1 Dispensing Device	8088	918774
620	Salbutamol respirator solution for use in nebuliser 5mg/ml	Each 5ml respules contains 5mg salbutamol	per respules	5ml 5 Respules In PKT	150000	1644000
621	Salbutamol Syrup 2 mg/5ml 100 ml	Sy. Salbutamol 2 mg/5 ml, Bottle of 100 ml	per bottle	100 ml bottle	700000	4084800
622	Salbutamol Tab 4 mg	Tab.Salbutamol Sulphate 4 mg Aluminium Blister - Strip of 10 Tab	Per Tab	strip of 10 tablets	24000000	3396800
623	Saline Nasal Drop 10 ml	Sodium Chloride 0.065% w/v Benzakonium Chloride Solution (As preservative) 0.02%w/v Sterile isotonic Aqueous Buffered base q.s.	per bottle	10 ml Bottle	360000	2779760
624	Saline Nasal Drop 15ml	Sodium Chloride 0.09 % w/v Benzakonium Chloride Solution (As preservative) 0.02 % w/v Sterile isotonic Aqueous Buffered base q.s.	per bottle	15 ml Bottle	148434	1061600

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
625	Salmeterol 25mcg + Fluticasone 250mcg Inhaler 120 mdi	SALMETEROL 25 mcg + FLUTICASONE 250 mcg INHALER 120 mdi	Per Packet	120 MDI In 1 Packet	1475	951144
626	Salmeterol 50mcg+ Fluticasone 250mcg Cap-powder puff	Salmeterol 50mcg+ Fluticasone 250mcg Cap- powder puff (30 cap x 6 pack with 1 Dispensing Device)	per Cap	30's cap x 6 pack with 1 Dispensing Device	1830	1039554
627	Secnidiazole Tab 1 gm	Tab Secnidiazole 1 gm	Per Tab	strip of 10 tablets	393700	1188056
628	Serratiopeptidase 10mg Tab	Tab. Serratiopeptidase 10mg	Per Tab	strip of 10 tablets	2710000	2774640
629	Sertraline Tab 50 mg	Tab. Sertraline 50mg	Per Tab	strip of 10 tablets	4298936	2464800
630	Sevoflurane 250ml	Sevoflurane amber-colored bottles.250 ml Liquid/ solution 1ml of sevoflurane vaporizes 184ml of gas	per bottle	250ml bottle	2511	7352542
631	Sevoflurane Injection 1%(A)+1:200000 (5mcg/ml)(B)	Sevoflurane Injection 1%(A)+1:200000 (5mcg/ml)(B) 1ml of sevoflurane vaporizes 184ml of gas	per bottle	250ml bottle	200	880000
632	Sildenafil 10mg/ 12.5 ml Inj	Contains ; Sildenafil Citrate USP 10mg/ 12.5 ml; Equivalent to 0.8mg Sildenafil, 50.5 mg Dextrose and Water for Injection	per vial	Single Dose Vial	1070	1284480
633	Silver Sulphadiazine Cream 2 to 4%	Each Tube contains Silver Sulphadiazine Cream 2 to 4%	Per Tube	30 gram tube	100000	14400000
634	Silver Sulphadiazine Cream 250 gm	Silversulphadiazine cream : Cream Sivlersulphadiazine 1% w/w 250 gm	Per Tube	250 gm tube	250100	26217040
635	Simethicone 62.5 mg Tablet	Each tablet Contains ; Simethicone 62.5mg	Per Tab	strip of 10 tablets	55457	1020409
636	Sodium bicarbonate Inj 7.5 % 10 ml	Sodium bicarbonate Inj 7.5 % 10 ml	per ampl	10ml ampl	637307	3696735
637	Sodium Bicarbonate IP 300mg Tab	Tab Sodium Bicarbonate IP 300mg	Per Tab	strip of 10 tablets	768684	959318

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
638	Sodium Chloride - Normal Saline 0.9% Inj. I.V. 100ml	I. V. Sodium Chloride (Normal Saline) 0.9% isotonic (equivalent to Na+ 154 mmol/L,Cl- 154 mmol/L).w/v AFFS/BFS/FFS Technology	per bottle	100 ml bottle	2862250	18888960
639	Sodium Chloride (Normal saline) 0.9% IV 500 ml Bottle	I. V. Sodium Chloride (Normal Saline) 0.9% isotonic (equivalent to Na+ 154 mmol/L,Cl- 154 mmol/L).w/v AFFS/BFS/FFS Technology	per bottle	500 ml bottle	3399750	44664446
640	Sodium Chloride 6% w/v/ Eye Drop	Sodium Chloride 6 % w/v Eye Drop 5ml	per bottle	5 ml bottle	29312	937984
641	Sodium Chloride 6% w/v/ Eye Ointment	Sodium Chloride 6 % w/v Eye Ointment 5gm	Per Tube	5 gm Tube	12612	1039229
642	Sodium Chloride IP 15% w/v,Glycerin IP 15% w/v ENEMA	Each 30ml pack contains Sodium Chloride IP 15% w/v, Glycerin IP 15% w/v	per bottle	30 ml bottle	29889	980366
643	Sodium Chromoglycate Eye Drops 2% 5ml	Sodium Chromoglycate Eye Drops 2% 5ml	per bottle	5ml bottle	100	3405
644	Sodium Hypochlorite Sol. 5000ml Jar	Sodium Hypochlorite Sol. Contains not less than 4% and not more than 6% Sodium Hypochlorite. 5000ml Jar	per jar	5000ml jar	142803	41433047
645	Sodium Hypochlorite Solution 200 ml	Sodium Hypochlorite Sol. Contains not less than 4% and not more than 6% Sodium Hypochlorite. 200ml Bottle	per bottle	200 ml bottle	244400	27072640
646	Sodium Nitrite Inj 30 mg/ml 10 ml	Inj. Sodium Nitrite 30 mg per ml i.e. 300 mg in 10 mL	per vial	10 ml Vial	1898	1518400
647	Sodium Nitroprusside Inj.10mg/ml	Sodium Nitroprusside Inj.10mg/ml	per ampl	2 ml amp	7000	896000
648	Sodium Perborate Monohydrate 810gm (Instrument Sterilant) 5 litre jar	Instrument Sterilant containing : Sodium Perborate Monohydrate 50 % w/w required Compatability report of International Standard Manufacturers for commonly used endoscopes i. e. Karl Storz/ Pentax/Fujinon/ Olympus Required	per can	5 litre can	680	1810432

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
		item wise WHO GMP 810gm 5 Litre jar				
649	Sodium Valproate 200 mg Tab	Sodium Valproate 200 mg Tab	Per Tab	strip of 10 tablets	15835000	10597080
650	Sodium Valproate 500mg Tab	Tab. Sodium Valproate 500 mg	Per Tab	strip of 10 tablets	11684561	15920900
651	Sodium Valproate Tab 100 mg	Sodium ValproateTab 100 mg	Per Tab	strip of 10 tablets	500000	528000
652	Sodium Valproate Tab 250 mg	Sodium Valproate Tab 250 mg	Per Tab	strip of 10 tablets	500000	624000
653	Sodium Valproate tablet 300mg	Each Tab sodium Valproate Contains 300mg	Per Tab	strip of 10 tablets	898548	1509561
654	Spironolactone 25mg Tab	Tab Spironolactone 25 mg Aluminium Blister - Strip of 10 Tab	Per Tab	strip of 10 tablets	1000	1960
655	Spironolactone 50 mg Tab	Tab Spironolactone 50 mg Aluminium Blister - Strip of 10 Tab	Per Tab	strip of 10 tablets	331986	1043211
656	Streptokinase Inj 15 Lac IU Vial	Inj.Streptokinase 15 lacs/Vial	per vial	10ml vial	4300	2765260
657	Succinylcholine Injection 50 mg/ml	Succinylcholine Injection 50 mg/ml	per ampl	1ml ampoule	50	5800
658	Sucralfate 10 mg tablet	Each Tab Sucralfate Contains 10mg	Per Tab	strip of 10 tablets	419622	973524
659	Sucralfate Oral Liquid 1mg/ml	Sucralfate Oral Liquid 1mg/ml	per bottle	100 ml bottle	50000	1200000
660	Sucralflate Oral Suspension 1gm, 100ml Bottle	Sucralflate Oral Suspension 1gm, 100ml Bottle	per bottle	100 ml bottle	35000	878080
661	Surfactant for Intratrecheal instillation (natural bovine lung surfactant) Minimum labelled Shelf Life (In Months 18) 4ml	Surfactant for Intratrecheal instillation 25mg/ml (natural bovine lung surfactant) Minimum labelled Shelf Life (In Months 18) 4ml single dose vial	per vial	4ml vial	345	1738800
662	Surfactant for Intratrecheal instillation (natural bovine lung surfactant) Minimum	Surfactant for Intratrecheal instillation (natural bovine lung surfactant) Minimum labelled	per vial	8ml vial	125	1023750

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
	labelled Shelf Life (In Months 18) 8ml	Shelf Life (In Months 18) 8ml				
663	Suxamethonium Hydrocholride Inj 50 mg 10 ml Vial	Inj. Suxamethonium Chloride 50 mg/ml	per vial	10 ml Vial	32702	906499
664	Teicoplanin Inj 200 mg Vial	Teicoplanin inj. 200 mg	per vial	10 ml Vial	2646	833291
665	Telmisartan 20mg Tab	Tab. Telmisartan 20mg Strip of 10 Tablets	Per Tab	strip of 10 tablets	5510000	1270640
666	Telmisartan 40mg Tab	Tab. Telmisartan 40mg Strip of 10 Tablets	Per Tab	strip of 10 tablets	290848442	119111263
667	Telmisartan 80mg Tab	Tab. Telmisartan 80mg Strip of 10 Tablets	Per Tab	strip of 10 tablets	24679723	20815307
668	Tenecteplase 20 mg Inj	Inj. Tenecteplase 20mg Vial	per vial	Vial	343	1253648
669	Tenecteplase 40mg Inj	Inj. Tenecteplase 40mg Vial	per vial	Vial	140	1458018
670	Terlipressin Acetate 1mg/10ml 10ml ampoule Injection	Terlipressin Acetate 1mg/10ml 10ml ampoule Injection	per ampl	10ml ampl	4600	1840000
671	Tetanus Toxoid 40 Adsorbed 41 I.P.	Tetanus Toxoid DPAP - Each 0.5 ml human dose contains:tetanus toxoid ≥ LF, Adsorbed on aluminium phosphate ≥ 1.5 mg(AIPO4) Thiomersal 0.01% as presevative (vaccine fulfils the I.P. requirement for Tetanus toxoid (Adsorbed)	per ampl	0.5 ml Amp	1500000	10752000
672	Theophylline tablet	Each Tab contains Theophylline 600mg	Per Tab	strip of 10 tablets	100000	1480000
673	Thiamine (Vitamin B1) 200mg/2ml Inj	Thiamine (Vitamin B1) 200mg/2ml Inj	per vial	2ml vial	26400	912384
674	Thiamine injection 100 mg	each Amp Contains Thiamine injection 100 mg	per ampl	3ml Amp	122189	1075261
675	Thiocolchicosid Tab 4 mg	Tab Thiocolchicosid 4 mg	Per Tab	strip of 10 tablets	262780	1181857
676	Thyroxine Sodium IP 50 mcg Tab	Tab Thyroxine sodium 50 mcg- 100 Tablets in Amber colour glass bottle	Per Tab	100 Tablets in Amber colour	2236923	1068283

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
				glass bottle		
677	Thyroxine Sodium Tab 25mcg	Tab Thyroxine sodium 25 mcg- 100 Tablets in Amber colour glass bottle	Per Tab	100 Tablets in Amber colour glass bottle	1020000	1183680
678	Timolol Maleate Eye Drops 5 ml	Timolol Maleate Eye Drops 0.5% w/v- 5 ml	per bottle	5 ml bottle	80000	934400
679	Tincture Iodine bottle 450 ml	Tincture Iodine - Active Ingredients Iodine 2% , Sodium Iodide 2.4% , Alcohol 47% (Liquid)	per bottle	450 ml bottle	6000	806400
680	Tinidazole Tab 300 mg	Tab. Tinidazole 300 mg	Per Tab	strip of 10 tablets	15681882	7065724
681	Tobramycin Eye Drop 0.3%	Tobramycin Eye Drop 0.3%, 5ml	per bottle	5 ml bottle	187020	2004859
682	Total Parentral Nutrition 1.440 ltr	Total Parentral Nutrition 1.440 ltr contains All in One multi chamber bag for Parenteral Nutrition in 1440ml, providing 1000kcal with intravenous Amino Acids 34gm containing lipid emulsion 51gm and glucose 97gm. Having Osmolarity of 750 mosm/L with Glucose to Lipid ratio of 44:56 with Sterile Self - Sealing parts which are along stable and have tamper evident arrow flaps	per bottle	1440 ml bottle	4180	1838980
683	Tramadol Inj 50 mg 2 ml Amp	Inj. Trammadol 50 mg / ml - 2 ml Ampoule	per ampl	2 ml amp	1102000	2100000
684	Tramadol Tab 50 mg	Tab. Tramadol 50 mg	Per Tab	strip of 10 tablets	5405000	2582680
685	Tranexamic Acid Inj. 500mg	Inj. Tranexamic Acid 500 mg contains Tranexamic Acid 500 mg / 5ml and Water for Injection	per vial	5ml vial	1315050	47043723
686	Tranexamic Acid Tab 500 mg	Tab Tranexamic Acid 500 mg	Per Tab	strip of 10 tablets	1030000	7082240

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
687	Triamcinolone 1%, 10mg/ml Inj	Inj Triamcinolone Acetonide IP 10mg/ml	per vial	1ml vial	15182	955229
688	Trifluoperazine + Trihexyphenidyl Tab 5 mg + 2 mg	Tab. Trifluoperazine HCL 5 mg + Trihexyphenidyl HCL 2 mg	Per Tab	strip of 10 tablets	15650000	8668400
689	Trihexyphenidyl Hydrochloride Tab 2 mg	Tab. Benzhexol (Trihexyphenidyl) 2 mg	Per Tab	strip of 10 tablets	8720000	1039424
690	Trimethoprim + Sulphamethoxazole Paed Tab	Tab. Cotrimazole (Trimethoprim + Sulphametaxazole) Paed Tab. Cotrimoxazole (Trimethoprim 20 mg + Sulphametaxazole 100 mg) Paed	Per Tab	10 Tablet	20000	24960
691	Tropicamide Eye Drop 1%	Tropicamide Eye Drop 1%	per bottle	5 ml bottle	60000	864000
692	Tropicamide+ Phenylephrine HCL Eye Drops 5 ml	Tropicamide + Phenylephrine HCL Eye Drop (Paediatric Dose) contains Tropicamide 0.8% w/v, Phenylephrine Hydrochloride 5% w/v, Chlorbutol IP 0.5% w/v	per bottle	5ml bottle	20000	1360000
693	Trypan Blue 0.06% Inj	(Trypan Blue Ophthalmic Solution 0.06%w/v) 0.6 mg/ml Each ml contains: 0.6 mg trypan blue;	per vial	5 ml vial	39026	1763975
694	Trypsin + Chemotrypsin Tab 1 Lac IU	Tab. Trypsin + Chemotrypsin E C 1,00.000 I.U Aluminium Blister of 10 Tablets	Per Tab	strip of 10 tablets	3539130	15193668
695	Vancomycin Inj 1 gm Vial	Inj. Vancomycin 1 gm	per vial	10 ml Vial	35400	2862739
696	Vancomycin Inj 500 mg Vial	Inj. Vancomycin 500 mg,	per vial	10 ml Vial	62200	2006598
697	Vasopressin 20 IU, 1ml Inj	Inj. Vasopressin 20 IU 1ml Each 1 ml contains 20 IU Vasopressin, Chlorbutol IP 0.5% w/v (as preservative) Water for Injections IP q.s.	per ampl	1ml ampl	9949	1552861
698	Vecuronium Bromide Inj. 10mg	Each ml contains Vecuronium Bromide 10mg	per ampl	per ampl	17500	1855504

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
699	Vecuronium Bromide Inj. 4 mg 2 ml Amp	Inj Vecuronium Bromide 4mg/2ml, Lyophillised Powder Vial	per vial	2 ml Vial	50	5000
700	Verapamil Inj. 5mg 2ml amp	Verapamil Inj. 5mg 2ml amp	per ampl	2ml ampoule	500	10392
701	Verapamil tab 40mg	Verapamil tab 40mg	Per Tab	10 Tab	1000	1000
702	Verapamil tab 80mg	Verapamil tab 80mg	Per Tab	10 Tab	1000	1584
703	Viglibose Tab 0.2mg	Viglibose Tab 0.2mg	Per Tab	10 Tab	300000	396000
704	Vildagliptin 50mg Tab	Tab Vildagliptin 50mg	Per Tab	strip of 10 tablets	475832	3854014
705	Vitamin A Capsule 100000 IU	Cap. Vitamin A 100000 IU	per Cap	strip of 10 capsules	1000000	920000
706	Vitamin A Capsule 50000 IU	Cap. Vitamin A 50000 IU	per Cap	strip of 10 capsules	1000000	1200000
707	Vitamin A Concetrated Solution 100 ml	Concentrated Vitamin A solution I P 1,00,000 I U Each ml contains Vitamin A I P Synthetic equivalent to about 109500 I U/gm - Bottle of 100 ml with Dropped marked for doses	per bottle	100 ml bottle	450200	29204320
708	VITAMIN B COMPLEX Tablets N.F.I.	Tab. Vitamin B complex (Therupetic) N F I	Per Tab	strip of 10 tablets	149020500	33713480
709	Vitamin D Drops 50 mg/ml, 30 ml Bottle	Each ml contains ; Cholecalciferol IP 400 IU (Vitamin D3) (as stabilized) in a flavoured syrupy base q.s.	per bottle	30 ml bottle	300000	3600000
710	VITAMIN K3 INJECTION 10 MG / ML	Inj. Menadion Bisulphate Trihydrate 10 mg/ml (aqueous)(Vitamin K3) - 1 ml	per ampl	1ml Amp	307574	1941407
711	Vitamin K3 Water Soluble Inj 1mg/ml	Vitamin K3 Water Soluble Inj 1mg/ml	per ampl	1ml ampl	700000	4989992
712	Vitamine-E 400mg Cap	Cap. Vitamine-E 400mg Each Capsule contains : Vit E (Alpha Tocopherol Acetate)	per Cap	strip of 10 capsules	100000	2080000
713	Water for injection 10 ml	Sterile Water for Injection.10 ml	per ampl	10 ml ampl	1010000	1394720
714	Water for injection 5 ml	Sterile Water for Injection.5 ml	per ampl	5 ml amp	4010000	4215120

Sr.No.	ITEM NAME	Specification	Unit	Packing	Proposed Quantity	Required Turnover
715	White Petroleum Jelly 1 Kg	White Petrolium Jelly 1 kg	per jar	1 Kg jar	15000	2880000
716	White soft paraffin 500gms	white soft paraffin 500gms	per container	500gm container	5800	2227200
717	Xylocard 2% Inj. I V	Lidocaine 2% without preservative for I.V. Use in cardiac 30ml Vial	per vial	30ml vial	50	1920
718	Xylometazoline nasal drops 0.05 % 10 ml	Xylometazoline nasal Drops 0.05% per ml	per bottle	10 ml Bottle	79078	1381022
719	Zinc sulphate DT 10 mg	Tab. Zinc Sulphate 10 mg Each dispersible Tablet contains Zinc Sulphate (as Monohydrate) 54.88mg equivalent to elemental Zinc 10mg.	Per Tab	strip of 10 tablets	3000000	1032000
720	Zinc sulphate DT 20 mg	Tab. Zinc Sulphate 20 mg Each dispersible Tablet contains Zinc Sulphate (as Monohydrate) 54.88mg equivalent to elemental Zinc 20mg.	Per Tab	strip of 10 tablets	118950000	13058400
721	Zinc sulphate or gluconate syrup	Zinc sulphate or gluconate Syrup : Each 5 ml of Syrup contains Zinc Sulphate or gliuconate equivalent to Elemental Zinc 20mg.	per bottle	60 ml bottle	2383680	14742328
722	Zolpidem Tab 10 mg	Tab. Zolpidem Tararate 10 mg	Per Tab	strip of 10 tablets	325000	119600

Delivery Terms : **To the consignee destination on door delivery basis as per Tender conditions**

Appendix-B: Checklist

(Mandatory Documents to be uploaded online in the Technical Bid)

TECHNICAL BID DOCUMENTS.			Page No. (as per the Bid)
1	Proof of Tender fees and EMD paid (if exempted as per Clause 3.4, attested copy of valid registration made by manufacturer for offered product under Micro & Small, Medium Industries Development Act, 2006 (if applicable).	Yes / No	
2	Copy of certificate of incorporation/registration along with charter documents, and other registration documents according to the nature of entity	Yes / No	
3	Pan Card Details	Yes / No	
4	GST Registration certificate along with copy of the GST return of last quarter.	Yes / No	
5	Copy of manufacturing drug license with product list duly approved by the Licensing Authority/ State drug authority for each and every product quoted as per specification in the bid. The license must have been duly renewed up to date and the items quoted shall be clearly highlighted in the license	Yes / No	
6	World Health Organization-Good Manufacturing Practice certificate with either product list or COPP	Yes / No	
7	Copy of permission from DCGI for "New drug & Fixed Dose Combination"	Yes / No	
8	Market Standing Certificate as issued by Central or State Licensing Authority for relevant period against quoted Drugs	Yes / No	
9	Non-Conviction Certificate issued by Licensing Authority.		
10	Annexure-1 (Technical Specifications and Compliance)	Yes / No	
11	Annexure-2 (Letter Comprising Technical Bid)	Yes / No	
12	Annexure-3 (Proforma for Production and Sale Statement)	Yes / No	
13	Annexure-4 (Details of Manufacturing Unit)	Yes / No	
14	Annexure-5 (Details of Items Quoted with Drug Code)	Yes / No	

15	Annexure-6 (Annual Turnover Statement for Three Years) along with Copies of Balance Sheet and Profit and Loss Accounts for last three years i.e., (2022-23, 2023-24, 2024-25) certified by the Statutory Auditor or Chartered Accountant.	Yes / No	
16	GST Registration certificate along with copy of the GST return of last quarter.	Yes / No	
17	Annexure-7 (Format of Power of Attorney for signing of Bid) except for proprietorship	Yes / No	
18	Annexure-8 (Affidavit for Blacklisting)	Yes / No	
19	Annexure-9 (Litigation Affidavit)	Yes / No	
20	Annexure-10 (Mandate Form)	Yes / No	
21	Import Export Certificate (IEC Code) for Importer	Yes / No	

For the avoidance of any confusion, scanned copies of the above mentioned documents shall be uploaded online on the Official Website on or prior to the Bid Due Date.

Annexure 1: Technical Specifications and Compliance

Tender reference No: E-215/MMGPA/ Essential Medicines (2025-26)

Item Name: Following are the minimum requirements. Products offered must meet these parameters herein.

Sr. No	Item Name	Technical specifications/ composition of tender enquiry	Compliance on each parameter with detailed substantiation how the offered product meets the requirement.	If Column B=C (write Yes or No)	Generic Name / Brand Name (only for Importer)	Drug Mfg. License (Form 25 or 28 & 26)/ Medical devices/ Import License (Form 10 & 41)	MSME/ SSI	Remarks, if any
	A	B	C	D	E	F	G	H

Note:

- Pharmacopoeia standards IP/BP/USP etc. should be clearly mentioned against each drug/constituent of the formulation quoted as per the provisions of the Applicable Laws.
- Active ingredient used in formulation of item quoted shall be of mentioned Pharmacopoeia quality & Specifications.

Sign

Stamp

Date

Annexure-2: Letter Comprising Technical Bid

To,
Chief Executive Officer,
Maharashtra Medical Goods Procurement Authority,
1st Floor, Aarogya Bhawan,
Near CSMT Railway Station,
Mumbai 400001 (Maharashtra)

Subject: Bid for the [*******]

Dear Sir,

With reference to your Tender document dated ……., I, having examined the Tender document and understood its contents, hereby submit my/our Bid for the aforesaid [*******]. The Bid is unconditional and unqualified.

1. I/ We acknowledge that the Purchaser will be relying on the information provided in the Bid and the documents accompanying such Bid for selection of the Supplier for the supply of the specified drugs, and we certify that all information provided therein is true and correct; nothing has been omitted which renders such information misleading; and all documents accompanying such Bid are true copies of their respective originals.
2. I/ We shall make available to the Purchaser any additional information it may find necessary or require supplementing or authenticate the Bid.
3. I/ We acknowledge the right of the Purchaser to reject our Bid without assigning any reason or otherwise and hereby waive, to the fullest extent permitted by applicable law, our right to challenge the same on any account whatsoever.
4. I/ We certify that in the last three years, we or our associates have neither failed to perform on any contract, as evidenced by imposition of a penalty by an arbitral or judicial authority or a judicial pronouncement or arbitration award, nor been expelled from any contract by any public authority nor have had any contract terminated by any public authority for breach on our part.
5. I/ We declare that:
   (a) I/ We have examined and have no reservations to the Tender Document, including any Addendum / Corrigendum issued by the Purchaser.
   (b) I/ We do not have any conflict of interest in accordance with the Tender Documents; and
   (c) I/We have not directly or indirectly or through an agent engaged or indulged in any unethical practice, as defined in the Tender Document, in respect of any tender or request for proposal issued by or any agreement entered into with the Purchaser or any other public sector enterprise or any government, Central or State.
6. I/ We understand that you may cancel the bidding process at any time and that you are neither bound to accept any Bid that you may receive nor to invite the Bidders to Bid for

the Tender , without incurring any liability to the Bidders, in accordance with the provisions of the Tender Document.

7. I/ We believe that we satisfy(ies) the Annual Turnover and Net Worth criteria and meet(s) all the requirements as specified in the Tender Document and am/ are qualified to submit a Bid.

8. I/ We certify that in regard to matters other than security and integrity of the country, we or any of our associates have not been convicted by a Court of Law or indicted or adverse orders passed by a regulatory authority which could cast a doubt on our ability to undertake the Contract or which relates to a grave offence that outrages the moral sense of the community.

9. I/ We further certify that in regard to matters relating to security and integrity of the country, we or any of our associates have not been charge-sheeted by any agency of the Government or convicted by a Court of Law.

10. I/ We further certify that no investigation by a regulatory authority is pending either against us or against our associates or against our CEO or any of our directors/ managers/ employees / Partners /Trustees.

11. I/We further certify that we or any of our Associates are not barred by the Central Government/ State Government or any entity controlled by it, from participating in any supply of drugs contract, and no bar subsists as on the Bid Due Date .

12. I/ We undertake that in case due to any change in facts or circumstances during the bidding process, we are attracted by the provisions of disqualification in terms of the provisions of this Tender Document, we shall intimate the Purchaser of the same immediately.

13. I/ We hereby irrevocably waive any right or remedy which we may have at any stage at law or howsoever otherwise arising to challenge or question any decision taken by the Purchaser in connection with the selection of the Bidder, or in connection with the bidding process itself, in respect of the above-mentioned Contract and the terms and implementation thereof.

14. In the event of my/ our being declared as the Selected Bidder, I/we agree to enter into a Contract in accordance with the draft that has been provided to me prior to the Bid Due Date along with the Tender Document. We agree not to seek any changes in the aforesaid draft and agree to abide by the same.

15. I/ We have studied all the Bidding Documents carefully. We understand that except to the extent as expressly set forth in the Contract and Purchase Order, we shall have no claim, right or title arising out of any documents or information provided to us by the Purchaser or in respect of any matter arising out of or relating to the bidding process including the award of Contract.

16. The power of attorney for signing of Bid, as per format provided at Annexure-7 of the Tender Document, is also enclosed.

17. I/ We agree and undertake to abide by all the terms and conditions of the Tender Document.

18. I/ We offer a Tender Fee of INR [****] and EMD of INR [********] to the Authority in accordance with the Tender Document.

19. I/We agree and understand that the Bid is subject to the provisions of the Tender Documents. In no case, I/We shall have any claim or right of whatsoever nature if the Contract is not awarded to me or our Bid is not opened or rejected.

20. The Price Bid has been quoted by me after taking into consideration all the terms and conditions stated in the Tender Document, our own estimates of costs and after a careful assessment of the all the conditions that may affect the price and implementation of the Contract.

21. I/We shall keep this offer valid for 180 days from the Bid Due Date as specified in the Tender Document.

22. I/ We hereby undertake to submit this Technical Bid for undertaking the aforesaid Contract in accordance with the Tender Documents and the Contract.

In witness thereof, I/we submit this Bid under and in accordance with the terms of the Tender Document.

Yours faithfully,

Date:

(Signature, Name and designation of the Authorised signatory)

Place:

(Name and seal of Bidder)

Annexure-3: Proforma for Production and Sale Statement

(For a period of last 3 Years preceding the Bid Due Date)

Name of the bidding entity:

Sr. No.	Year	Name and full Address of the Purchaser	Purchasing Entity (Gov./Semi Gov./Other)	Name of the Product	Purchase Order No. & Date	Purchase Order Quantity	Batch No.		PO Copy enclosed on Pg. No.
							Manufactured Qty	Sold Qty	
1	**2022-23**								
2	**2023-24**								
3	**2024-25**								

Add rows as per requirement.

Note:

1. In support of above statement, enclose the copies of supply orders and client's satisfactory certificates. All purchase orders should be enclosed in the serial as per the data provided in table above.
2. In case of importer, sold quantity shall be provided, production and manufactured good details may not be provided-
3. All the data of the bidding entity, as provided in the above table has been verified by undersigned Chartered Accountant/Statutory Auditor.
4. The issuer of this certificate must ensure that the above information/details are related to the bidding entity only.

Name, Membership number and signature of the Chartered Accountant/Statutory Auditor:

UDIN

Name and seal of the firm:
Location, Date:
Authorized Signature *(PoA holder)*

[In full and initials with Seal]:

Name and Title of Signatory:

Name of Bidder (Firm/ Organization's name):

Address:
Telephone:
Email:
(Name and seal of the Bidder)
[*Location, Date*]

Annexure-4: Details of Manufacturing Unit

(The details of manufacturing facility to be furnished)

Name of the Bidder and Office Address	:
Factory Address	:
PAN	:
GST No.	:
Phone Nos.	:
Fax	:
E-Mail[1]	:
Date of Inception	:
License No. & Date	:
Issued by	:
Valid up to	:
Details of installed Production Capacity	:

[9] Bidder shall ensure that, all correspondence with the Purchaser shall be through the official email id mentioned herein.

Details of Installed Production Capacity for 30 days
(In Terms of Unit Packs)

Tablets :

Capsules

General :

Beta-Lactum :

Injection

Ampoules :

Vials :

I.V.Fluids :

Sterile Powder:

Liquids

Suspension :

Syrups :

Drops :

Ointment :

Powders :

Antiseptics/
Disinfectants :

Name & designation of the authorized signatory:

Specimen signature of the authorized Signatory:

*The details of manufacturing unit should be for the premises where drugs quoted are actually manufactured

THE DETAILS OF FACTORY PREMISES

Person In-charge of Factory

Name :

Phone No. :

Mobile No. :

Nearest Landmark of Factory:

Layout

Km from Airport :

Name of the Airport and City:

Km from Railway Station :

Name of the Railway Station:

Km from Bus Stand :

Name of the Bus Stand :
And City

All the data provided in the above table has been verified by undersigned Chartered Accountant/Statutory Auditor.

Name, Membership number and signature of the Chartered Accountant/Statutory Auditor:

UDIN

Name and seal of the firm:
Location, Date:
Authorized Signature *(PoA holder)*

[In full and initials with Seal]:

Name and Title of Signatory:

Name of Bidder (Firm/ Organization's name):

Address:
Telephone:
Email:

(Name and seal of the Bidder)
[*Location, Date*]

Annexure-4 (A): Proof of Distribution Network

1. Sales / Distribution of License no :
   (Copy of license is enclosed herewith)

2. Details of Authorized distributors in Maharashtra State :

Sr No	Name	Address	Contact Details
1			
2			

(Name and seal of the Bidder)
[*Location, Date*]

Annexure-5: Details of Items Quoted with Drug Code

1. Name of the firm:

2. Address as given in drug licence:

3. Drug Licence No. in Form 25 &28:

4. Import Licence No. :

5. Date of issue:

6. Validity:

7. Non-conviction Certificate obtained on:

8. Market standing certificate obtained on:

9. Details of endorsement for all products:

Sr. No.	Drug name	Specifications IP/BP/USP	Date of endorsement obtained from State Drugs Commissioner	Whether Endorsement is in Generic or Brand Name

Add As Many Rows as possible You Want to Add

(Additional column should be inserted asking date of permission from CDSCO, in case of all newly introduced drugs and Fixed dose combinations)

Annexure 6: Annual Turnover Statement for Three Years

(To be submitted on the letterhead of the Statutory Auditor/ Chartered Accountant of the Bidder)

M/s. ..... is participating in tender No…… Items details as per Below Table.

Sr No of Item (as per Appendix A)	Name of Item	Required Turnover (In Rs)
Total Required Turnover		

The Average Annual Turnover and Net Worth details of M/s _____ for participation under the Tender Document are given below and certified that the statement is true and correct.

Sr. No.	Year	Turnover (In Rs.)
1	2022-23	
2	2023-24	
3	2024-25	
4	Average Annual Turnover of above 3 years	
Net Worth		
5	Net worth in the latest financial year preceding the Bid Due Date (positive/negative)	

"Net Worth" in case of Company shall mean the aggregate value of the paid-up share capital and all reserves created out of the profits and securities premium account, after deducting the aggregate value of the accumulated losses, deferred expenditure and miscellaneous expenditure not written off, as per the audited balance sheet, but does not include reserves created out of revaluation of assets, write-back of depreciation and amalgamation.

For other eligible entities, the Net Worth shall mean the amount derived by subtracting the liabilities from the assets as certified by the chartered accountant/statutory auditor having valid registration.

Note:

1. Certificate issued by a statutory auditor/chartered accountant along with audited financial statements confirming the average annual turnover of the Bidder during the stated financial years must be submitted on the letterhead of the statutory auditor/chartered accountant.
2. Provide supporting audited financial statements (Balance Sheets, Profit and Loss Statements, etc.) of the bidding entity.
3. The Net Worth of the bidder in the financial year immediately preceding the Bid Due Date should be positive.
4. "Turnover" for the purposes of this Tender Document shall mean the monetary value of

goods sold by the Bidder.

Name, Membership number and signature of the Chartered Accountant:

UDIN
Name and seal of the firm:
Location, Date:

Authorized Signature of Bidder *(PoA holder)*
[In full and initials with Seal]:
Name and Title of Signatory:
Name of Bidder (Firm/ Organization's name):
Address:
Telephone:
Email:
(Name and seal of the Bidder)
[*Location, Date*]

Annexure-7: Format for Power of Attorney for signing of Bid

(Refer Clause 3.2)

(To be executed as an Affidavit on a Stamp paper of appropriate value)

Know all men by these presents, We, …… (name of the firm and address of the registered office) do hereby irrevocably constitute, nominate, appoint and authorize Mr. / Ms (Name), son/daughter/wife of……. and presently residing at ……., who is presently employed with us and holding the position of ……, as our true and lawful attorney (hereinafter referred to as the "**Attorney**") to do in our name and on our behalf, all such acts, deeds and things as are necessary or required in connection with or incidental to submission of our bid for the [******] ,proposed or being developed by the [*******] (the "**Purchaser**") including but not limited to signing and submission of all applications, bids and other documents and writings, participate in bidders' and other conferences and providing information / responses to the Purchaser, representing us in all matters before the Purchaser, signing and execution of all contracts including the rate Contract and undertakings consequent to acceptance of our bid, and generally dealing with the Purchaser in all matters in connection with or relating to or arising out of our bid for the said rate Contract and/or upon award thereof to us and/or till the entering into of the Contract with the Purchaser.

AND we hereby agree to ratify and confirm and do hereby ratify and confirm all acts, deeds and things done or caused to be done by our said Attorney pursuant to and in exercise of the powers conferred by this Power of Attorney and that all acts, deeds and things done by our said Attorney in exercise of the powers hereby conferred shall and shall always be deemed to have been done by us.

IN WITNESS WHEREOF WE, ……., THE ABOVE NAMED PRINCIPAL HAVE EXECUTED THIS POWER OF ATTORNEY ON THIS ……. DAY OF ……., 20…...

For …….

(Signature, name, designation and address
of person authorized by Board Resolution
in case of Firms/Company)/Partner in case of
Partnership Firms

Witnesses:

1.

2.

Notarised
Person identified by me/personally appeared before me
/Signed before me/Attested/Authenticated*
(*Notary to specify as applicable)
(Signature, Name and Address of the Notary)
Seal of the Notary
Registration Number of the Notary
Date_____

Accepted

(Signature, name, designation and address of the Attorney)

Notes:

- *The mode of execution of the Power of Attorney should be in accordance with the procedure, if any, laid down by the applicable law and the charter documents of the executants (s) and when it is so required, the same should be under common seal affixed in accordance with the required procedure.*

  Wherever required, the Bidder should submit for verification the extract of the charter documents and documents such as a board or shareholders resolution/power of attorney in favour of the person executing this Power of Attorney for the delegation of power hereunder on behalf of the Bidder.

- *For a Power of Attorney executed and issued overseas, the document will also have to be legalized by the Indian Embassy and notarized in the jurisdiction where the Power of Attorney is being issued. However, the Power of Attorney provided by Bidders from countries that have signed the Hague Legislation Convention, 1961 are not required to be legalized by the Indian Embassy if it carries a conforming Apostille certificate issued by the designated competent authority and has been notarized by the public notary.*

Annexure-8: Affidavit for blacklisting

(Non-Judicial Stamp Paper of Rs. 100/-)

Undertaking for rates, specification, blacklisting status on Stamp paper duly notarized

Tender reference No: 215/MMGPA/ Essential Medicines

(2025-26)

1. This is to certify that the rates quoted in the bid are not higher than D.P.C.O., N.P.P.A, or not higher than MRP.
2. I/We undertake to provide the drugs/medicines/equipment's as required by Maharashtra Medical Goods Procurement Authority, Mumbai and there will be no deviation in composition, quality, packing etc.
3. The Bidder ……..(Name of the Bidder) has not been found guilty of malpractices, misconduct or Blacklisted/Debarred/ deregistered for the quoted product by any department of Govt. of Maharashtra or by any local authority and semi Govt. organization and other State Government/Central Government's organizations/ procurement corporation as on the date of submission tender document for the quoted items.
4. I/We undertake that I/we are not involved in any major litigation such as fraud, FEMA violations and any other civil or criminal proceedings.

Seal **Signature of Authorised Signatory**

Date

Place

Verification

I, the above named *[Name of the Bidder]*, do hereby solemnly verify that the contents of the above Affidavit are true and correct to my knowledge and belief. Nothing false has been stated therein or material concealed therefrom.

Verified at *{location}* on *{Date}*

Note: The Bidder shall mandatorily enclose Non-Conviction Certificate issued by Licensing Authority/ State FDA along with this Affidavit for blacklisting.

Annexure- 9: Litigation Affidavit

(on Non-judicial Stamp Paper of Rs.100/-)

Tender reference No: E-215/MMGPA/ Essential Medicines (2025-26)

I ---------- age ----------
address---------- (authorized signatory to sign the contract), hereby submit, vide this affidavit in truth, that I am the owner/authorized signatory of the bidding entity----------and I am submitting the documents in Envelope no.1 for the purpose of security of the contract. I hereby agree to the conditions mentioned below:-

1. I am liable for action under Bharatiya Nyaya Sanhita (BNS) for submission of any false/ fraudulent paper/information submitted in Envelope no.1

2. I am liable for action under Bharatiya Nyaya Sanhita (BNS) if during contract period and any false information, false bill of purchases supporting proof of purchase, proof of testing submitted by my staff, subletting company or by myself, I will be liable for action under Bharatiya Nyaya Sanhita (BNS).

3. I am liable for action under Bharatiya Nyaya Sanhita (BNS) if any paper is found false / fraudulent during contract period and even after the completion of contract (finalization of final bill).

Authorised Signature of Bidder

Seal of Company

<u>Verification</u>

I, the above named *[Name of the Bidder]*, do hereby solemnly verify that the contents of the above Affidavit are true and correct to my knowledge and belief. Nothing false has been stated therein or material concealed therefrom.

Verified at *{location}* on *{Date}*

Annexure-10: Mandate Form

01	Company Name	
02	Postal Address of the company with Telephone No., Fax No. and Mail address	
03	Name of the Managing Director/ Director/Manager Mobile No. /Phone No. E-mail address	
04	Name and designation of the authorized company official Mobile No. /Phone No. E-mail address	

Bank Details

01	Name of the Bank Branch Name & Address; Branch Code No. Branch Manager Mobile No. Branch Telephone no. Branch E-mail ID	
02	9-digit MICR code number of the bank and branch appearing on the MICR cheque issued by the bank.	
03	IFSC code of the Branch	
04	Type of Account (Current/Savings)	
05	Account Number (as appear in cheque book)	

(in lieu of the bank certificate to be obtained, please **attach the original cancelled cheque** issued by your bank for verification of the above particulars)

I/We hereby declare that the particulars given above are correct and complete. If the transaction is delayed or not effected at all for reasons of incomplete or incorrect information, I would not hold Maharashtra Medical Goods Procurement Authority, Mumbai. I have read the conditions of tender/ agreement entered and agree to discharge the responsibility expected of me/from the company as a tenderer/ successful bidder.

Date: Company seal Signature

Place: (Name of the person signing & designation)

CERTIFIED THAT THE PARTICULARS FURNISHED ABOVE BY THE COMPANY ARE CORRECT AS PER OUR RECORDS

Bank Seal with address

Signature of the Authorized Official of the bank

Annexure-11: Indicative format for PRICE BID (BOQ) to be submitted online only

(To be kept in Envelope No. 2)

Item Description	Packaging	Unit	Quantity	Ex-factory cost per unit	GST applicable for Govt. Supply (In Rs.)	Other incidental charges (please specify) (In Rs.)	Total landed cost per unit (5+6+7) (In Rs.)	Total Cost Rs. (4 x8)
1	**2**	**3**	4	5	6	7	8	9

Total tender price (in words.....)

The price should be quoted only in Indian currency Note:

In case of discrepancy between unit price and total price, the unit price shall prevail. Only total landed cost per unit considered for rate comparison.

Signature of the Tenderer
Name
Designation
Business address

A separate price schedule to be used for each item while quoting rates. Each price schedule to be sealed in separate envelopee mentioning PRICE BID for Item _____. All such price schedule should be enclosed in envelope no. 2 which should be sealed.

To be uploaded in the form of Excel.

Annexure-12: Statement showing comparative prices offered by the tenderer in other tenders of the same product

ONLY FOR ADDITIONAL INFORMATION AS TO RATES OFFERD BY THE TENDERER IN VARIOUS OTHER TENDES.

Please mention quoted rates of above item of different years

Sr. No.	Year	MRP per unit	Price as per DPCO /NPPA	Unit Price offered in other Bids/ Tenders/Rate contracts					
				HBPCL	DMER (Govt. of Maha.)	MCGM	ESIC	Other State Govt.(s)	Tenders of Central Govt.
1	2022-23								
2	2023-24								
3	2024-25								
Additional rows for information of other years can be inserted									

Signature

Seal

Schedule 1: Contract Form

(Stamp duty as applicable as per Maharashtra Stamp Act, 1958)

THIS AGREEMENT("Contract") made the .....day of....., 20... , at …….between

Maharashtra Medical Goods Procurement Authority (MMGPA), Mumbai, formed as per the Maharashtra Medical Goods Procurement Authority Act 2023 (Mah. Act No. XIII of 2023), represented by its Chief Executive Officer and having its registered office at 1st Floor, Aarogya Bhawan, St. George's Hospital Compound, Near C.S.M.T. Railway Station, Mumbai - 400001, Maharashtra, (hereinafter "the Purchaser") of the One Part;

and

[insert name of entity], a [●] incorporated/ registered under the provisions of the [insert name of relevant statute, if applicable] and having its registered office at [●], (hereinafter referred to as the "**Supplier**" which expression shall, unless repugnant to the context or meaning thereof, include its successors, permitted assigns and substitutes) of the **OTHER PART**.

WHEREAS

A. the Purchaser is desirous that certain specified drugs to be procured and has accepted a bid by the Supplier for the supply of …… [name of the drug as per the list annexed] in the sum of..... (contract price in words and figures) (hereinafter called "Contract Price").
B. Whereas the Supplier has deposited a Bank Guarantee of Rs..... (Rs. in words.....) as Performance Security towards the fulfilment of this Contract.

NOW THIS AGREEMENT WITNESSETH AS FOLLOWS:

1. In this Contract words and expressions shall have the same meanings as are respectively assigned to them in the conditions of Contract referred to.
2. The Supplier has accepted the Contract on the terms and condition set out in notice No.- ---------- as well in the NOA Acceptance Letter No : - ---------- Dt:---------- which will hold good during the period of this Contract .
3. The following documents shall be deemed to form and be read and construed as part of this Agreement, viz.:
    i. Purchase order(s) issued under this Contract, if any.
    ii. Supplier's Acceptance to NOA
    iii. Notification of Award (NOA)
    iv. Supplier's Bid including response to the clarification (if any)
    v. The Price Bid submitted by the Supplier;
    vi. The schedule of requirements;
    vii. The technical specifications;
    viii. Tender Documents and all of its terms & conditions;

4. In consideration of the payments to be made by the Purchaser to the Supplier as hereinafter mentioned, the Supplier hereby covenants with the Purchaser to provide the drugs and to remedy defects therein in conformity in all respects with the provisions of the Contract.

5. The Purchaser hereby covenants to pay the Supplier in consideration of the provision of the drugs and the remedying of defects therein, the Contract Price or such other sum as may become payable under the provisions of the Contract at the times and in the manner prescribed by the Contract.

6. Upon breach by the Supplier of any of the condition of the Contract, the Purchaser may by a notice in writing, determine and terminate this Contract without prejudice to the right of the Purchaser to claim damages for antecedent breaches thereof on the part of the Supplier , as certified in writing by the Purchaser which certificate shall be conclusive evidence of the amount of such compensation payable by the Supplier to the Purchaser.

7. This Contract shall remain in force until the expiry of the date of delivery of material but notwithstanding herein or in the tender and acceptance forms contained the 'Purchaser shall not be bound to take the whole or any part of the estimated quantity herein or therein mentioned and may cancel the Contract at any time upon giving one month's notice in writing without compensating the Supplier.

8. The Supplier has fully read understood & shall abide by all the term and conditions as stipulated in Tender Document, failing which the Contract is liable to be terminated at any time without assigning any reason by the Purchaser.

9. Any change/amendments if required to be incorporated in the Contract at a later stage shall be discussed & mutually agreed by both the parties and supplementary agreements shall be binding on both the parties and shall form the part of this Contract .

10. This Contract shall be governed by and construed in accordance with the laws of Republic on India.

Brief particulars of the goods and services which shall be supplied/provided by the Supplier are as under:

Sr. No.	Brief Description Of Goods & Services	Quantity to be Supplied *	Unit Price	Total Price	Delivery Terms
					As per the supply order

***Note**:

1. Actual quantity to be supplied may vary & will be strictly as per actual requirement.
2. Actual supply to take place only after & as per the supply order(s) issued by Maharashtra Medical Goods Procurement Authority, Mumbai from time to time.
3. Tender Document is part and parcel of Contract.
4. In addition to the above, all terms & conditions as specified in Revised Manual of Office Procedures for Procurement by Government Departments: Government Resolution no.

Bha.kha.sa-2014/ Pra. Kra. 82/Section-III/Industry–4, dated 1.12.2016 issued by Department of Industries and Labour, Government of Maharashtra will apply on the Contract.

IN WITNESS whereof the parties hereto have caused this Contract to be executed in accordance with their respective laws the day and year first above written.

Signed, Sealed and Delivered (on behalf of the Purchaser)	Signed, Sealed and Delivered (on behalf of the Supplier)
Address for communication:	Address for communication:
In presence of	
1.	2.

Office of the-

Sd/-
Chief Executive Officer,
Maharashtra Medical Goods Procurement Authority, Mumbai

1st Floor, Aarogya Bhawan, Near CSMT Railway Station, Mumbai 400001 (Maharashtra)

Schedule-2 Performance Security Form

To,

Chief Executive Officer,
Maharashtra Medical Goods Procurement Authority,
1st Floor, Aarogya Bhawan,
Near CSMT Railway Station,
Mumbai 400001 (Maharashtra)

Dear Sir

Whereas you intent to enter into a contract, as per your Notification of Award, Reference No. _____ dated _____(hereinafter referred to as "the contract") with M/s _____ as Supplier for the supply of_____ defined in contracts schedule, (hereinafter referred to as "drugs") and whereas the Supplier has undertaken to produce a performance cum warranty bond for amount of Rs _____ being equal to 3% of the total contract value of the drugs to be delivered as specified in NOA No _____dated _____ .

1. We _____ (Name of the Bank), hereby expressly, irrevocably, and unreservedly undertake and guarantee as principal obligators on behalf of the Supplier that in the event that the Maharashtra Medical Goods Procurement Authority ("MMGPA") submits a written demand to us stating that the Supplier has not performed according to the terms and conditions of the contract, we will pay MMGPA on demand and without demur any sum up to a maximum amount of (3% of the contract value). Any claims must bear the confirmation of MMGPA's bankers that the signatures thereon are authentic. MMGPA's written demand shall be conclusive evidence for us to make payment to MMGPA. For the avoidance of doubt, any documents received by way of facsimile or similar electronic means is/are not acceptable for any purpose(s) under this guarantee.
2. We shall not be discharged or released from this undertaking and guarantee by any arrangements, variations made between beneficiary and the seller or any forbearance whether as to payment, time performance or otherwise.
3. Unless a demand under this guarantee is received by us in writing on or before the expiry dates (unless this guarantee is extended by the Supplier), all MMGPA's rights under this guarantee shall be forfeited and we shall be discharged from the liabilities hereunder.
4. This guarantee shall be a continuing guarantee (which means guarantee will also be valid if the bank is in under liquidation or bankruptcy) and shall not be discharged by any change in the constitution of the bank or in the constitution of the Supplier.
5. Please return this letter of guarantee immediately after our liability thereafter has ceased to be valid.
6. Our liability under this guarantee will cease to be valid even if the guaranteed deed is not returned to us.
7. This guarantee is personal to MMGPA and not assignable to a third party without our prior written consent.

8. This guarantee shall be governed by Indian Law. This guarantee is valid until <<mention date { date of validity should not be less than 24 months from signing of the Contract} >>.

Signature and Seal of Guarantors _____

Date _____

Address: _____

_____

Schedule-3: Supply Schedule

(in accordance with clause 4.10)

Dt:

Supplier Name:

PO No:

PO Date:

Drug Name:

Total Ordered Qty:

Sr.No.	Consignee Name	Ordered Qty	Expected Date of drug to be manufactured at manufacturing unit	Expected Date of in house/NABL testing	Expected Date of Delivery	No. of days taken from PO Date	Remarks, if any
1.							
2.							
3.							

Seal **Signature**

Date
Place

Schedule 4: Schedule for Packing of Drugs and Medicines

A. General Specifications: All drugs should be packed & supplied in prescribed packing only.

1. No corrugate package should weigh more than 15 Kgs (i.e., Product + Inner Carton Corrugated box)
2. All corrugated boxes should be of 'A' grade paper .i.e. Virgin.
3. All items should be packed only in first hand boxes only.
4. Flute - The corrugated boxes should be of narrow flute.
5. Joint - Every box should be preferably single joint and not more than two joints.
6. Stitching - Every box should be stitched using pairs of metal pins with an interval of two inches between each pair. The boxes should be stitched and not joined using calico at the corners.
7. Flap - The flaps should uniformly meet but should not overlap each other. The flap when turned by 45 - 60 degree should not crack.
8. Tape - Every box should be sealed with gum tape running along the top and lower opening.
9. Carry strap- Every box should be strapped with two parallel nylon carry straps (they should intersect).
10. Label - Every corrugated box should carry a large outer label clearly indicating that the drug is for **'Government of Maharashtra (MMGPA) Supply - Not for Sale', wherein 'Government of Maharashtra (MMGPA) Supply' should be in readable purple colour and 'Not for Sale' should be in green colour**
11. The product label on the carton should be large at least 15 cm. x 10 cm. dimension. It should carry the correct technical name, strength or the drug, date of manufacture &distributor, date of expiry, quantity packed and net weight of the box.
12. Other - No box should contain mixed drugs or mixed batches of the same drug.

B. Specification for Corrugated Boxes Holding Tablets / Capsules / Pessaries

1. The box should not weigh more than 7-8 Kilograms. The grammage of outer box should be 150 gsm and inside partition / lining should be 120gsm.
2. The box should be of 5 ply with bursting strength of 9 Kg/ Cm2

C. Specifications for Ointment / Cream / Gels Packed in Tubes

1. No corrugate box should weigh more than 7-8 Kgs.
2. Every Ointment tube should be individually packed in carton and then packed in 20's in a White board box, which may be packed in a corrugated box.
3. The grammage of outer box should be 150 gsm and inside partition / lining should be 120gsm.

D. Specifications for Injectable (in Vials and Ampoules)

1. Vials may be packed in corrugated boxes weighing up to 15 Kilograms. Ampoules should be packed in C.B weighing not more than 8 Kilograms.
2. Corrugated box for vials should be of 150 gsm (outer box should be 150 gsm and inside partition / lining should be 120 gsm) and 7 ply, while corrugated box for

ampoules should be of 150 gsm (outer box should be 150 gsm and inside partition / lining should be 120 gsm) and 5 ply.

3. Bursting strength for CB boxes for
    a. Vials : Note less than 13 Kg/Cm2
    b. Amp : Note less than 9 Kg/Cm2
4. In the case of 10 ml Ampoules, 100 or 50 ampoules may be packed in a White board box. Multiples of White board boxes packed in corrugated box. In case of Ampoules larger than 10 ml, only 25 ampoules may be packed in a White board box with partition.
5. If the vial is packed in individual carton, there is no necessity for White board box packing. The individual carton may be packed as such in the corrugated box with centre pad.
6. In case of ampoules, every White board box should carry 5 amps. Cutters placed in a polythene bag.
7. Vials of Eye and Ear drops should be packed in an individual carton with a dispensing device. If the vial is of FFS/BFS technology, they should be packed in 50's in a White board box.

E. Primary Package

1. Tablets & Capsules

- 10 Tablets/Capsules or multiples of 10 should be packed in an Aluminum strip / Aluminum – P V C blister pack.
- Aluminum strips: Thickness of Aluminum foil: 40 microns with LDPE 25-micron coating/heat seal lacquer
- PVC Film : Transparent, clear/amber, food grade, blister forming PVC film, Film gauge 200 microns, P E coating : 25 microns, PVdC coating : 60 gsm.
- Aluminum foil: Hard tempered Blister foil, VMCH coated, Thickness: 0.025 mm.

'Government of Maharashtra (MMGPA) Supply - Not for Sale' in readable purple or green colour on each strip.

2. Injections

- Injection in ampoule form should be supplied in Double constructed neck ampoules with the label bearing the words **'Government of Maharashtra (MMGPA) Supply - Not for Sale' in readable purple or Green colour.**
- The vials should be supplied with Aluminum seal ampoules with the label bearing the words **'Government of Maharashtra (MMGPA) Supply - Not for Sale' in readable purple or Green colour.**

3. Liquid Orals

Liquid preparations should be in FDA approved glass/plastic bottles with pilfer-proof caps. The top of the cap and the label to be affixed on the containers should bear a distinct colour different from the colour of the label of the trade packs and they should be overprinted in readable purple colour with the words **'Government of Maharashtra (MMGPA) Supply - Not for Sale'.**

4. Ointments

Ointments should be supplied in tube and bearing the words **'Government of Maharashtra (MMGPA) Supply - Not for Sale**' in readable purple or green colour.

F. Secondary Package

The strips/ampoules/vials, tubes and bottles should be packed in boxes for easy handling, transport and distribution. It shall be fabricated from Millboard/grey board/cardboard with appropriate bursting strength. The secondary packaging material must be clearly labelled with the names of item, batch number, mfg date, expiry date and the number of units per box. The secondary box shall bear the words **'Government of Maharashtra (MMGPA) Supply - Not for Sale**' in readable purple or Green colour.

G. Tertiary Package

The boxes shall be packed in weather resistant triple walled insulated corrugated 5 ply cartons, each ply having strength of minimum 150 gsm It should be fabricated from virgin quality "A" grade material. The overall dimension of the carton should be such that the drug does not get damaged during transportation and storage. Each international shipping carton should weigh less than 50 kg. It is important that individual boxes are not too heavy during transport as they are frequently loaded and off loaded manually at airports and intermediate stores.

H. Case Identification

All cases should prominently indicate the following:

1. Purchaser's line and code numbers
2. The generic name of the drug
3. The dosage form (Tablet, Ampoule, Syrup)
4. Date of manufacture and expiry (month and year) (in clear language not code)
5. Batch number
6. Quantity per case (Carton containing -------- secondary packages)
7. Special instructions for storage and handling
8. Name and address of manufacture
9. Any additional cautionary statements.

SPECIMEN LABEL FOR OUTER CARTON (20cm x 15cm)

Government of Maharashtra (MMGPA) Supply - Not for Sale

~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Generic Name of Drug I.P.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~

10 x 10 TABLETS
Batch No: XXXXXX
Quantity Packed: XXXXXX
Mfg. Date: XXXX- 2025
Exp. Date: XXXX -2027

Manufactured by: M/s. XXXXXX

Carton containing -------- secondary packages
Special instructions for storage and handling - Store in a Cool and Dry Place
Bar Code

Schedule 5 Prebid Queries Format

Name of the Bidder :

(A): Prebid Query Format for Tender Terms & Conditions

Sr no	Tender Page no	Tender Clause no	Clause Title	Query / Clarification	Justification by Bidder
1					
2					
3					
4					

(B): Prebid Query Format for Itemwise (Medicines)

Sr no	Item Sr no (As per Appendix A)	Name of the Item	Specifications	Query / Clarification	Justification by Bidder
1					
2					
3					
4					